---
created: 2024-11-19
tags:
  - web
---
## Introduction 介绍

Vitamin D (also referred to as calciferol) is a fat-soluble vitamin that is naturally present in a few foods, added to others, and available as a dietary supplement. It is also produced endogenously when ultraviolet (UV) rays from sunlight strike the skin and trigger vitamin D synthesis.  
维生素 D（也称为钙化醇）是一种脂溶性维生素，天然存在于一些食物中，添加到其他食物中，并作为膳食补充剂提供。当阳光的紫外线 （UV） 照射皮肤并触发维生素 D 合成时，它也会在内源性产生。

Vitamin D obtained from sun exposure, foods, and supplements is biologically inert and must undergo two hydroxylations in the body for activation. The first hydroxylation, which occurs in the liver, converts vitamin D to 25-hydroxyvitamin D \[25(OH)D\], also known as calcidiol. The second hydroxylation occurs primarily in the kidney and forms the physiologically active 1,25-dihydroxyvitamin D \[1,25(OH)2D\], also known as calcitriol \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\].  
从阳光照射、食物和补充剂中获得的维生素 D 具有生物惰性，必须在体内经历两次羟基化才能激活。第一次羟基化发生在肝脏中，将维生素 D 转化为 25-羟基维生素 D \[25（OH）D\]，也称为骨化二醇。第二次羟基化主要发生在肾脏中，形成具有生理活性的 1,25-二羟基维生素 D \[1,25（OH）2D\]，也称为骨化三醇 \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。

Vitamin D promotes calcium absorption in the gut and maintains adequate serum calcium and phosphate concentrations to enable normal bone mineralization and to prevent hypocalcemic tetany (involuntary contraction of muscles, leading to cramps and spasms). It is also needed for bone growth and bone remodeling by osteoblasts and osteoclasts \[[1-3](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]. Without sufficient vitamin D, bones can become thin, brittle, or misshapen. Vitamin D sufficiency prevents rickets in children and osteomalacia in adults. Together with calcium, vitamin D also helps protect older adults from osteoporosis.  
维生素 D 促进肠道对钙的吸收，并维持足够的血清钙和磷酸盐浓度，以实现正常的骨矿化并防止低钙血症性手足搐搦（肌肉不自主收缩，导致痉挛和痉挛）。它也是成骨细胞和破骨细胞的骨骼生长和骨重塑所必需的\[[1-3](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。如果没有足够的维生素 D，骨骼会变薄、变脆或畸形。维生素 D 充足可预防儿童佝偻病和成人骨软化症。维生素 D 与钙一起还有助于保护老年人免受骨质疏松症的侵害。

Vitamin D has other roles in the body, including reduction of inflammation as well as modulation of such processes as cell growth, neuromuscular and immune function, and glucose metabolism \[[1-3](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]. Many genes encoding proteins that regulate cell proliferation, differentiation, and apoptosis are modulated in part by vitamin D. Many tissues have vitamin D receptors, and some convert 25(OH)D to 1,25(OH)2D.  
维生素 D 在体内还有其他作用，包括减少炎症以及调节细胞生长、神经肌肉和免疫功能以及葡萄糖代谢等过程 \[[1-3](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。许多编码调节细胞增殖、分化和凋亡的蛋白质的基因部分受维生素 D 调节。许多组织具有维生素 D 受体，有些组织将 25（OH）D 转化为 1,25（OH）2D。

In foods and dietary supplements, vitamin D has two main forms, D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">2</sub> (ergocalciferol) and D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> (cholecalciferol), that differ chemically only in their side-chain structures. Both forms are well absorbed in the small intestine. Absorption occurs by simple passive diffusion and by a mechanism that involves intestinal membrane carrier proteins \[[4](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en4)\]. The concurrent presence of fat in the gut enhances vitamin D absorption, but some vitamin D is absorbed even without dietary fat. Neither aging nor obesity alters vitamin D absorption from the gut \[[4](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en4)\].  
在食品和膳食补充剂中，维生素 D 有两种主要形式，D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">2</sub>（麦角钙化醇）和 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub>（胆钙化醇），它们的化学区别仅在于它们的侧链结构。这两种形式在小肠中都能很好地吸收。吸收是通过简单的被动扩散和涉及肠膜载体蛋白的机制发生的 \[[4](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en4)\]。肠道中脂肪的并发存在增强了维生素 D 的吸收，但即使没有膳食脂肪，一些维生素 D 也会被吸收。衰老和肥胖都不会改变肠道对维生素 D 的吸收 \[[4](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en4)\]。

Serum concentration of 25(OH)D is currently the main indicator of vitamin D status. It reflects vitamin D produced endogenously and that obtained from foods and supplements \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]. In serum, 25(OH)D has a fairly long circulating half-life of 15 days \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]. Serum concentrations of 25(OH)D are reported in both nanomoles per liter (nmol/L) and nanograms per milliliter (ng/mL). One nmol/L is equal to 0.4 ng/mL, and 1 ng/mL is equal to 2.5 nmol/L.  
血清 25（OH）D 浓度是目前维生素 D 状况的主要指标。它反映了内源性产生的维生素 D 以及从食物和补充剂中获得的维生素 D \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。在血清中，25（OH）D 具有相当长的循环半衰期，为 15 天 \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。血清 25（OH）D 浓度以纳摩尔每升 （nmol/L） 和纳克每毫升 （ng/mL） 两种形式报告。1 nmol/L 等于 0.4 ng/mL，1 ng/mL 等于 2.5 nmol/L。

Assessing vitamin D status by measuring serum 25(OH)D concentrations is complicated by the considerable variability of the available assays (the two most common ones involve antibodies or chromatography) used by laboratories that conduct the analyses \[[5](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en5),[6](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en6)\]. As a result, a finding can be falsely low or falsely high, depending on the assay used and the laboratory. The international Vitamin D Standardization Program has developed procedures for standardizing the laboratory measurement of 25(OH)D to improve clinical and public health practice \[[5](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en5),[7-10](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en7)\].  
通过测定血清 25（OH）D 浓度来评估维生素 D 状态很复杂，因为进行分析的实验室使用的可用检测方法（最常见的两种方法涉及抗体或色谱法）存在相当大的差异\[[5,6](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en5)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en6)因此，结果可能是假低或假高，具体取决于所使用的检测和实验室。国际维生素 D 标准化计划制定了标准化实验室 25（OH）D 测量的程序，以改善临床和公共卫生实践 \[[5,7-10](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en7)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en5)

In contrast to 25(OH)D, circulating 1,25(OH)2D is generally not a good indicator of vitamin D status because it has a short half-life measured in hours, and serum levels are tightly regulated by parathyroid hormone, calcium, and phosphate \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]. Levels of 1,25(OH)2D do not typically decrease until vitamin D deficiency is severe \[[2](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en2)\].  
与 25（OH）D 相比，循环 1,25（OH）2D 通常不是维生素 D 状态的良好指标，因为它的半衰期很短，以小时为单位，并且血清水平受到甲状旁腺激素、钙和磷酸盐的严格调节 \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。1,25（OH）2D 的水平通常不会降低，直到维生素 D 严重缺乏 \[[2](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en2)\]。

### Serum concentrations of 25(OH)D and health 血清 25（OH）D 浓度与健康状况

Although 25(OH)D functions as a biomarker of exposure, the extent to which 25(OH)D levels also serve as a biomarker of effect on the body (i.e., relating to health status or outcomes) is not clear \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1),[3](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en3)\].  
尽管 25（OH）D 作为暴露的生物标志物发挥作用，但 25（OH）D 水平在多大程度上也作为对身体影响的生物标志物（即与健康状况或结果有关）尚不清楚 \[[1,3](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en3)

Researchers have not definitively identified serum concentrations of 25(OH)D associated with deficiency (e.g., rickets), adequacy for bone health, and overall health. After reviewing data on vitamin D needs, an expert committee of the Food and Nutrition Board (FNB) at the National Academies of Sciences, Engineering, and Medicine (NASEM) concluded that people are at risk of vitamin D deficiency at serum 25(OH)D concentrations less than 30 nmol/L (12 ng/mL; see Table 1 for definitions of deficiency and inadequacy) \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]. Some people are potentially at risk of inadequacy at 30 to 50 nmol/L (12–20 ng/mL). Levels of 50 nmol/L (20 ng/mL) or more are sufficient for most people. The FNB committee also noted that serum concentrations greater than 125 nmol/L (50 ng/mL) can be associated with adverse effects \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\] (Table 1). The Endocrine Society has not identified 25(OH)D concentrations associated with vitamin D sufficiency, insufficiency, and deficiency and does not recommend routine testing of 25(OH)D concentrations in healthy individuals \[[11](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en11),[12](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en12)\].  
研究人员尚未明确确定与缺乏症（例如佝偻病）、骨骼健康和整体健康状况相关的 25（OH）D 血清浓度。美国国家科学、工程和医学学院（NASEM）食品与营养委员会（Food and Nutrition Board， FNB）的一个专家委员会在审查了维生素D需求数据后得出结论，当血清25（OH）D浓度低于30 nmol/L（12 ng/mL;缺乏和不足的定义见表1）时，人们有患维生素D缺乏的风险\[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\].有些人在 30 至 50 nmol/L （12-20 ng/mL） 时可能存在不足的风险。50 nmol/L （20 ng/mL） 或更高的水平对大多数人来说就足够了。FNB 委员会还指出，血清浓度大于 125 nmol/L （50 ng/mL） 可能与不良反应有关 \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]（表 1）。内分泌学会尚未确定与维生素 D 充足、不足和缺乏相关的 25（OH）D 浓度，也不推荐对健康个体进行 25（OH）D 浓度的常规检测 \[[11,12](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en11)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en12)

Table 1: Serum 25-Hydroxyvitamin D \[25(OH)D\] Concentrations and Health \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]  
表 1：血清 25-羟基维生素 D \[25（OH）D\] 浓度和健康状况 \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]
| nmol/L\* 纳摩尔/升\* | ng/mL\* | Health status 健康状况 |
| --- | --- | --- |
| <30 | <12 | Associated with vitamin D deficiency, which can lead to rickets in infants and children and osteomalacia in adults  
与维生素 D 缺乏有关，维生素 D 缺乏可导致婴儿和儿童佝偻病和成人骨软化症 |
| 30 to <50 30 至 <50 | 12 to <20 12 至 <20 | Generally considered inadequate for bone and overall health in healthy individuals  
通常被认为对健康个体的骨骼和整体健康不足 |
| ≥50 | ≥20 | Generally considered adequate for bone and overall health in healthy individuals  
通常被认为对健康个体的骨骼和整体健康足够 |
| \>125 | \>50 | Linked to potential adverse effects, particularly at >150 nmol/L (>60 ng/mL)  
与潜在的不良反应有关，尤其是在 >150 nmol/L （>60 ng/mL） 时 |

\*Serum concentrations of 25(OH)D are reported in both nanomoles per liter (nmol/L) and nanograms per milliliter (ng/mL). One nmol/L = 0.4 ng/mL, and 1 ng/mL = 2.5 nmol/L.  
\*血清 25（OH）D 浓度以纳摩尔每升 （nmol/L） 和纳克每毫升 （ng/mL） 为单位。1 nmol/L = 0.4 ng/mL，1 ng/mL = 2.5 nmol/L。

Optimal serum concentrations of 25(OH)D for bone and general health have not been established because they are likely to vary by stage of life, by race and ethnicity, and with each physiological measure used \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1),[13](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en13),[14](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en14)\]. In addition, although 25(OH)D levels rise in response to increased vitamin D intake, the relationship is nonlinear \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]. The amount of increase varies, for example, by baseline serum levels and duration of supplementation.  
25（OH）D 对骨骼和一般健康的最佳血清浓度尚未确定，因为它们可能因生命阶段、种族和民族以及所使用的每种生理指标而异 \[[1,13,14](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en13)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en14)此外，尽管 25（OH）D 水平会随着维生素 D 摄入量的增加而升高，但这种关系是非线性的 \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。增加的量因基线血清水平和补充持续时间等而异。

## Recommended Intakes 推荐摄入量

Intake recommendations for vitamin D and other nutrients are provided in the Dietary Reference Intakes (DRIs) developed by expert committees of NASEM \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]. DRI is the general term for a set of reference values used for planning and assessing nutrient intakes of healthy people. These values, which vary by age and sex, include the following:  
维生素 D 和其他营养素的摄入量建议在 NASEM 专家委员会制定的膳食参考摄入量 （DRI） 中提供 \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。DRI 是一组参考值的总称，用于规划和评估健康人的营养摄入量。这些值因年龄和性别而异，包括：

-   Recommended Dietary Allowance (RDA): Average daily level of intake sufficient to meet the nutrient requirements of nearly all (97%–98%) healthy individuals; often used to plan nutritionally adequate diets for individuals  
    推荐膳食供给量 （RDA）：平均每日摄入量足以满足几乎所有 （97%-98%） 健康个体的营养需求;通常用于为个人规划营养充足的饮食
-   Adequate Intake (AI): Intake at this level is assumed to ensure nutritional adequacy; established when evidence is insufficient to develop an RDA  
    充足摄入量 （AI）：假设摄入此水平以确保营养充足;当证据不足以形成 RDA 时确定
-   Estimated Average Requirement (EAR): Average daily level of intake estimated to meet the requirements of 50% of healthy individuals; usually used to assess the nutrient intakes of groups of people and to plan nutritionally adequate diets for them; can also be used to assess the nutrient intakes of individuals  
    估计平均需求量 （EAR）：估计满足 50% 健康个体的平均每日摄入量水平;通常用于评估人群的营养摄入量并为他们规划营养充足的饮食;也可用于评估个体的营养摄入量
-   Tolerable Upper Intake Level (UL): Maximum daily intake unlikely to cause adverse health effects  
    可耐受的摄入量上限 （UL）：每日最大摄入量不太可能对健康造成不利影响

An FNB committee established RDAs for vitamin D to indicate daily intakes sufficient to maintain bone health and normal calcium metabolism in healthy people. RDAs for vitamin D are listed in both micrograms (mcg) and International Units (IU); 1 mcg vitamin D is equal to 40 IU (Table 2). Even though sunlight is a major source of vitamin D for some people, the FNB based the vitamin D RDAs on the assumption that people receive minimal sun exposure \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]. For infants, the FNB committee developed AIs based on the amount of vitamin D that maintains serum 25(OH)D levels above 20 ng/mL (50 nmol/L) and supports bone development.  
FNB 委员会建立了维生素 D 的 RDA，以表明每天摄入足以维持健康人骨骼健康和正常钙代谢的摄入量。维生素 D 的 RDA 以微克 （mcg） 和国际单位 （IU） 列出;1 微克维生素 D 等于 40 IU（表 2）。尽管阳光是某些人维生素 D 的主要来源，但 FNB 基于人们接受最少阳光照射的假设来构建维生素 D RDA \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。对于婴儿，FNB 委员会根据维生素 D 的量开发了 AI，维生素 D 可维持血清 25（OH）D 水平高于 20 ng/mL （50 nmol/L） 并支持骨骼发育。

Table 2: Recommended Dietary Allowances (RDAs) for Vitamin D \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]  
表 2：维生素 D 的推荐膳食摄入量 （RDA） \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]

| Age | Male | Female | Pregnancy | Lactation |
| --- | --- | --- | --- | --- |
| 0-12 months\* | 10 mcg  
(400 IU) | 10 mcg  
(400 IU) |  |  |
| 1–13 years | 15 mcg  
(600 IU) | 15 mcg  
(600 IU) |  |  |
| 14–18 years | 15 mcg  
(600 IU) | 15 mcg  
(600 IU) | 15 mcg  
(600 IU) | 15 mcg  
(600 IU) |
| 19–50 years | 15 mcg  
(600 IU) | 15 mcg  
(600 IU) | 15 mcg  
(600 IU) | 15 mcg  
(600 IU) |
| 51–70 years | 15 mcg  
(600 IU) | 15 mcg  
(600 IU) |  |  |
| \>70 years | 20 mcg  
(800 IU) | 20 mcg  
(800 IU) |  |  |

\*Adequate Intake (AI)

Many other countries around the world and some professional societies have somewhat different guidelines for vitamin D intakes \[[15](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en15)\]. These differences are a result of an incomplete understanding of the biology and clinical implications of vitamin D, different purposes for the guidelines (e.g., for public health in a healthy population or for clinical practice), and/or the use in some guidelines of observational studies in addition to randomized clinical trials to establish recommendations \[[9](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en9),[15](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en15)\]. For example, the United Kingdom Scientific Advisory Committee on Nutrition recommends intakes of 10 mcg (400 IU)/day for individuals age 4 years and older \[[16](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en16)\]. The Endocrine Society recommends routine vitamin D supplementation for children and teens age 1 to 18 years, people who are pregnant, adults with pre-diabetes, and adults age 75 years and older, but not for healthy adults age 19 to 74 \[[11](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en11),[12](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en12)\]. The Endocrine Society does not recommend specific doses but notes that all individuals should adhere to the RDA.  
世界上许多其他国家和一些专业协会对维生素 D 摄入量的指导方针略有不同 \[[15](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en15)\]。这些差异是由于对维生素 D 的生物学和临床意义了解不完全、指南的目的不同（例如，用于健康人群的公共卫生或临床实践）和/或一些指南中除随机临床试验外还使用观察性研究来建立推荐的结果\[[9,15](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en15)[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en9)\].例如，英国营养科学咨询委员会建议 4 岁及以上个体的摄入量为 10 μg（400 IU）/天 \[[16](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en16)\]。内分泌学会推荐 1-18 岁的儿童和青少年、孕妇、糖尿病前期成人和 75 岁及以上的成人常规补充维生素 D，但不建议 19-74 岁的健康成人补充维生素 D\[[11,12](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en11)[\]。](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en12)内分泌学会不推荐特定剂量，但指出所有人都应遵守 RDA。

## Sources of Vitamin D 维生素 D 的来源

### Food 食物

Few foods naturally contain vitamin D. The flesh of fatty fish (such as trout, salmon, tuna, and mackerel) and fish liver oils are among the best sources \[[17](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en17),[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]. An animal’s diet affects the amount of vitamin D in its tissues. Beef liver, egg yolks, and cheese have small amounts of vitamin D, primarily in the form of vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> and its metabolite 25(OH)D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub>. Mushrooms provide variable amounts of vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">2</sub> \[[17](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en17)\]. Some mushrooms available on the market have been treated with UV light to increase their levels of vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">2</sub>. In addition, the Food and Drug Administration (FDA) has approved UV-treated mushroom powder as a food additive for use as a source of vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">2</sub> in food products \[[18](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en18)\]. Very limited evidence suggests no substantial differences in the bioavailability of vitamin D from various foods \[[19](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en19)\].  
很少有食物天然含有维生素 D。富含脂肪的鱼（如鳟鱼、鲑鱼、金枪鱼和鲭鱼）的肉和鱼肝油是最好的来源\[[17,1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en17)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)动物的饮食会影响其组织中维生素 D 的含量。牛肝、蛋黄和奶酪含有少量维生素 D，主要以维生素 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> 及其代谢物 25（OH）D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> 的形式存在。蘑菇提供不同数量的维生素<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">D 2</sub> \[[17](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en17)\]。市场上的一些蘑菇已经过紫外线处理，以提高其维生素 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">2</sub> 的水平。此外，美国食品药品监督管理局 （FDA） 已批准将经过紫外线处理的蘑菇粉作为食品添加剂，用作食品中维生素 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">2</sub> 的来源 \[[18](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en18)\]。非常有限的证据表明，各种食物中维生素 D 的生物利用度没有显著差异 \[[19](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en19)\]。

Animal-based foods typically provide some vitamin D in the form of 25(OH)D in addition to vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub>. The impact of this form on vitamin D status is an emerging area of research. Studies show that 25(OH)D appears to be approximately five times more potent than the parent vitamin for raising serum 25(OH)D concentrations \[[17](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en17),[20](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en20),[21](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en21)\]. One study found that when the 25(OH)D content of beef, pork, chicken, turkey, and eggs is taken into account, the total amount of vitamin D in the food is 2 to 18 times higher than the amount in the parent vitamin alone, depending on the food \[[20](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en20)\].  
除了维生素<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">D 3</sub> 外，动物性食物通常以 25（OH）D 的形式提供一些维生素 D。这种形式对维生素 D 状况的影响是一个新兴的研究领域。研究表明，25（OH）D 在提高血清 25（OH）D 浓度方面的效力似乎是母体维生素的大约 5 倍 \[[17,20,21](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en20)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en21)[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en17)一项研究发现，当考虑到牛肉、猪肉、鸡肉、火鸡和鸡蛋的 25（OH）D 含量时，食物中维生素 D 的总量比单独母体维生素中的维生素 D 含量高 2 到 18 倍，具体取决于食物 \[[20](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en20)\]。

Fortified foods provide most of the vitamin D in American diets \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1),[22](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en22)\]. For example, almost all of the U.S. milk supply is voluntarily fortified with about 3 mcg/cup (120 IU), usually in the form of vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> \[[23](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en23)\]. In Canada, milk must be fortified with 0.88–1.0 mcg/100 mL (35–40 IU), and the required amount for margarine is at least 13.25 mcg/100 g (530 IU). Other dairy products made from milk, such as cheese and ice cream, are not usually fortified in the United States or Canada. Plant milk alternatives (such as beverages made from soy, almond, or oats) are often fortified with similar amounts of vitamin D to those in fortified cow’s milk (about 3 mcg \[120 IU\]/cup); the Nutrition Facts label lists the actual amount \[[24](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en24)\]. Ready-to-eat breakfast cereals often contain added vitamin D, as do some brands of orange juice, yogurt, margarine, and other food products.  
强化食品提供了美国饮食中的大部分维生素 D \[[1,22](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en22)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)例如，几乎所有的美国牛奶供应都是自愿添加约 3 微克/杯（120 IU）的，通常以维生素 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> 的形式出现 \[[23](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en23)\]。在加拿大，牛奶必须添加 0.88-1.0 微克/100 毫升（35-40 国际单位），人造黄油所需的量至少为 13.25 微克/100 克（530 国际单位）。其他由牛奶制成的乳制品，如奶酪和冰淇淋，在美国或加拿大通常不进行强化。植物奶替代品（如由大豆、杏仁或燕麦制成的饮料）通常含有与强化牛奶相似量的维生素 D（约 3 微克 \[120 IU\]/杯）;营养成分标签列出了实际量 \[[24](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en24)\]。即食早餐麦片通常含有添加的维生素 D，一些品牌的橙汁、酸奶、人造黄油和其他食品也是如此。

The United States mandates the fortification of infant formula with 1–2.5 mcg/100 kcal (40–100 IU) vitamin D; 1–2 mcg/100 kcal (40–80 IU) is the required amount in Canada \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\].  
美国强制要求婴儿配方奶粉中添加 1-2.5 微克/100 大卡（40-100 IU）维生素 D;在加拿大，1-2 mcg/100 kcal （40-80 IU） 是所需的量 \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。

A variety of foods and their vitamin D levels per serving are listed in Table 3.  
表 3 列出了各种食物及其每份维生素 D 水平。

Table 3: Vitamin D Content of Selected Foods \[[25](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en25)\]  
表 3：选定食物的维生素 D 含量 \[[25](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en25)\]
| Food 食物 | Micrograms 微克  
(mcg) per （微克）  
serving 服务 | International 国际  
Units (IU) 单位 （IU）  
per serving 每份 | Percent DV\* 每日摄入量百分比\* |
| --- | --- | --- | --- |
| Cod liver oil, 1 tablespoon  
鱼肝油，1 汤匙 | 34.0 | 1,360 | 170 |
| Trout (rainbow), farmed, cooked, 3 ounces  
鳟鱼（彩虹），养殖，熟，3 盎司 | 16.2 | 645 | 81 |
| Salmon (sockeye), cooked, 3 ounces  
鲑鱼（红鲑），煮熟，3 盎司 | 14.2 | 570 | 71 |
| Mushrooms, white, raw, sliced, exposed to UV light, ½ cup  
蘑菇，白色，生的，切片，暴露在紫外线下，1/2 杯 | 9.2 | 366 | 46 |
| Milk, 2% milkfat, vitamin D fortified, 1 cup  
牛奶，2% 乳脂，维生素 D，1 杯 | 2.9 | 120 | 15 |
| Soy, almond, and oat milks, vitamin D fortified, various brands, 1 cup  
大豆、杏仁和燕麦奶，维生素 D 强化，各种品牌，1 杯 | 2.5–3.6 | 100–144 | 13–18 |
| Ready-to-eat cereal, fortified with 10% of the DV for vitamin D, 1 serving  
即食麦片，添加了 10% 的维生素 D DV，1 份 | 2.0 | 80 | 10 |
| Sardines (Atlantic), canned in oil, drained, 2 sardines  
沙丁鱼（大西洋），油罐头，沥干，2 条沙丁鱼 | 1.2 | 46 | 6 |
| Egg, 1 large, scrambled\*\*  
鸡蛋，1 个大的，炒熟\*\* | 1.1 | 44 | 6 |
| Liver, beef, braised, 3 ounces  
肝脏、牛肉、红烧 3 盎司 | 1.0 | 42 | 5 |
| Tuna fish (light), canned in water, drained, 3 ounces  
金枪鱼（清淡），水罐装，沥干，3 盎司 | 1.0 | 40 | 5 |
| Cheese, cheddar, 1.5 ounce  
奶酪，切达干酪，1.5 盎司 | 0.4 | 17 | 2 |
| Mushrooms, portabella, raw, diced, ½ cup  
蘑菇，生的，切丁，1/2 杯 | 0.1 | 4 | 1 |
| Chicken breast, roasted, 3 ounces  
烤鸡胸肉，3 盎司 | 0.1 | 4 | 1 |
| Beef, ground, 90% lean, broiled, 3 ounces  
牛肉粉，90% 瘦肉，烤制，3 盎司 | 0 | 1.7 | 0 |
| Broccoli, raw, chopped, ½ cup  
西兰花，生的，切碎的，1/2 杯 | 0 | 0 | 0 |
| Carrots, raw, chopped, ½ cup  
胡萝卜，生的，切碎的，1/2 杯 | 0 | 0 | 0 |
| Almonds, dry roasted, 1 ounce  
干烤杏仁，1 盎司 | 0 | 0 | 0 |
| Apple, large 苹果，大 | 0 | 0 | 0 |
| Banana, large 香蕉，大号 | 0 | 0 | 0 |
| Rice, brown, long-grain, cooked, 1 cup  
米，糙米，长粒米，煮熟，1 杯 | 0 | 0 | 0 |
| Whole wheat bread, 1 slice  
全麦面包，1 片 | 0 | 0 | 0 |
| Lentils, boiled, ½ cup 扁豆，煮熟的，1/2 杯 | 0 | 0 | 0 |
| Sunflower seeds, roasted, ½ cup  
葵花籽，烤，1/2 杯 | 0 | 0 | 0 |
| Edamame, shelled, cooked, ½ cup  
毛豆，去壳，煮熟，1/2 杯 | 0 | 0 | 0 |

\* DV = Daily Value. The FDA developed DVs to help consumers compare the nutrient contents of foods and dietary supplements within the context of a total diet. The DV for vitamin D is 20 mcg (800 IU) for adults and children age 4 years and older \[[26](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en26)\]. The labels must list vitamin D content in mcg per serving and have the option of also listing the amount in IUs in parentheses. Foods providing 20% or more of the DV are considered to be high sources of a nutrient, but foods providing lower percentages of the DV also contribute to a healthful diet.  
\* DV = 每日价值。FDA 开发了 DV 来帮助消费者在总饮食的背景下比较食品和膳食补充剂的营养成分。维生素 D 的每日摄入量为 20 微克（800 IU），成人和 4 岁及以上儿童 \[[26](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en26)\]。标签必须以每份 mcg 为单位列出维生素 D 含量，并可以选择在括号中以 IU 列出含量。提供 20% 或更多 DV 的食物被认为是营养物质的高来源，但提供较低 DV 百分比的食物也有助于健康饮食。  
\*\* Vitamin D is in the yolk.  
\*\* 维生素 D 在蛋黄中。

The U.S. Department of Agriculture’s (USDA’s) [FoodData Central](https://fdc.nal.usda.gov/)[![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png)](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website") lists the nutrient content of many foods and provides a comprehensive list of foods containing vitamin D arranged by [nutrient content](https://ods.od.nih.gov/pubs/usdandb/VitaminD-Content.pdf) and by [food name](https://ods.od.nih.gov/pubs/usdandb/VitaminD-Food.pdf). However, FoodData Central does not include the amounts of 25(OH)D in foods.  
美国农业部 （USDA） 的 [FoodData Central](https://fdc.nal.usda.gov/)  [![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png)](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website")列出了许多食物的营养成分，并提供了按[营养成分](https://ods.od.nih.gov/pubs/usdandb/VitaminD-Content.pdf)和[食物名称](https://ods.od.nih.gov/pubs/usdandb/VitaminD-Food.pdf)排列的含有维生素 D 的食物的综合清单。但是，FoodData Central 不包括食品中 25（OH）D 的含量。

### Sun exposure 阳光照射

Most people in the world meet at least some of their vitamin D needs through exposure to sunlight \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]. Type B UV (UVB) radiation with a wavelength of approximately 290–320 nanometers penetrates uncovered skin and converts cutaneous 7-dehydrocholesterol to previtamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub>, which in turn becomes vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub>. Season, time of day, length of day, cloud cover, smog, skin melanin content, and sunscreen are among the factors that affect UV radiation exposure and vitamin D synthesis. Older people and people with dark skin are less able to produce vitamin D from sunlight \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]. UVB radiation does not penetrate glass, so exposure to sunshine indoors through a window does not produce vitamin D \[[27](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en27)\].  
世界上大多数人通过暴露在阳光下至少满足了部分维生素 D 需求 \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。波长约为 290-320 纳米的 B 型紫外线 （UVB） 辐射穿透裸露的皮肤，将皮肤 7-脱氢胆固醇转化为维生素前体 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub>，进而转化为维生素 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub>。季节、一天中的时间、一天的长度、云量、烟雾、皮肤黑色素含量和防晒霜是影响紫外线辐射暴露和维生素 D 合成的因素。老年人和深色皮肤的人从阳光中产生维生素 D 的能力较差 \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。UVB 辐射不会穿透玻璃，因此透过窗户暴露在室内阳光下不会产生维生素 D \[[27](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en27)\]。

The factors that affect UV radiation exposure, individual responsiveness, and uncertainties about the amount of sun exposure needed to maintain adequate vitamin D levels make it difficult to provide guidelines on how much sun exposure is required for sufficient vitamin D synthesis \[[15](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en15),[28](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en28)\]. Some expert bodies and vitamin D researchers suggest, for example, that approximately 5–30 minutes of sun exposure, particularly between 10 a.m. and 4 p.m., either daily or at least twice a week to the face, arms, hands, and legs without sunscreen usually leads to sufficient vitamin D synthesis \[[13](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en13),[15](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en15),[28](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en28)\]. Moderate use of commercial tanning beds that emit 2% to 6% UVB radiation is also effective \[[13](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en13),[29](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en29)\].  
影响紫外线辐射暴露、个体反应性以及维持足够维生素D水平所需日照量的不确定性，使得很难提供关于合成充足维生素D需要多少日照量的指南\[[15,28](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en15)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en28)例如，一些专家机构和维生素 D 研究人员建议，每天或每周至少两次在没有防晒霜的情况下，面部、手臂、手和腿每天或至少两次暴露在阳光下 5-30 分钟，尤其是上午 10 点至下午 4 点之间，通常可以产生足够的维生素 D 合成 \[[13,15,28](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en15)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en13)[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en28)适度使用发射 2%-6% UVB 辐射的商业日光浴床也是有效的 \[[13,29](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en13)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en29)

However, despite the importance of the sun for vitamin D synthesis, limiting skin exposure to sunlight and UV radiation from tanning beds is prudent \[[28](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en28)\]. UV radiation is a carcinogen, and UV exposure is the most preventable cause of skin cancer. Federal agencies and national organizations advise taking photoprotective measures to reduce the risk of skin cancer, including using sunscreen with a sun protection factor (SPF) of 15 or higher, whenever people are exposed to the sun \[[28](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en28),[30](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en30)\]. Sunscreens with an SPF of 8 or more appear to block vitamin D-producing UV rays. In practice, however, people usually do not apply sufficient amounts of sunscreen, cover all sun-exposed skin, or reapply sunscreen regularly. Their skin probably synthesizes some vitamin D, even with typically applied sunscreen amounts \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1),[28](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en28)\].  
然而，尽管阳光对维生素 D 的合成很重要，但限制皮肤暴露在阳光和日光浴床的紫外线辐射下是谨慎的做法 \[[28](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en28)\]。紫外线辐射是一种致癌物，紫外线照射是皮肤癌最可预防的原因。联邦机构和国家组织建议采取光保护措施来降低患皮肤癌的风险，包括在人们暴露在阳光下时使用防晒系数（sun protection factor， SPF）为15或更高的防晒霜\[[28,30](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en28)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en30)SPF 为 8 或更高的防晒霜似乎可以阻挡产生维生素 D 的紫外线。然而，在实践中，患者通常不会涂抹足量的防晒霜，不会覆盖所有暴露在阳光下的皮肤，也不会定期重新涂抹防晒霜。他们的皮肤可能合成了一些维生素 D，即使通常涂抹的防晒霜量也是如此 \[[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)[1,28](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en28)\]。

### Dietary supplements 膳食补充剂

Dietary supplements can contain vitamins D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">2</sub> or D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub>. Vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">2</sub> is manufactured using UV irradiation of ergosterol in yeast, and vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> is typically produced with irradiation of 7-dehydrocholesterol from lanolin obtained from the wool of sheep \[[13](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en13),[31](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en31)\]. An animal-free version of vitamin D3 sourced from lichen is also available \[[32](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en32)\]. People who avoid all animal-sourced products can contact dietary supplement manufacturers to ask about their sourcing and processing techniques.  
膳食补充剂可能含有维生素 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">2</sub> 或 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub>。维生素 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">2</sub> 是通过紫外线照射酵母中的麦角甾醇制成的，维生素 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> 通常是通过照射从绵羊羊毛中获得的羊毛脂中的 7-脱氢胆固醇来生产的 \[[13,31](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en13)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en31)还有一种来源于地衣的无动物成分的维生素 D3 \[[32](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en32)\]。避免使用所有动物源性商品的用户可以联系膳食补充剂制造商，询问他们的采购和加工技术。

Both vitamins D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">2</sub> and D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> raise serum 25(OH)D levels, and they seem to have equivalent ability to cure rickets \[[4](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en4)\]. In addition, most steps in the metabolism and actions of vitamins D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">2</sub> and D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> are identical. However, most evidence indicates that vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> increases serum 25(OH)D levels to a greater extent and maintains these higher levels longer than vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">2</sub>, even though both forms are well absorbed in the gut \[[33-36](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en33)\].  
维生素 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">2</sub> 和 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> 都会提高血清 25（OH）D 水平，它们似乎具有治疗佝偻病的同等能力 \[[4](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en4)\]。此外，维生素 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">2</sub> 和 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> 的代谢和作用的大多数步骤是相同的。然而，大多数证据表明，维生素 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> 比维生素 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">2</sub> 更大程度地提高了血清 25（OH）D 水平，并且保持这些较高水平的时间更长，即使这两种形式在肠道中都能很好地吸收 \[[33-36](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en33)\]。

Some studies have used dietary supplements containing the 25(OH)D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> form of vitamin D. Per equivalent microgram dose, 25(OH)D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> is three to five times as potent as vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> \[[37](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en37),[38](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en38)\]. However, no 25(OH)D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> dietary supplements appear to be available to consumers on the U.S. market at this time \[[32](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en32)\].  
一些研究使用了含有 25（OH）D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> 形式的维生素 D 的膳食补充剂。每等效微克剂量，25（OH）D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> 的效力是维生素 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> 的 3 到 5 倍 \[[37,38](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en37)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en38)然而，目前美国市场上似乎没有 25（OH）D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> 膳食补充剂可供消费者购买 \[[32](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en32)\]。

## Vitamin D Intakes and Status 维生素 D 摄入量和状态

Most people in the United States consume less than recommended amounts of vitamin D. An analysis of data from the 2015–2016 National Health and Nutrition Examination Survey (NHANES) found that average daily vitamin D intakes from foods and beverages were 5.1 mcg (204 IU) in men, 4.2 mcg (168 IU) in women, and 4.9 mcg (196 IU) in children age 2–19 years \[[39](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en39)\]. In fact, 2013–2016 NHANES data showed that 92% of men, more than 97% of women, and 94% of people age 1 year and older ingested less than the EAR of 10 mcg (400 IU) of vitamin D from food and beverages \[[40](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en40)\].  
大多数美国人摄入的维生素 D 少于推荐量。对 2015-2016 年全国健康和营养检查调查 （NHANES） 数据的分析发现，男性平均每日从食品和饮料中摄入的维生素 D 为 5.1 微克（204 IU），女性为 4.2 微克（168 IU），2-19 岁儿童为 4.9 微克（196 IU）\[[39](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en39)\]。事实上，2013-2016 年 NHANES 数据显示，92% 的男性、超过 97% 的女性和 94% 的 1 岁及以上人群从食品和饮料中摄入的维生素 D 少于 10 微克（400 IU）的 EAR \[[40\]。](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en40)

The analysis of 2015–2016 data also showed that 28% of all individuals age 2 years and older in the United States took a dietary supplement containing vitamin D \[[39](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en39)\]. In addition, 26% of participants age 2–5 years and 14% of those age 6–11 years took supplements; rates increased with age from 10% of those age 12–19 years to 49% of men and 59% of women age 60 and older. Total vitamin D intakes were three times higher with supplement use than with diet alone; the mean intake from foods and beverages alone for individuals age 2 and older was 4.8 mcg (192 IU) but increased to 19.9 mcg (796 IU) when dietary supplements were included.  
对 2015-2016 年数据的分析还显示，在美国 2 岁及以上的所有个体中，有 28% 的人服用含有维生素 D 的膳食补充剂 \[[39](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en39)\]。此外，26% 的 2-5 岁参与者和 14% 的 6-11 岁参与者服用了补充剂;发病率随年龄增长而增加，从 12-19 岁人群的 10% 增加到 60 岁及以上男性的 49% 和女性的 59%。使用补充剂的维生素 D 总摄入量是单独饮食的三倍;2 岁及以上个体仅从食物和饮料中的平均摄入量为 4.8 微克（192 IU），但当包括膳食补充剂时，则增加到 19.9 微克（796 IU）。

Some people take very high doses of vitamin D supplements. In 2013–2014, an estimated 3.2% of the U.S. adult population took supplements containing 100 mcg (4,000 IU) or more vitamin D \[[41](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en41)\].  
有些人服用非常高剂量的维生素 D 补充剂。在2013-2014年，估计有3.2%的美国成年人服用了含有100微克（4000 IU）或更多维生素D的补充剂\[[41](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en41)\]。

One might expect a large proportion of the U.S. population to have vitamin D inadequacy on the basis of vitamin D intakes from foods, beverages, and even dietary supplements. However, comparing vitamin D intakes to serum 25(OH)D levels is problematic. One reason is that sun exposure affects vitamin D status, so serum 25(OH)D levels are usually higher than would be predicted on the basis of vitamin D dietary intakes alone \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]. Another reason is that animal foods contain some 25(OH)D. This form of vitamin D is not included in intake surveys and is considerably more potent than vitamins D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">2</sub> or D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> at raising serum 25(OH)D levels \[[42](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en42)\].  
人们可能会认为，根据从食物、饮料甚至膳食补充剂中摄入的维生素 D，很大一部分美国人口维生素 D 不足。然而，将维生素 D 摄入量与血清 25（OH）D 水平进行比较是有问题的。原因之一是阳光照射会影响维生素 D 状态，因此血清 25（OH）D 水平通常高于仅根据维生素 D 饮食摄入量预测的水平 \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。另一个原因是动物性食物含有一些 25（OH）D。这种形式的维生素 D 不包括在摄入量调查中，并且在提高血清 25（OH）D 水平方面比维生素 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">2</sub> 或 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> 更有效 \[[42](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en42)\]。

An analysis of NHANES 2011–2014 data on serum 25(OH)D levels found that most people in the United States age 1 year and older had sufficient vitamin D intakes according to the FNB thresholds \[[43](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en43)\]. However, 18% were at risk of inadequacy (levels of 30–49 nmol/L \[12–19.6 ng/mL\]), and 5% were at risk of deficiency (levels below 30 nmol/L \[12 ng/mL\]). Four percent had levels higher than 125 nmol/L (50 ng/mL). Proportions at risk of deficiency were lowest among children age 1–5 years (0.5%), peaked at 7.6% in adults age 20–39 years, and fell to 2.9% among adults age 60 years and older; patterns were similar for risks of inadequacy. Rates of deficiency varied by race and ethnicity: 17.5% of non-Hispanic Blacks were at risk of vitamin D deficiency, as were 7.6% of non-Hispanic Asians, 5.9% of Hispanics, and 2.1% of non-Hispanic White people. Again, the pattern was similar for the risk of inadequacy. Vitamin D status in the United States remained stable in the decade between 2003–2004 and 2013–2014.  
对 NHANES 2011-2014 血清 25（OH）D 水平数据的分析发现，根据 FNB 阈值，大多数 1 岁及以上的美国人都摄入了足够的维生素 D \[[43](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en43)\]。然而，18% 存在不足风险（水平为 30-49 nmol/L \[12-19.6 ng/mL\]），5% 存在缺乏风险（水平低于 30 nmol/L \[12 ng/mL\]）。4% 的水平高于 125 nmol/L （50 ng/mL）。1-5 岁儿童有缺陷风险的比例最低 （0.5%），在 20-39 岁的成年人中达到 7.6% 的峰值，在 60 岁及以上的成年人中下降到 2.9%;对于不足的风险，模式相似。维生素 D 缺乏率因种族和民族而异：17.5% 的非西班牙裔黑人有维生素 D 缺乏症的风险，7.6% 的非西班牙裔亚洲人、5.9% 的西班牙裔和 2.1% 的非西班牙裔白人也有维生素 D 缺乏症的风险。同样，对于不足的风险，模式相似。在 2003-2004 年和 2013-2014 年的十年间，美国的维生素 D 状况保持稳定。

## Vitamin D Deficiency 维生素 D 缺乏症

People can develop vitamin D deficiency when usual intakes are lower over time than recommended levels, exposure to sunlight is limited, the kidneys cannot convert 25(OH)D to its active form, or absorption of vitamin D from the digestive tract is inadequate. Diets low in vitamin D are more common in people who have milk allergy or lactose intolerance and those who consume an ovo-vegetarian or vegan diet \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\].  
当人们的正常摄入量随着时间的推移低于推荐水平、暴露在阳光下受到限制、肾脏无法将 25（OH）D 转化为其活性形式或消化道对维生素 D 的吸收不足时，人们可能会患上维生素 D 缺乏症。维生素 D 含量低的饮食在牛奶过敏或乳糖不耐症患者以及蛋素食者或纯素食者中更为常见 \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。

In children, vitamin D deficiency is manifested as rickets, a disease characterized by a failure of bone tissue to become properly mineralized, resulting in soft bones and skeletal deformities \[[44](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en44)\]. In addition to bone deformities and pain, severe rickets can cause failure to thrive, developmental delay, hypocalcemic seizures, tetanic spasms, cardiomyopathy, and dental abnormalities \[[45](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en45),[46](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en46)\].  
在儿童中，维生素 D 缺乏表现为佝偻病，这种疾病的特征是骨组织无法正常矿化，导致骨骼软化和骨骼畸形 \[[44](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en44)\]。除了骨骼畸形和疼痛外，重度佝偻病还可导致生长迟缓、发育迟缓、低钙性癫痫发作、破伤风性痉挛、心肌病和牙齿异常\[[45,46](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en45)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en46)

Prolonged exclusive breastfeeding without vitamin D supplementation can cause rickets in infants, and, in the United States, rickets is most common among breastfed Black infants and children \[[47](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en47)\]. In one Minnesota county, the incidence rate of rickets in children younger than 3 years in the decade beginning in 2000 was 24.1 per 100,000 \[[48](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en48)\]. Rickets occurred mainly in Black children who were breastfed longer, were born with low birthweight, weighed less, and were shorter than other children. The incidence rate of rickets in the infants and children (younger than 7) seen by 2,325 pediatricians throughout Canada was 2.9 per 100,000 in 2002–2004, and almost all patients with rickets had been breastfed \[[49](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en49)\].  
长期纯母乳喂养而不补充维生素D可导致婴儿佝偻病，在美国，佝偻病最常见于母乳喂养的黑人婴儿和儿童\[[47](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en47)\]。在明尼苏达州的一个县，从2000年开始的10年里，3岁以下儿童佝偻病的发病率为24.1/100,000\[[48](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en48)\]。佝偻病主要发生在黑人儿童中，他们母乳喂养时间长，出生时出生体重低，体重较轻，比其他儿童矮小。2002-2004年，加拿大有2,325名儿科医生发现婴儿和儿童（7岁以下）的佝偻病发病率为2.9/100,000，几乎所有佝偻病患者都接受过母乳喂养\[[49](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en49)\]。

The fortification of milk (a good source of calcium) and other staples, such as breakfast cereals and margarine, with vitamin D beginning in the 1930s along with the use of cod liver oil made rickets rare in the United States \[[28](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en28),[50](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en50)\]. However, the incidence of rickets is increasing globally, even in the United States and Europe, especially among immigrants from African, Middle-Eastern, and Asian countries \[[51](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en51)\]. Possible explanations for this increase include genetic differences in vitamin D metabolism, dietary preferences, and behaviors that lead to less sun exposure \[[45](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en45),[46](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en46)\].  
从1930年代开始，牛奶（钙的良好来源）和其他主食（如早餐麦片和人造黄油）中加入维生素D，并使用鱼肝油，使佝偻病在美国很少见\[[28,50](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en28)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en50)然而，佝偻病的发病率在全球范围内不断增加，甚至在美国和欧洲也是如此，尤其是在来自非洲、中东和亚洲国家的移民中\[[51](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en51)\]。这种增加的可能解释包括维生素D代谢、饮食偏好和导致日照暴露减少的行为的遗传差异\[[45,46](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en45)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en46)

In adults and adolescents, vitamin D deficiency can lead to osteomalacia, in which existing bone is incompletely or defectively mineralized during the remodeling process, resulting in weak bones \[[46](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en46)\]. Signs and symptoms of osteomalacia are similar to those of rickets and include bone deformities and pain, hypocalcemic seizures, tetanic spasms, and dental abnormalities \[[45](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en45)\].  
在成人和青少年中，维生素 D 缺乏会导致骨软化症，即现有的骨骼在重塑过程中不完全或有缺陷地矿化，导致骨骼脆弱 \[[46](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en46)\]。骨软化症的症状和体征与佝偻病相似，包括骨骼畸形和疼痛、低钙血症性癫痫发作、破伤风性痉挛和牙齿异常\[[45](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en45)\]。

Screening for vitamin D status is becoming a more common part of the routine laboratory bloodwork ordered by primary-care physicians, irrespective of any indications for this practice \[[6](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en6),[52-54](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en52)\]. No studies have examined whether such screening for vitamin D deficiency results in improved health outcomes \[[55](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en55)\]. The U.S. Preventive Services Task Force (USPSTF) found insufficient evidence to assess the benefits and harms of screening for vitamin D deficiency in asymptomatic adults \[[6](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en6)\]. It added that no national professional organization recommends population screening for vitamin D deficiency.  
在初级保健医生要求的常规实验室血液检查中，筛查维生素D状态正变得越来越常见，无论这种做法的适应证如何\[[6,52-54](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en52)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en6)尚无研究检查这种维生素 D 缺乏症筛查是否能改善健康结局 \[[55](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en55)\]。美国预防服务工作组（U.S. Preventive Services Task Force， USPSTF）发现，没有足够的证据来评估对无症状成人进行维生素D缺乏筛查的利弊\[[6](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en6)\]。它补充说，没有全国性专业组织建议对维生素 D 缺乏症进行人群筛查。

## Groups at Risk of Vitamin D Inadequacy 有维生素 D 缺乏风险的群体

Obtaining sufficient vitamin D from natural (nonfortified) food sources alone is difficult. For many people, consuming vitamin D-fortified foods and exposing themselves to some sunlight are essential for maintaining a healthy vitamin D status. However, some groups might need dietary supplements to meet their vitamin D requirements. The following groups are among those most likely to have inadequate vitamin D status.  
仅从天然（非强化）食物来源获得足够的维生素 D 是很困难的。对于许多人来说，食用维生素 D 强化食品并暴露在阳光下对于保持健康的维生素 D 状态至关重要。然而，一些群体可能需要膳食补充剂来满足他们的维生素 D 需求。以下群体是最有可能维生素 D 状态不足的人群。

### Breastfed infants 母乳喂养的婴儿

Consumption of human milk alone does not ordinarily enable infants to meet vitamin D requirements, because it provides less than 0.6 to 2.0 mcg/L (25 to 78 IU/L) \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1),[56](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en56),[57](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en57)\]. The vitamin D content of human milk is related to the mother’s vitamin D status; studies suggest that the breastmilk of mothers who take daily supplements containing at least 50 mcg (2,000 IU) vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> have higher levels of the nutrient \[[57](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en57),[58](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en58)\].  
仅食用母乳通常不能使婴儿满足维生素D需求，因为它提供的维生素D低于0.6-2.0μg/L（25-78IU/L）\[[1,56,57](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en56)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en57)母乳中的维生素 D 含量与母亲的维生素 D 状况有关;研究表明，每天服用至少含有 50 微克（2000 国际单位）维生素<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">D 3</sub> 的补充剂的母亲的母乳中营养物质含量更高 \[[57,58](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en57)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en58)

Although UVB exposure can produce vitamin D in infants, the American Academy of Pediatrics (AAP) advises parents to keep infants younger than 6 months out of direct sunlight, dress them in protective clothing and hats, and apply sunscreen on small areas of exposed skin when sun exposure is unavoidable \[[59](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en59)\]. The AAP recommends 10 mcg (400 IU)/day vitamin D supplements for exclusively and partially breastfed infants starting shortly after birth and lasting until they are weaned and consume at least 1,000 mL/day vitamin D-fortified formula or whole milk \[[57](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en57)\]. The AAP also recommends 10 mcg (400 IU)/day supplemental vitamin D for all infants who are not breastfed and ingest less than 1,000 mL/day vitamin D-fortified formula or milk. An analysis of NHANES 2009–2016 data found that only 20.5% of breastfed infants and 31.1% of infants who were not breastfed ingested these recommended amounts of supplements \[[60](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en60)\].  
虽然 UVB 暴露可在婴儿体内产生维生素 D，但美国儿科学会（American Academy of Pediatrics， AAP）建议父母让 6 月龄以下的婴儿避免阳光直射，给他们穿上防护服和帽子，并在不可避免地暴露在阳光下的小面积皮肤上涂抹防晒霜\[[59](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en59)\]。AAP 建议纯母乳喂养和部分母乳喂养的婴儿在出生后不久开始补充 10 微克（400 IU）/天的维生素 D 补充剂，一直持续到断奶，并每天至少摄入 1,000 毫升维生素 D 强化配方奶粉或全脂牛奶 \[[57](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en57)\]。AAP 还建议所有非母乳喂养且摄入量低于 1,000 毫升/天的维生素 D 强化配方奶粉或牛奶的婴儿每天补充 10 微克（400 国际单位）维生素 D。对NHANES 2009-2016数据的分析发现，只有20.5%的母乳喂养婴儿和31.1%的非母乳喂养婴儿摄入了这些推荐量的补充剂\[[60](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en60)\]。

### Older adults 老年人

Older adults are at increased risk of developing vitamin D insufficiency, partly because the skin’s ability to synthesize vitamin D declines with age \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1),[61](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en61)\]. In addition, older adults are likely to spend more time than younger people indoors, and they might have inadequate dietary intakes of the vitamin \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\].  
老年人患维生素 D 不足的风险增加，部分原因是皮肤合成维生素 D 的能力随着年龄的增长而下降 \[[1,61](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en61)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)此外，老年人可能比年轻人在室内花费更多的时间，并且他们的维生素摄入量可能不足 \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。

### People with limited sun exposure 日晒受限的人

Homebound individuals; people who wear long robes, dresses, or head coverings for religious reasons; and people with occupations that limit sun exposure are among the groups that are unlikely to obtain adequate amounts of vitamin D from sunlight \[[62](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en62)\]. The use of sunscreen also limits vitamin D synthesis from sunlight. However, because the extent and frequency of sunscreen use are unknown, the role that sunscreen may play in reducing vitamin D synthesis is unclear \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\].  
无家可归的人;出于宗教原因穿着长袍、连衣裙或头巾的人;从事限制阳光照射的职业的人属于不太可能从阳光中获得足够维生素 D 的群体 \[[62](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en62)\]。使用防晒霜还会限制阳光下维生素 D 的合成。然而，由于防晒霜的使用范围和频率尚不清楚，因此防晒霜在减少维生素 D 合成方面可能发挥的作用尚不清楚 \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。

### People with dark skin 皮肤黝黑的人

Greater amounts of the pigment melanin in the epidermal layer of the skin result in darker skin and reduce the skin’s ability to produce vitamin D from sunlight \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]. Black Americans, for example, typically have lower serum 25(OH)D levels than White Americans. However, whether these lower levels in persons with dark skin have significant health consequences is not clear \[[14](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en14)\]. Those of African American ancestry, for example, have lower rates of bone fracture and osteoporosis than do Whites (see the section below on bone health and osteoporosis).  
皮肤表皮层中大量的黑色素会导致皮肤变黑，并降低皮肤从阳光中产生维生素 D 的能力 \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。例如，美国黑人的血清 25（OH）D 水平通常低于美国白人。然而，尚不清楚深色皮肤人群的这些较低水平是否会对健康产生重大影响 \[[14](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en14)\]。例如，非裔美国人的骨折和骨质疏松症的发生率低于白人（见下文关于骨骼健康和骨质疏松症的部分）。

### People with conditions that limit fat absorption 患有限制脂肪吸收的疾病的人

Because vitamin D is fat soluble, its absorption depends on the gut’s ability to absorb dietary fat \[[4](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en4)\]. Fat malabsorption is associated with medical conditions that include some forms of liver disease, cystic fibrosis, celiac disease, Crohn’s disease, and ulcerative colitis \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1),[63](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en63)\]. In addition to having an increased risk of vitamin D deficiency, people with these conditions might not eat certain foods, such as dairy products (many of which are fortified with vitamin D), or eat only small amounts of these foods. Individuals who have difficulty absorbing dietary fat might therefore require vitamin D supplementation \[[63](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en63)\].  
因为维生素 D 是脂溶性的，所以它的吸收取决于肠道吸收膳食脂肪的能力 \[[4](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en4)\]。脂肪吸收不良与某些形式的肝病、囊性纤维化、乳糜泻、克罗恩病和溃疡性结肠炎等疾病有关\[[1,63](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en63)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)除了增加维生素 D 缺乏症的风险外，患有这些疾病的人可能不吃某些食物，例如乳制品（其中许多富含维生素 D），或者只吃少量这些食物。因此，难以吸收膳食脂肪的个体可能需要补充维生素 D \[[63](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en63)\]。

### People with obesity or who have undergone gastric bypass surgery 肥胖症患者或接受过胃旁路手术的人

Individuals with a body mass index (BMI) of 30 or more have lower serum 25(OH)D levels than individuals without obesity. Obesity does not affect the skin’s capacity to synthesize vitamin D. However, greater amounts of subcutaneous fat sequester more of the vitamin \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]. People with obesity might need greater intakes of vitamin D to achieve 25(OH)D levels similar to those of people with normal weight \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1),[64](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en64),[65](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en65)\].  
体重指数 （BMI） 为 30 或以上的个体的血清 25（OH）D 水平低于没有肥胖的个体。肥胖不会影响皮肤合成维生素 D 的能力。然而，更多的皮下脂肪会螯合更多的维生素 \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。肥胖者可能需要更多的维生素 D 摄入量才能达到与正常体重者相似的 25（OH）D 水平 \[[1,64,65](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en64)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en65)

Individuals with obesity who have undergone gastric bypass surgery can also become vitamin D deficient. In this procedure, part of the upper small intestine, where vitamin D is absorbed, is bypassed, and vitamin D that is mobilized into the bloodstream from fat stores might not raise 25(OH)D to adequate levels over time \[[66](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en66),[67](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en67)\]. Various expert groups—including the American Association of Metabolic and Bariatric Surgery, The Obesity Society, and the British Obesity and Metabolic Surgery Society—have developed guidelines on vitamin D screening, monitoring, and replacement before and after bariatric surgery \[[66](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en66),[68](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en68)\]  
接受过胃旁路手术的肥胖症患者也可能缺乏维生素 D。在此过程中，吸收维生素 D 的部分上小肠被绕过，并且随着时间的推移，从脂肪储存中动员到血液中的维生素 D 可能无法将 25（OH）D 升高到足够的水平 \[[66,67](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en66)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en67)包括美国代谢与减重外科协会（American Association of Metabolic and Bariatric Surgery）、肥胖学会（The Obesity Society）和英国肥胖与代谢外科学会（British Obesity and Metabolic Surgery Society）在内的多个专家组已经制定了减重手术前后维生素D筛查、监测和补充维生素D的指南\[[66,68](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en66)\][](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en68)

## Vitamin D and Health 维生素 D 与健康

The FNB committee that established DRIs for vitamin D found that the evidence was inadequate or too contradictory to conclude that the vitamin had any effect on a long list of potential health outcomes (e.g., on resistance to chronic diseases or functional measures), except for measures related to bone health. Similarly, in a review of data from nearly 250 studies published between 2009 and 2013, the Agency for Healthcare Research and Quality concluded that no relationship could be firmly established between vitamin D and health outcomes other than bone health \[[69](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en69)\]. However, because research has been conducted on vitamin D and numerous health outcomes, this section focuses on seven diseases, conditions, and interventions in which vitamin D might be involved: bone health and osteoporosis, cancer, cardiovascular disease (CVD), depression, multiple sclerosis (MS), type 2 diabetes, and weight loss.  
建立维生素 D DRI 的 FNB 委员会发现，证据不足或过于矛盾，无法得出结论，除了与骨骼健康相关的措施外，维生素对一长串潜在的健康结果（例如，对慢性病的抵抗力或功能指标）有任何影响。同样，在对 2009 年至 2013 年间发表的近 250 项研究数据的回顾中，医疗保健研究和质量局得出结论，维生素 D 与骨骼健康以外的健康结局之间没有明确的关系\[[69](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en69)\]。然而，由于已经对维生素 D 和许多健康结果进行了研究，本节重点介绍维生素 D 可能涉及的七种疾病、病症和干预措施：骨骼健康和骨质疏松症、癌症、心血管疾病 （CVD）、抑郁症、多发性硬化症 （MS）、2 型糖尿病和体重减轻。

Most of the studies described in this section measured serum 25(OH)D levels using various methods that were not standardized by comparing them to the best methods. Use of unstandardized 25(OH)D measures can raise questions about the accuracy of the results and about the validity of conclusions drawn from studies that use such measures and, especially, from meta-analyses that pool data from many studies that use different unstandardized measures \[[5](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en5),[9](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en9),[70](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en70)\]. More information about assay standardization is available from the [Vitamin D Standardization Program](https://ods.od.nih.gov/Research/VitaminD.aspx#vdsp) webpage.  
本节中描述的大多数研究使用各种方法测量血清 25（OH）D 水平，这些方法未通过将它们与最佳方法进行比较来标准化。使用非标准化的25（OH）D指标可能会引发对结果准确性以及从使用此类指标的研究中得出的结论的有效性的质疑，尤其是从meta分析中得出的结论是否有效，这些meta分析汇集了许多使用不同非标准化指标的研究的数据\[[5,9,70](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en9)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en70)[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en5)有关检测标准化的更多信息，请访问[维生素 D 标准化计划](https://ods.od.nih.gov/Research/VitaminD.aspx#vdsp)网页。

### Bone health and osteoporosis 骨骼健康和骨质疏松症

Bone is constantly being remodeled. However, as people age—and particularly in women during menopause—bone breakdown rates overtake rates of bone building. Over time, bone density can decline, and osteoporosis can eventually develop \[[71](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en71)\].  
骨骼不断被重塑。然而，随着年龄的增长，尤其是更年期的女性，骨骼分解率超过了骨骼构建率。随着时间的推移，骨密度会下降，最终会发展为骨质疏松症\[[71](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en71)\]。

More than 53 million adults in the United States have or are at risk of developing osteoporosis, which is characterized by low bone mass and structural deterioration of bone tissue that increases bone fragility and the risk of bone fractures \[[72](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en72)\]. About 2.3 million osteoporotic fractures occurred in the United States in 2015 \[[73](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en73)\]. Osteoporosis is, in part, a long-term effect of calcium and/or vitamin D insufficiency, in contrast to rickets and osteomalacia, which result from vitamin D deficiency. Osteoporosis is most often associated with inadequate calcium intakes, but insufficient vitamin D intakes contribute to osteoporosis by reducing calcium absorption \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\].  
在美国，超过 5300 万成人患有骨质疏松症或有发生骨质疏松症的风险，骨质疏松症的特征是骨量低和骨组织结构恶化，从而增加骨脆性和骨折风险 \[[72](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en72)\]。2015年，美国约有230万例骨质疏松性骨折\[[73](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en73)\]。骨质疏松症在一定程度上是钙和/或维生素 D 缺乏的长期影响，与维生素 D 缺乏引起的佝偻病和骨软化症相反。骨质疏松症最常与钙摄入不足有关，但维生素 D 摄入不足会减少钙吸收，从而导致骨质疏松症 \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。

Bone health also depends on support from the surrounding muscles to assist with balance and postural sway and thereby reduce the risk of falling. Vitamin D is also needed for the normal development and growth of muscle fibers. In addition, inadequate vitamin D levels can adversely affect muscle strength and lead to muscle weakness and pain (myopathy) \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\].  
骨骼健康还依赖于周围肌肉的支持，以帮助保持平衡和姿势摇摆，从而降低跌倒的风险。维生素 D 也是肌肉纤维正常发育和生长所必需的。此外，维生素 D 水平不足会对肌肉力量产生不利影响，并导致肌肉无力和疼痛（肌病）\[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。

Most trials of the effects of vitamin D supplements on bone health also included calcium supplements, so isolating the effects of each nutrient is difficult. In addition, studies provided different amounts of nutrients and used different dosing schedules.  
大多数关于维生素 D 补充剂对骨骼健康影响的试验还包括钙补充剂，因此很难分离每种营养素的影响。此外，研究提供了不同数量的营养物质，并使用了不同的给药方案。

#### Clinical trial evidence on older adults  
老年人的临床试验证据

Among postmenopausal women and older men, many clinical trials have shown that supplements of both vitamin D and calcium result in small increases in bone mineral density throughout the skeleton \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1),[74](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en74)\]. They also help reduce fracture rates in institutionalized older people. However, the evidence on the impact of vitamin D and calcium supplements on fractures in community-dwelling individuals is inconsistent.  
在绝经后女性和老年男性中，许多临床试验表明，维生素 D 和钙补充剂可导致整个骨骼的骨密度略有增加 \[[1,74](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en74)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)它们还有助于降低机构化老年人的骨折率。然而，关于维生素 D 和钙补充剂对社区居民个体骨折影响的证据并不一致。

The USPSTF evaluated 11 randomized clinical trials of vitamin D and/or calcium supplementation in a total of 51,419 healthy, community-dwelling adults age 50 years and older who did not have osteoporosis, vitamin D deficiency, or prior fractures \[[75](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en75),[76](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en76)\]. It concluded that the current evidence was insufficient to evaluate the benefits and harms of supplementation to prevent fractures. In addition, the USPSTF recommended against supplementation with 10 mcg (400 IU) or less of vitamin D and 1,000 mg or less of calcium to prevent fractures in this population, but it could not determine the balance of benefits and harms from higher doses.  
USPSTF 评估了 11 项补充维生素 D 和/或钙的随机临床试验，共纳入 51,419 例年龄在 50 岁及以上、无骨质疏松症、维生素 D 缺乏或既往骨折的健康社区居民成人\[[75,76](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en75)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en76)研究得出的结论是，目前的证据不足以评估补充剂预防骨折的益处和危害。此外，USPSTF 建议不要补充 10 微克（400 国际单位）或更少的维生素 D 和 1,000 毫克或更少的钙来预防该人群的骨折，但它无法确定更高剂量的益处和危害的平衡。

The USPSTF also reviewed the seven published studies on the effects of vitamin D supplementation (two of them also included calcium supplementation) on the risk of falls in community-dwelling adults age 65 years or older who did not have osteoporosis or vitamin D deficiency. It concluded with moderate certainty that vitamin D supplementation does not reduce the numbers of falls or injuries, such as fractures, resulting from falls \[[77](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en77),[78](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en78)\]. Another recent systematic review also found that vitamin D and calcium supplements had no beneficial effects on fractures, falls, or bone mineral density \[[79](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en79),[80](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en80)\]. In contrast, a meta-analysis of six trials in 49,282 older adults found that daily vitamin D (10 or 20 mcg \[400 IU or 800 IU\]/day) and calcium (800 or 1,200 mg/day) supplementation for a mean of 5.9 years reduced the risk of any fracture by 6% and of hip fracture by 16% \[[81](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en81)\].  
USPSTF 还审查了已发表的七项关于维生素 D 补充剂（其中两项还包括钙补充剂）对 65 岁或以上没有骨质疏松症或维生素 D 缺乏症的社区居民跌倒风险影响的研究。该研究得出中等质量的结论，补充维生素D不会减少跌倒或受伤（如骨折）的数量\[[77,78](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en78)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en77)最近的另一项系统评价也发现，维生素 D 和钙补充剂对骨折、跌倒或骨密度没有有益影响 \[[79,80](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en79)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en80)相比之下，一项meta分析纳入了6项试验，共49,282例老年人，发现每日补充维生素D（10或20μg\[400IU或800 IU\]/d）和钙（800或1,200mg/d），平均5.9年，骨折风险降低6%，髋部骨折风险降低16%\[[81](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en81)\]。

One systematic review and meta-analysis of 11 randomized, controlled trials published through 2018 of vitamin D supplementation alone (10–20 mcg \[400–800 IU\]/day or more at least every week or as rarely as once a year) for 9 months to 5 years found that the supplements provided no protection from fractures in 34,243 older adults \[[81](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en81)\].  
一项系统评价和荟萃分析纳入了 2018 年发表的 11 项随机对照试验，这些试验涉及单独补充维生素 D（10-20 微克 \[400-800 IU\]/天或更多，至少每周一次或每年一次），持续 9 个月至 5 年，发现补充剂对 34,243 名老年人的骨折没有保护作用 \[[81](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en81)\]。

More recently, a 2022 ancillary study of the Vitamin D and Omega-3 Trial (VITAL; described in the Cancer section below) investigated whether supplemental vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> (50 mcg \[2,000 IU\]/day) would lower the risk of fractures in 25,871 generally healthy men age 50 years and older and women age 55 years and older over a median follow-up of 5.3 years \[[82](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en82)\]. The mean age of all participants was 67.1 years; 50.6% were women and 20.2% were Black. Most participants were vitamin D sufficient; at baseline, only 2.4% had serum 25(OH)D levels less than 30 nmol/L (12 ng/mL), and 12.9% less than 50 nmol/L (20 ng/mL). Vitamin D supplementation did not lower the risk of total fractures, hip fractures, or nonvertebral fractures as compared with placebo. No substantial between-group differences in fracture incidence were found by race, ethnic group, BMI, age, baseline 25(OH)D levels, or whether participants took supplemental calcium, were at high fracture risk, or had a history of fragility fractures.  
最近，2022 年一项关于维生素 D 和 Omega-3 试验（VITAL;见下文癌症部分）的辅助研究调查了补充维生素<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">D 3</sub>（50 mcg \[2,000 IU\]/天）是否会降低 25,871 名 50 岁及以上的一般健康男性和 55 岁及以上女性的骨折风险，中位随访时间为 5.3 年\[[82](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en82)\].所有参与者的平均年龄为 67.1 岁;50.6% 是女性，20.2% 是黑人。大多数参与者维生素 D 充足;基线时，只有 2.4% 的患者血清 25 （OH）D 水平低于 30 nmol/L （12 ng/mL），12.9% 的患者血清 25 （OH）D 水平低于 50 nmol/L （20 ng/mL）。与安慰剂相比，维生素 D 补充剂并未降低全骨折、髋部骨折或非椎体骨折的风险。在种族、族群、BMI、年龄、基线 25（OH）D 水平或参与者是否服用补充钙、骨折风险高或有脆性骨折病史方面，未发现骨折发生率的组间显著差异。

#### Vitamin D supplements for bone health in minority populations  
维生素 D 补充剂促进少数族裔的骨骼健康

Bone mineral density, bone mass, and fracture risk are correlated with serum 25(OH)D levels in White Americans and Mexican Americans, but not in Black Americans \[[14](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en14),[83](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en83)\]. Factors such as adiposity, skin pigmentation, vitamin D binding protein polymorphisms, and genetics contribute to differences in 25(OH)D levels between Black and White Americans.  
美国白人和墨西哥裔美国人的骨密度、骨量和骨折风险与血清25（OH）D水平相关，但在美国黑人中则不相关\[[14,83](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en14)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en83)肥胖、皮肤色素沉着、维生素 D 结合蛋白多态性和遗传学等因素导致美国黑人和白人之间 25（OH）D 水平的差异。

One clinical trial randomized 260 Black women age 60 years and older (mean age 68.2 years) to receive 60 to 120 mcg (2,400 to 4,800 IU) per day vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> supplementation to maintain serum 25(OH)D levels above 75 nmol/L (30 ng/mL) for 3 years \[[84](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en84)\]. The results showed no association between 25(OH)D levels or vitamin D dose and the risk of falling in the 184 participants who completed the study. In fact, Black Americans might have a greater risk than White Americans of falls and fractures with daily vitamin D intakes of 50 mcg (2,000 IU) or more \[[14](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en14)\]. Furthermore, the bone health of older Black American women does not appear to benefit from raising serum 25(OH)D levels beyond 50 nmol/L (20 ng/mL) \[[84](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en84)\].  
一项临床试验将260例年龄≥60岁（平均年龄68.2岁）的黑人女性随机分配，每天补充60-120μg（2,400-4,800IU）维生素<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">D3</sub>，以维持血清25（OH）D水平高于75 nmol/L（30ng/mL），持续3年\[[84](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en84)\]。结果显示，25（OH）D 水平或维生素 D 剂量与完成研究的 184 名参与者跌倒的风险之间没有关联。事实上，每日维生素 D 摄入量为 50 μg（2000 IU）或更多时，美国黑人比美国白人更容易跌倒和骨折\[[14](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en14)\]。此外，将血清 25（OH）D 水平提高到 50 nmol/L （20 ng/mL） 以上似乎对老年美国黑人女性的骨骼健康没有益处 \[[84](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en84)\]。

#### Vitamin D supplements and muscle function  
维生素 D 补充剂和肌肉功能

Studies examining the effects of supplemental vitamin D on muscle strength and on rate of decline in muscle function have had inconsistent results \[[55](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en55)\]. One recent clinical trial, for example, randomized 78 frail and near-frail adults age 65 years and older to receive 20 mcg (800 IU) vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub>, 10 mcg 25(OH)D, or placebo daily for 6 months. The groups showed no significant differences in measures of muscle strength or performance \[[85](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en85)\]. Another study randomized 100 community-dwelling men and women age 60 years and older (most were White) with serum 25(OH)D levels of 50 nmol/L (20 ng/ml) or less to 800 IU vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> or placebo for 1 year \[[86](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en86)\]. Participants in the treatment group whose serum 25(OH)D level was less than 70 nmol/L (28 ng/ml) after 4 months received an additional 800 IU/day vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub>. Despite increasing serum 25(OH)D levels to an average of more than 80 nmol/L (32 ng/ml), vitamin D supplementation did not affect lower-extremity power, strength, or lean mass.  
研究研究维生素 D 补充剂对肌肉力量和肌肉功能下降速度的影响，结果不一致 \[[55](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en55)\]。例如，最近的一项临床试验将 78 名 65 岁及以上的虚弱和接近虚弱的成年人随机分配，每天接受 20 微克（800 国际单位）维生素<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">D 3</sub>、10 微克 25（OH）D 或安慰剂，持续 6 个月。两组在肌肉力量或性能的测量方面没有显著差异\[[85](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en85)\]。另一项研究将100例血清25（OH）D水平为50nmol/L（20ng/ml）或更低的60岁及以上的社区男性和女性（大多数为白人）随机分配至800 IU维生素<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">D3</sub>组或安慰剂组，为期1年\[[86](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en86)\]。4 个月后血清 25（OH）D 水平低于 70 nmol/L （28 ng/ml） 的治疗组参与者额外接受了 800 IU/天的维生素 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub>。尽管血清 25（OH）D 水平增加到平均 80 nmol/L （32 ng/ml） 以上，但维生素 D 补充剂并不影响下肢力量、力量或瘦体重。

#### Conclusions about vitamin D supplements and bone health  
关于维生素 D 补充剂和骨骼健康的结论

All adults should consume recommended amounts of vitamin D and calcium from foods and supplements if needed. Older women and men should consult their health care providers about their needs for both nutrients as part of an overall plan to maintain bone health and to prevent or treat osteoporosis.  
如果需要，所有成年人都应从食物和补充剂中摄入推荐量的维生素 D 和钙。老年女性和男性应咨询他们的医疗保健提供者，了解他们对这两种营养素的需求，作为维持骨骼健康和预防或治疗骨质疏松症的整体计划的一部分。

### Cancer 癌症

Laboratory and animal studies suggest that vitamin D might inhibit carcinogenesis and slow tumor progression by, for example, promoting cell differentiation and inhibiting metastasis. Vitamin D might also have anti-inflammatory, immunomodulatory, proapoptotic, and antiangiogenic effects \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1),[87](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en87)\]. Observational studies and clinical trials provide mixed evidence on whether vitamin D intakes or serum levels affect cancer incidence, progression, or mortality risk.  
实验室和动物研究表明，维生素 D 可能通过促进细胞分化和抑制转移等方式抑制癌变和减缓肿瘤进展。维生素 D 还可能具有抗炎、免疫调节、促凋亡和抗血管生成作用 \[[1,87](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en87)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)观察性研究和临床试验提供了关于维生素 D 摄入量或血清水平是否影响癌症发病率、进展或死亡风险的混合证据。

#### Total cancer incidence and mortality  
癌症总发病率和死亡率

Some observational studies show associations between low serum levels of 25(OH)D and increased risks of cancer incidence and death. In a meta-analysis of 16 prospective cohort studies in a total of 137,567 participants who had 8,345 diagnoses of cancer, 5,755 participants died from cancer \[[88](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en88)\]. A 50 nmol/L (20 ng/mL) increase in 25(OH)D levels was associated with an 11% reduction in total cancer incidence rates and, in women but not men, a 24% reduction in cancer mortality rates. A meta-analysis of prospective studies that evaluated the association between serum 25(OH)D levels and cancer incidence (8 studies) or cancer mortality (16 studies) found that cancer risk decreased by 7% and cancer mortality rates decreased by 2% with each 20 nmol/L (8 ng/mL) increase in serum 25(OH)D levels \[[89](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en89)\]. Importantly, not all observational studies found higher vitamin D status to be beneficial, and the studies varied considerably in study populations, baseline comorbidities, and measurement of vitamin D levels.  
一些观察性研究表明，血清 25（OH）D 水平低与癌症发病率和死亡风险增加之间存在关联。一项meta分析纳入了16项前瞻性队列研究，共137,567例参与者，其中8,345例诊断为癌症，其中5,755例参与者死于癌症\[[88](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en88)\]。25（OH）D 水平增加 50 nmol/L （20 ng/mL） 与癌症总发病率降低 11% 相关，女性但男性与癌症死亡率降低 24% 相关。一项前瞻性研究的meta分析评估了血清25（OH）D水平与癌症发病率（8项研究）或癌症死亡率（16项研究）之间的关联，发现血清25（OH）D水平每增加20 nmol/L（8 ng/mL），癌症风险降低7%，癌症死亡率降低2%\[[89](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en89)\]。重要的是，并非所有观察性研究都发现较高的维生素 D 水平是有益的，并且这些研究在研究人群、基线合并症和维生素 D 水平测量方面差异很大。

Clinical trial evidence provides some support for the observational findings. For example, three meta-analyses of clinical trial evidence found that vitamin D supplementation does not affect cancer incidence but does significantly reduce total cancer mortality rates by 12%–13% \[[90-92](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en90)\]. In the most recent meta-analysis, 10 randomized clinical trials (including the VITAL trial described below) that included 6,537 cancer cases provided 10 to 50 mcg (400 to 2,000 IU) vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> daily (six trials) or 500 mcg (20,000 IU)/week to 12,500 mcg (500,000 IU)/year boluses of vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> (four trials) \[[91](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en91)\]. The study reports included 3–10 years of follow-up data. The vitamin D supplements were associated with serum 25(OH)D levels of 54 to 135 nmol/L (21.6 to 54 ng/mL). Vitamin D supplementation reduced cancer mortality rates by 13%, and most of the benefit occurred with daily supplementation.  
临床试验证据为观察结果提供了一些支持。例如，三项临床试验证据的荟萃分析发现，补充维生素D不会影响癌症发病率，但确实可将癌症总死亡率显著降低12%-13%\[[90-92](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en90)\]。在最近的meta分析中，10项随机临床试验（包括下文描述的VITAL试验）提供了10-50μg（400-2000 IU）维生素<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">D 3</sub>/d（6项试验）或500μg（20,000 IU）/周至12,500μg（500,000 IU）维生素D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub>推注（4项试验）\[[91](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en91)\]。研究报告包括 3-10 年的随访数据。维生素 D 补充剂与 54 至 135 nmol/L （21.6 至 54 ng/mL） 的血清 25（OH）D 水平相关。补充维生素 D 可将癌症死亡率降低 13%，大部分益处来自每日补充。

The VITAL clinical trial that investigated the effects of vitamin D supplementation on the primary prevention of cancer in the general population gave 50 mcg (2,000 IU)/day vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> supplements with or without 1,000 mg/day marine omega-3 fatty acids or a placebo for a median of 5.3 years \[[93](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en93)\]. The study included 25,871 men age 50 years and older and women age 55 years and older who had no history of cancer, and most had adequate serum 25(OH)D levels at baseline. Rates of breast, prostate, and colorectal cancer did not differ significantly between the vitamin D and placebo groups. However, normal-weight participants had greater reductions in cancer incidence and mortality rates than those with overweight or obesity.  
一项VITAL临床试验调查了维生素D补充剂对普通人群癌症一级预防的影响，给予维生素<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">D3</sub>补充剂50μg（2,000IU）/d，联合或不联合1,000mg/d海洋ω-3脂肪酸或安慰剂，中位时间为5.3年\[[93](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en93)\]。该研究包括 25,871 名 50 岁及以上的男性和 55 岁及以上的女性，他们没有癌症病史，并且大多数人在基线时血清 25（OH）D 水平足够。维生素 D 组和安慰剂组之间的乳腺癌、前列腺癌和结直肠癌发病率没有显著差异。然而，与超重或肥胖的参与者相比，正常体重参与者的癌症发病率和死亡率降低幅度更大。

The Women’s Health Initiative (WHI) clinical trial randomized 36,282 postmenopausal women to receive 10 mcg (400 IU) vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> plus 1,000 mg calcium daily or a placebo for a mean of 7 years \[[94](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en94)\]. Results showed no effect of supplemental vitamin D and calcium on cancer incidence or mortality during the 7-year trial. Similarly, the supplements did not affect cancer incidence over a long-term median follow-up of 22.3 years, but they did reduce cancer mortality by 7% over this period of time \[[95](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en95)\].  
女性健康倡议（Women's Health Initiative， WHI）临床试验将36,282例绝经后女性随机分配至每日10μg（400IU）维生素<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">D3</sub>加1,000mg钙或安慰剂组，平均持续7年\[[94](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en94)\]。结果显示，在 7 年的试验中，补充维生素 D 和钙对癌症发病率或死亡率没有影响。同样，在中位随访 22.3 年期间，补充剂不会影响癌症发病率，但它们确实在此期间将癌症死亡率降低了 7% \[[95](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en95)\]。

A few studies have examined the effect of vitamin D supplementation on specific cancers. Below are brief descriptions of studies of vitamin D and its association with, or effect on, breast, colorectal, lung, pancreatic, and prostate cancers.  
一些研究检查了维生素 D 补充剂对特定癌症的影响。以下是维生素 D 研究及其与乳腺癌、结直肠癌、肺癌、胰腺癌和前列腺癌的相关性或影响的简要说明。

#### Breast cancer 乳腺癌

Some observational studies support an inverse association between 25(OH)D levels and breast cancer risk and mortality, but others do not \[[96-99](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en96)\]. In the WHI clinical trial described above, vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> and calcium supplements did not reduce breast cancer incidence, and 25(OH)D levels at the start of the study were not associated with breast cancer risk \[[100](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en100)\].  
一些观察性研究支持 25（OH）D 水平与乳腺癌风险和死亡率呈负相关，但其他研究则不支持 \[[96-99](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en96)\]。在上述 WHI 临床试验中，维生素 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> 和钙补充剂并没有降低乳腺癌的发病率，研究开始时的 25（OH）D 水平与乳腺癌风险无关 \[[100](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en100)\]。

In a subsequent investigation for 4.9 years after the study’s end, women who had taken the vitamin D and calcium supplements (many of whom continued to take them) had an 18% lower risk of in situ (noninvasive) breast cancer \[[101](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en101)\]. However, women with vitamin D intakes higher than 15 mcg (600 IU)/day at the start of the trial and who received the supplements experienced a 28% increased risk of invasive (but not in situ) breast cancer.  
在研究结束后 4.9 年的后续调查中，服用维生素 D 和钙补充剂的女性（其中许多人继续服用）患原位（非浸润性）乳腺癌的风险降低了 18% \[[101](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en101)\]。然而，在试验开始时维生素 D 摄入量高于 15 微克（600 IU）/天且接受补充剂的女性患浸润性（但不是原位）乳腺癌的风险增加了 28%。

#### Colorectal cancer 结直肠癌

A large case-control study included 5,706 individuals who developed colorectal cancer and whose 25(OH)D levels were assessed a median of 5.5 years from blood draw to cancer diagnosis and 7,105 matched controls \[[102](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en102)\]. The results showed an association between 25(OH)D levels lower than 30 nmol/L (12 ng/mL) and a 31% higher colorectal cancer risk. Levels of 75 to less than 87.5 nmol/L (30 to less than 35 ng/mL) and 87.5 to less than 100 nmol/L (35 to less than 40 ng/mL) were associated with a 19% and 27% lower risk, respectively. The association was substantially stronger in women.  
一项大型病例对照研究纳入了 5,706 例发生结直肠癌的个体，评估其 25（OH）D 水平从抽血到诊断为癌症的中位时间为 5.5 年，其中 7,105 例匹配的对照 \[[102](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en102)\]。结果显示，25（OH）D 水平低于 30 nmol/L （12 ng/mL） 与结直肠癌风险增加 31% 之间存在关联。75 至低于 87.5 nmol/L（30 至低于 35 ng/mL）和 87.5 至低于 100 nmol/L（35 至低于 40 ng/mL）的水平分别与风险降低 19% 和 27% 相关。女性的关联要强得多。

In the WHI clinical trial described above, vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> and calcium supplements had no effect on rates of colorectal cancer \[[103](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en103)\]. In a subsequent investigation for 4.9 years after the study’s end, women who had taken the vitamin D and calcium supplements (many of whom continued to take them) still had the same colorectal cancer risk as those who received placebo \[[101](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en101)\].  
在上述 WHI 临床试验中，维生素 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> 和钙补充剂对结直肠癌的发病率没有影响 \[[103](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en103)\]。在研究结束后 4.9 年的后续调查中，服用维生素 D 和钙补充剂的女性（其中许多人继续服用）仍然与接受安慰剂的女性具有相同的结直肠癌风险 \[[101](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en101)\]。

Another study included 2,259 healthy individuals age 45 to 75 years who had had one or more serrated polyps (precursor lesions to colorectal cancer) that had been removed \[[104](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en104)\]. These participants were randomized to take 25 mcg (1,000 IU) vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub>, 1,200 mg calcium, both supplements, or a placebo daily for 3–5 years, followed by an additional 3–5 years of observation after participants stopped the treatment. Vitamin D alone did not significantly affect the development of new serrated polyps, but the combination of vitamin D with calcium increased the risk almost fourfold. The VITAL trial found no association between vitamin D supplementation and the risk of colorectal adenomas or serrated polyps \[[105](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en105)\].  
另一项研究纳入了2,259例年龄在45-75岁之间的健康个体，这些个体曾有一个或多个锯齿状息肉（结直肠癌的前兆病变）被切除\[[104](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en104)\]。这些参与者被随机分配每天服用 25 微克（1,000 IU）维生素 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub>、1,200 毫克钙、两种补充剂或安慰剂，持续 3-5 年，然后在参与者停止治疗后再观察 3-5 年。单独使用维生素 D 对新锯齿状息肉的发育没有显着影响，但维生素 D 与钙的组合使风险增加了近四倍。VITAL 试验发现维生素 D 补充剂与结直肠腺瘤或锯齿状息肉的风险之间没有关联 \[[105](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en105)\]。

#### Lung cancer 肺癌

A study of cohorts that included 5,313 participants who developed lung cancer and 5,313 matched controls found no association between serum 25(OH)D levels and risk of subsequent lung cancer, even when the investigators analyzed the data by sex, age, race and ethnicity, and smoking status \[[106](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en106)\].  
一项纳入 5,313 例肺癌患者和 5,313 例匹配对照组的队列研究发现，血清 25（OH）D 水平与后续肺癌风险之间没有关联，即使研究人员按性别、年龄、种族和民族以及吸烟状况分析数据也是如此 \[[106](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en106)\]。

#### Pancreatic cancer 胰腺癌

One study comparing 738 men who developed pancreatic cancer to 738 matched controls found no relationship between serum 25(OH)D levels and risk of pancreatic cancer \[[107](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en107)\]. Another study that compared 200 male smokers in Finland with pancreatic cancer to 400 matched controls found that participants in the highest quintile of 25(OH)D levels (more than 65.5 nmol/L \[26.2 ng/mL\]) had a threefold greater risk of developing pancreatic cancer over 16.7 years than those in the lowest quintile (less than 32 nmol/L \[12.8 ng/mL\]) \[[108](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en108)\]. An investigation that pooled data from 10 studies of cancer in 12,205 men and women found that concentrations of 25(OH)D greater than 75 nmol/L (30 ng/mL) but less than 100 nmol/L (40 ng/mL) did not reduce the risk of pancreatic cancer. However, the results did show an increased risk of pancreatic cancer with 25(OH)D levels of 100 nmol/L (40 ng/mL) or above \[[109](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en109)\].  
一项研究将 738 例胰腺癌男性与 738 例匹配的对照组进行了比较，发现血清 25（OH）D 水平与胰腺癌风险之间没有关系 \[[107](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en107)\]。另一项研究将芬兰 200 名患有胰腺癌的男性吸烟者与 400 名匹配的对照组进行了比较，发现 25（OH）D 水平最高五分位数（超过 65.5 nmol/L \[26.2 ng/mL\]）的参与者在 16.7 年内患胰腺癌的风险是最低五分位数（低于 32 nmol/L \[12.8 ng/mL\]）的 3 倍\[[108](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en108)\]\].一项汇总了 10 名男性和女性的 12,205 项癌症研究数据的研究发现，25（OH）D 浓度大于 75 nmol/L （30 ng/mL） 但低于 100 nmol/L （40 ng/mL） 并不能降低患胰腺癌的风险。然而，结果确实显示，当 25（OH）D 水平为 100 nmol/L （40 ng/mL） 或更高时，患胰腺癌的风险会增加 \[[109](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en109)\]。

#### Prostate cancer 前列腺癌

Research to date provides mixed evidence on whether levels of 25(OH)D are associated with the development of prostate cancer. Several studies published in 2014 suggested that high levels of 25(OH)D might increase the risk of prostate cancer. For example, a meta-analysis of 21 studies that included 11,941 men with prostate cancer and 13,870 controls found a 17% higher risk of prostate cancer for participants with higher levels of 25(OH)D \[[110](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en110)\]. What constituted a higher level varied by study but was typically at least 75 nmol/L (30 ng/mL). In a cohort of 4,733 men, of which 1,731 had prostate cancer, those with 25(OH)D levels of 45–70 nmol/L (18–28 ng/mL) had a significantly lower risk of the disease than men with either lower or higher values \[[111](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en111)\]. This U-shaped association was most pronounced for men with the most aggressive forms of prostate cancer. A case-control analysis of 1,695 cases of prostate cancer and 1,682 controls found no associations between 25(OH)D levels and prostate cancer risk \[[112](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en112)\]. However, higher serum 25(OH)D levels (at a cut point of 75 nmol/L \[30 ng/mL\]) were linked to a modestly higher risk of slow-growth prostate cancer and a more substantial lower risk of aggressive disease.  
迄今为止的研究提供了关于 25（OH）D 水平是否与前列腺癌发展相关的混合证据。2014 年发表的几项研究表明，高水平的 25（OH）D 可能会增加患前列腺癌的风险。例如，一项对 21 项研究（包括 11,941 名男性前列腺癌患者和 13,870 名对照组）的荟萃分析发现，25（OH）D 水平较高的参与者患前列腺癌的风险高出 17% \[[110](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en110)\]。构成较高水平的水平因研究而异，但通常至少为 75 nmol/L （30 ng/mL）。在4,733名男性的队列中，其中1,731名患有前列腺癌，25（OH）D水平为45-70 nmol/L（18-28 ng/mL）的男性患前列腺癌的风险显著低于较低或较高的男性\[[111](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en111)\]。这种 U 形关联在患有最具侵袭性前列腺癌的男性中最为明显。一项对 1,695 例前列腺癌和 1,682 例对照的病例对照分析发现，25（OH）D 水平与前列腺癌风险之间没有关联 \[[112](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en112)\]。然而，较高的血清 25（OH）D 水平（在 75 nmol/L \[30 ng/mL\] 的临界点）与缓慢生长的前列腺癌风险适度升高和侵袭性疾病风险的显著降低有关。

Since 2014, however, several published studies and meta-analyses have found no relationship between 25(OH)D levels and prostate cancer risk \[[113](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en113),[114](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en114)\]. For example, an analysis was conducted of 19 prospective studies that provided data on prediagnostic levels of 25(OH)D for 13,462 men who developed prostate cancer and 20,261 control participants \[[115](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en115)\]. Vitamin D deficiency or insufficiency did not increase the risk of prostate cancer, and higher 25(OH)D concentrations were not associated with a lower risk.  
然而，自 2014 年以来，一些已发表的研究和荟萃分析发现 25（OH）D 水平与前列腺癌风险之间没有关系 \[[113,114](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en113)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en114)例如，对 19 项前瞻性研究进行了分析，这些研究提供了 13,462 名前列腺癌男性和 20,261 名对照组参与者的诊断前 25（OH）D 水平数据 \[[115](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en115)\]。维生素 D 缺乏或不足不会增加患前列腺癌的风险，较高的 25（OH）D 浓度与较低的风险无关。

Several studies have examined whether levels of 25(OH)D in men with prostate cancer are associated with a lower risk of death from the disease or from any cause. One study included 1,119 men treated for prostate cancer whose plasma 25(OH)D levels were measured 4.9 to 8.6 years after their diagnosis. Among the 198 participants who died (41 deaths were due to prostate cancer), 25(OH)D levels were not associated with risk of death from prostate cancer or any cause \[[116](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en116)\]. However, a meta-analysis of seven cohort studies that included 7,808 men with prostate cancer found higher 25(OH)D levels to be significantly associated with lower mortality rates from prostate cancer or any other cause \[[117](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en117)\]. A dose-response analysis found that each 20 nmol/L \[8 ng/mL\] increase in 25(OH)D was associated with a 9% lower risk of both all-cause and prostate cancer-specific mortality.  
几项研究检查了前列腺癌男性患者的 25（OH）D 水平是否与较低的疾病或任何原因死亡风险有关。一项研究包括 1,119 名接受前列腺癌治疗的男性，他们在诊断后 4.9 至 8.6 年测量了血浆 25（OH）D 水平。在 198 名死亡参与者中（41 名死于前列腺癌），25（OH）D 水平与前列腺癌或任何原因的死亡风险无关 \[[116](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en116)\]。然而，一项meta分析纳入了7项队列研究（共7,808例前列腺癌患者），发现25（OH）D水平较高与前列腺癌或任何其他原因死亡率较低显著相关\[[117](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en117)\]。剂量反应分析发现，25（OH）D 每增加 20 nmol/L \[8 ng/mL\] 与全因和前列腺癌特异性死亡风险降低 9% 相关。

For men with prostate cancer, whether vitamin D supplementation lengthens cancer-related survival is not clear. A meta-analysis of three randomized controlled trials in 1,273 men with prostate cancer found no significant differences in total mortality rates between those receiving vitamin D supplementation (from 10 mcg \[400 IU\]/day for 28 days to 45 mcg \[1,800 IU\] given in three doses total at 2-week intervals) and those receiving a placebo \[[118](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en118)\].  
对于患有前列腺癌的男性，维生素 D 补充剂是否能延长癌症相关生存期尚不清楚。一篇meta分析纳入了3项随机对照试验，共纳入1,273例前列腺癌患者，发现维生素D补充剂组（从10μg（400IU）/d，持续28日到45μg（1,800 IU）分3次给药，间隔2周）与安慰剂组的总死亡率无显著差异\[[118](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en118)\]。

#### Conclusions about vitamin D and cancer  
关于维生素 D 与癌症的结论

The USPSTF stated that, due to insufficient evidence, it was unable to assess the balance of benefits and harms of supplemental vitamin D to prevent cancer \[[119](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en119)\]. Taken together, studies to date do not indicate that vitamin D with or without calcium supplementation reduces the incidence of cancer, but adequate or higher 25(OH)D levels might reduce cancer mortality rates. Further research is needed to determine whether vitamin D inadequacy increases cancer risk, whether greater exposure to the nutrient can prevent cancer, and whether some individuals could have an increased risk of cancer because of their vitamin D status over time.  
USPSTF 表示，由于证据不足，它无法评估补充维生素 D 预防癌症的益处和危害的平衡 \[[119](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en119)\]。综上所述，迄今为止的研究并未表明维生素 D 加或不加钙可降低癌症发病率，但足够或更高的 25（OH）D 水平可能会降低癌症死亡率。需要进一步的研究来确定维生素 D 不足是否会增加癌症风险，更多地接触这种营养素是否可以预防癌症，以及随着时间的推移，某些人是否会因为他们的维生素 D 状况而增加患癌症的风险。

### Cardiovascular disease 心血管疾病

Vitamin D helps regulate the renin-angiotensin-aldosterone system (and thereby blood pressure), vascular cell growth, and inflammatory and fibrotic pathways \[[120](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en120)\]. Vitamin D deficiency is associated with vascular dysfunction, arterial stiffening, left ventricular hypertrophy, and hyperlipidemia \[[121](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en121)\]. For these reasons, vitamin D has been linked to heart health and risk of CVD.  
维生素 D 有助于调节肾素-血管紧张素-醛固酮系统（从而调节血压）、血管细胞生长以及炎症和纤维化途径 \[[120](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en120)\]。维生素 D 缺乏与血管功能障碍、动脉硬化、左心室肥大和高脂血症有关\[[121](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en121)\]。由于这些原因，维生素 D 与心脏健康和 CVD 风险有关。

Observational studies support an association between higher serum 25(OH)D levels and a lower risk of CVD incidence and mortality. For example, a meta-analysis included 34 observational studies that followed 180,667 participants (mean age greater than 50 years) for 1.3 to more than 32 years. The results showed that baseline serum 25(OH)D levels were inversely associated with total number of CVD events (including myocardial infarction, ischemic heart disease, heart failure, and stroke) and mortality risk \[[122](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en122)\]. Overall, the risk of CVD events was 10% lower for each 25 nmol/L (10 ng/mL) increase in serum 25(OH)D.  
观察性研究支持较高的血清 25（OH）D 水平与较低的 CVD 发病率和死亡率风险之间存在关联。例如，一项荟萃分析包括 34 项观察性研究，对 180,667 名参与者（平均年龄大于 50 岁）进行了 1.3 至 32 年的随访。结果显示，基线血清 25（OH）D 水平与 CVD 事件总数（包括心肌梗死、缺血性心脏病、心力衰竭和中风）和死亡风险呈负相关 \[[122](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en122)\]。总体而言，血清 25 （OH）D 每增加 25 nmol/L （10 ng/mL），CVD 事件的风险降低 10%。

Another large observational study that followed 247,574 adults from Denmark for 0–7 years found that levels of 25(OH)D that were low (about 12.5 nmol/L \[5 ng/mL\]) and high (about 125 nmol/L \[50 ng/mL\]) were associated with a greater risk of mortality from CVD, stroke, and acute myocardial infarction \[[123](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en123)\]. Other meta-analyses of prospective studies have found associations between lower vitamin D status measured by serum 25(OH)D levels or vitamin D intakes and an increased risk of ischemic stroke, ischemic heart disease, myocardial infarction, and early death \[[124](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en124),[125](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en125)\].  
另一项对丹麦 247,574 名成年人进行了 0-7 年随访的大型观察性研究发现，25（OH）D 水平为低（约 12.5 nmol/L \[5 ng/mL\]）和高（约 125 nmol/L \[50 ng/mL\]）与 CVD、中风和急性心肌梗死的死亡风险增加相关 \[[123](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en123)\]。其他前瞻性研究的荟萃分析发现，通过血清 25（OH）D 水平或维生素 D 摄入量测量的维生素 D 状态较低与缺血性卒中、缺血性心脏病、心肌梗死和早期死亡风险增加之间存在关联 \[[124,125](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en124)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en125)

In contrast to the observational studies, clinical trials have provided little support for the hypothesis that supplemental vitamin D reduces the risk of CVD or CVD mortality. For example, a 3-year trial in New Zealand randomized 5,110 adults (mean age 65.9 years) to a single dose of 5,000 mcg (200,000 IU) vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> followed by 2,500 mcg (100,000 IU) each month or a placebo for a median of 3.3 years \[[126](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en126)\]. Vitamin D supplementation had no effect on the incidence rate of myocardial infarction, angina, heart failure, arrhythmia, arteriosclerosis, stroke, venous thrombosis, or death from CVD. Similarly, the VITAL clinical trial described above found that vitamin D supplements did not significantly decrease rates of heart attacks, strokes, coronary revascularization, or deaths from cardiovascular causes \[[93](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en93)\]. Moreover, the effects did not vary by baseline serum 25(OH)D levels or whether participants took the trial’s omega-3 supplement in addition to vitamin D.  
与观察性研究相比，临床试验对补充维生素 D 可降低 CVD 或 CVD 死亡风险的假设几乎没有提供支持。例如，新西兰一项为期3年的研究将5,110例成人（平均年龄65.9岁）随机分配至单剂5,000μg（200,000 IU）维生素<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">D3</sub>组，然后每月2,500μg（100,000 IU）或安慰剂组，中位时间为3.3年\[[126](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en126)\]。维生素 D 补充剂对心肌梗死、心绞痛、心力衰竭、心律失常、动脉硬化、中风、静脉血栓形成或 CVD 死亡的发生率没有影响。同样，上述 VITAL 临床试验发现，维生素 D 补充剂并未显著降低心脏病发作、中风、冠状动脉血运重建或心血管原因导致的死亡率 \[[93](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en93)\]。此外，效果不会因基线血清 25（OH）D 水平或参与者是否除维生素 D 外服用试验的 omega-3 补充剂而变化。

However, another clinical trial designed to investigate bone fracture risk found that 20 mcg (800 IU)/day vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> (with or without calcium) or a placebo in 5,292 adults age 70 years and older for a median of 6.2 years offered protection from cardiac failure, but not myocardial infarction or stroke \[[127](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en127)\]. In the WHI clinical trial described above, daily supplementation with 10 mcg (400 IU) vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> and 1,000 mg calcium did not affect cardiovascular disease risk during the 7-year trial \[[128](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en128)\] or during a long-term median follow-up of 22.3 years \[[95](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en95)\]. However, during this long-term follow-up period, women who received the supplements had a 6% higher risk of death from cardiovascular disease than those who received placebo \[[95](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en95)\].   
然而，另一项旨在调查骨折风险的临床试验发现，在5,292例70岁及以上的成人中，每天服用20μg（800IU）维生素<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">D3</sub>（含钙或不含钙）或安慰剂，中位年龄为6.2年，可预防心力衰竭，但不能预防心肌梗死或脑卒中\[[127](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en127)\]。在上述WHI临床试验中，在为期7年的试验中\[[128](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en128)\]或长期中位随访22.3年期间，每天补充10μg（400IU）维生素<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">D3</sub>和1000mg钙并不影响心血管疾病风险\[[95](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en95)\]。然而，在长期随访期间，接受补充剂的女性死于心血管疾病的风险比接受安慰剂的女性高 6% \[[95](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en95)\]。

High serum cholesterol levels and hypertension are two of the main risk factors for CVD. The data on supplemental vitamin D and cholesterol levels are mixed, as shown in one meta-analysis of 41 clinical trials in a total of 3,434 participants (mean age 55 years). The results of this analysis showed that 0.5 mcg (20 IU) to 214 mcg (8,570 IU)/day vitamin D supplementation (mean of 2,795 IU) for 6 weeks to 3 years reduced serum total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels, but not high-density lipoprotein cholesterol levels \[[129](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en129)\].  
高血清胆固醇水平和高血压是 CVD 的两个主要危险因素。补充维生素 D 和胆固醇水平的数据喜忧参半，正如一项对总共 3,434 名参与者（平均年龄 55 岁）的 41 项临床试验的荟萃分析所示。该分析结果显示，补充维生素D0.5μg（20IU）至214μg（8,570 IU）/天（平均值2,795 IU），持续6周至3年，可降低血清总胆固醇、低密度脂蛋白胆固醇和甘油三酯水平，但不能降低高密度脂蛋白胆固醇水平\[[129](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en129)\]。

Studies of the effects of vitamin D supplements on hypertension have also had mixed findings. In one meta-analysis of 46 clinical trials that included 4,541 participants, vitamin D supplements (typically 40 mcg \[1,600 IU\]/day or less) for a minimum of 4 weeks had no significant effects on systolic or diastolic blood pressure \[[130](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en130)\]. In contrast, another meta-analysis of 30 clinical trials in 4,744 participants (mean age 54.5 years) that administered 5 mcg (200 IU) to 300 mcg (12,000 IU)/day vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> for a mean of 5.6 months showed that more than 20 mcg (800 IU)/day significantly reduced systolic and diastolic blood pressure in normal-weight participants who had hypertension \[[131](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en131)\]. However, more than 20 mcg (800 IU)/day vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub>, when taken with calcium supplements, significantly increased blood pressure in participants with overweight and obesity. Another meta-analysis of genetic studies in 146,581 participants (primarily adults) found that a low vitamin D status increased blood pressure and hypertension risk in people with genetic variants associated with low endogenous production of 25(OH)D \[[132](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en132)\].  
关于维生素 D 补充剂对高血压影响的研究也有好坏参半的结果。一项meta分析纳入了46项临床试验，共4,541例参与者，结果显示，维生素D补充剂（通常为40μg（1,600IU）或更少）至少4周对收缩压或舒张压没有显著影响\[[130](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en130)\]。相比之下，另一项meta分析纳入了30项临床试验，涉及4,744名参与者（平均年龄54.5岁），这些试验每天给予5μg（200 IU）至300 μg（12,000 IU）维生素<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">D3</sub>，平均持续5.6个月，结果显示，超过20 μg（800 IU）/d可显著降低正常体重高血压参与者的收缩压和舒张压\[[131](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en131)\]。然而，当与钙补充剂一起服用时，超过 20 微克（800 IU）/天的维生素 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> 会显著增加超重和肥胖参与者的血压。另一项针对146,581名参与者（主要是成人）的遗传研究的荟萃分析发现，与25（OH）D内源性产生量低相关的遗传变异人群，低维生素D状态会增加血压和高血压风险\[[132](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en132)\]。

Overall, clinical trials show that vitamin D supplementation does not reduce CVD risk, even for people with low 25(OH)D status (below 20 nmol/L \[12 ng/mL\]) at baseline \[[93](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en93),[126](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en126)\].  
总体而言，临床试验表明，补充维生素 D 并不能降低 CVD 风险，即使对于基线时 25（OH）D 状态较低（低于 20 nmol/L \[12 ng/mL\]）的人也是如此 \[[93,126](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en126)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en93)

### Depression 抑郁症

Vitamin D is involved in various brain processes, and vitamin D receptors are present on neurons and glia in areas of the brain thought to be involved in the pathophysiology of depression \[[133](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en133)\].  
维生素 D 参与各种大脑过程，维生素 D 受体存在于被认为与抑郁症病理生理学有关的大脑区域的神经元和神经胶质细胞上 \[[133](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en133)\]。

A systematic review and meta-analysis of 14 observational studies that included a total of 31,424 adults (mean age ranging from 27.5 to 77 years) found an association between deficient or low levels of 25(OH)D and depression \[[133](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en133)\].  
一项系统评价和meta分析纳入了14项观察性研究，共纳入31,424例成人（平均年龄为27.5-77岁），发现25（OH）D水平缺乏或偏低与抑郁之间存在关联\[[133](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en133)\]。

Clinical trials, however, do not support these findings. For example, a meta-analysis of nine trials with a total of 4,923 adult participants diagnosed with depression or depressive symptoms found no significant reduction in symptoms after supplementation with vitamin D \[[134](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en134)\]. The trials administered different amounts of vitamin D (ranging from 10 mcg \[400 IU\]/day to 1,000 mcg \[40,000 IU\]/week). They also had different study durations (5 days to 5 years), mean participant ages (range, 22 years to 75 years), and baseline 25(OH)D levels; furthermore, some but not all studies administered concurrent antidepressant medications.  
然而，临床试验并不支持这些发现。例如，一项对9项试验的荟萃分析，共涉及4923名被诊断患有抑郁或抑郁症状的成年参与者，发现补充维生素D后症状没有显著减轻\[[134](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en134)\]。这些试验给予了不同量的维生素D（从10微克\[400 IU\]/天到1,000微克\[40,000 IU\]/周不等）。他们的研究持续时间 （5 天至 5 年） 、平均参与者年龄 （范围，22 岁至 75 岁） 和基线 25（OH）D 水平也不同;此外，一些但不是全部研究同时使用抗抑郁药物。

Three trials conducted since that meta-analysis also found no effect of vitamin D supplementation on depressive symptoms. One trial included 206 adults (mean age 52 years) who were randomized to take a bolus dose of 2,500 mcg (100,000 IU) vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> followed by 500 mcg (20,000 IU)/week or a placebo for 4 months \[[135](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en135)\]. Most participants had minimal or mild depression, had a low mean baseline 25(OH) level of 33.8 nmol/L (13.5 ng/mL), and were not taking antidepressants. The second trial included 155 adults age 60–80 years who had clinically relevant depressive symptoms, no major depressive disorder, and serum 25(OH)D levels less than 50 to 70 nmol/L (20 to 28 ng/mL) depending on the season; in addition, they were not taking antidepressants \[[136](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en136),[137](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en137)\]. Participants were randomized to take either 30 mcg (1,200 IU)/day vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> or a placebo for 1 year. In the VITAL trial described above, 16,657 men and women 50 years of age and older with no history of depression and 1,696 with an increased risk of recurrent depression (that had not been medically treated for the past 2 years) were randomized to take 50 mcg (2,000 IU)/day vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> (with or without fish oil) or a placebo for a median of 5.3 years \[[138](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en138)\]. The groups showed no significant differences in the incidence and recurrent rates of depression, clinically relevant depressive symptoms, or changes in mood scores.  
自该荟萃分析以来进行的三项试验也发现维生素 D 补充剂对抑郁症状没有影响。一项试验纳入了206例成人患者（平均年龄52岁），他们被随机分配至推注剂量2,500μg（100,000IU）维生素<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">D3</sub>，然后每周500μg（20,000IU）或安慰剂组，持续4个月\[[135](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en135)\]。大多数参与者有轻微或轻度抑郁，平均基线 25（OH） 水平较低，为 33.8 nmol/L （13.5 ng/mL），并且没有服用抗抑郁药。第二项试验包括 155 名年龄在 60-80 岁之间的成年人，他们有临床相关的抑郁症状，没有重度抑郁症，血清 25（OH）D 水平低于 50 至 70 nmol/L（20 至 28 ng/mL），具体取决于季节;此外，他们没有服用抗抑郁药\[[136,137](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en136)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en137)参与者被随机分配服用 30 微克（1,200 IU）/天的维生素 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> 或安慰剂，持续 1 年。在上述VITAL试验中，16,657例年龄在50岁及以上且无抑郁病史的男性和女性，以及1,696例复发性抑郁风险增加的男性和女性（在过去2年内未接受药物治疗），随机分配至每天服用50μg（2,000 IU）维生素D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub>（含或不含鱼油）或安慰剂组，中位时间为5.3年\[[138](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en138)\].各组在抑郁症的发生率和复发率、临床相关抑郁症状或情绪评分变化方面没有显著差异。

Overall, clinical trials did not find that vitamin D supplements helped prevent or treat depressive symptoms or mild depression, especially in middle-age to older adults who were not taking prescription antidepressants. No studies have evaluated whether vitamin D supplements may benefit individuals under medical care for clinical depression who have low or deficient 25(OH)D levels and are taking antidepressant medication.  
总体而言，临床试验没有发现维生素 D 补充剂有助于预防或治疗抑郁症状或轻度抑郁症，尤其是在未服用处方抗抑郁药的中老年人中。没有研究评估维生素 D 补充剂是否有益于接受 25（OH）D 水平低或缺乏且正在服用抗抑郁药物的临床抑郁症患者。

### Multiple sclerosis 多发性硬化症

MS is an autoimmune disease of the central nervous system that damages the myelin sheath surrounding and protecting nerve cells in the brain and spinal cord. This damage hinders or blocks messages between the brain and body, leading to clinical features, such as vision loss, motor weakness, spasticity, ataxia, tremor, sensory loss, and cognitive impairment \[[139](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en139),[140](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en140)\]. Some people with MS eventually lose the ability to write, speak, or walk.  
MS 是一种中枢神经系统的自身免疫性疾病，会损害围绕和保护大脑和脊髓神经细胞的髓鞘。这种损伤会阻碍或阻断大脑和身体之间的信息，导致临床特征，如视力丧失、运动无力、痉挛状态、共济失调、震颤、感觉丧失和认知障碍\[[139,140](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en139)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en140)一些 MS 患者最终会失去书写、说话或走路的能力。

The geographical distribution of MS around the world is unequal. Few people near the equator develop the disease, whereas the prevalence is higher further north and south. This uneven distribution has led to speculation that lower vitamin D levels in people who have less sunlight exposure might predispose them to the disease \[[140](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en140)\].  
MS 在世界各地的地理分布是不平等的。赤道附近很少有人患上这种疾病，而北部和南部的患病率更高。这种不均匀的分布导致人们猜测，阳光照射较少的人的维生素 D 水平较低可能会使他们易患这种疾病 \[[140](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en140)\]。

Many epidemiological and genetic studies have shown an association between MS and low 25(OH)D levels before and after the disease begins \[[140](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en140)\]. Observational studies suggest that adequate vitamin D levels might reduce the risk of contracting MS and, once MS is present, decrease the risk of relapse and slow the disease’s progression \[[141](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en141)\]. One study, for example, tested 25(OH)D levels in 1,092 women in Finland an average of 9 years before their MS diagnosis and compared their outcomes with those of 2,123 similar women who did not develop MS \[[142](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en142)\]. More than half the women who developed MS had deficient or insufficient vitamin D levels. Women with 25(OH)D levels of less than 30 nmol/L (12 ng/mL) had a 43% higher MS risk than women with levels of 50 nmol/L (20 ng/mL) or higher. Among the women with two or more serum 25(OH)D samples taken before diagnosis (which reduced random measurement variation), a 50 nmol/L increase in 25(OH)D was associated with a 41% reduced risk of MS, and 25(OH)D levels less than 30 nmol/L were associated with an MS risk that was twice as high as levels of 50 nmol/L or higher.  
许多流行病学和遗传学研究表明，MS 与疾病开始前后的低 25（OH）D 水平之间存在关联 \[[140](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en140)\]。观察性研究表明，充足的维生素 D 水平可能会降低感染 MS 的风险，一旦出现 MS，可以降低复发风险并减缓疾病进展 \[[141](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en141)\]。例如，一项研究在芬兰 1,092 例女性诊断 MS 前平均 9 年检测了 25（OH）D 水平，并将她们的结局与 2,123 例未发生 MS 的类似女性的结果进行了比较 \[[142](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en142)\]。超过一半的 MS 女性维生素 D 水平不足或不足。25（OH）D 水平低于 30 nmol/L （12 ng/mL） 的女性比 20 nmol/L （20 ng/mL） 或更高的女性的 MS 风险高 43%。在诊断前采集了两个或两个以上血清 25（OH）D 样本的女性中（这减少了随机测量变异），25（OH）D 增加 50 nmol/L 与 MS 风险降低 41% 相关，低于 30 nmol/L 的 25（OH）D 水平与 MS 风险相关，是 50 nmol/L 水平或更高水平的两倍。

Two earlier prospective studies of similar design—one in the United States with 444 non-Hispanic White individuals \[[143](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en143)\] and the other with 576 individuals in northern Sweden \[[144](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en144)\]—found that levels of 25(OH)D greater than 99.1 nmol/L (39.6 ng/mL) and at least 75 nmol/L (30 ng/mL), respectively, were associated with a 61%–62% lower risk of MS.  
两项早期的类似设计的前瞻性研究——一项在美国，有444名非西班牙裔白人\[[143](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en143)\]，另一项在瑞典北部有576名\[[144](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en144)\]——发现，25（OH）D水平分别大于99.1 nmol/L （39.6 ng/mL）和至少75 nmol/L （30 ng/mL），与MS风险降低61%-62%相关。

No clinical trials have examined whether vitamin D supplementation can prevent the onset of MS, but several have investigated whether supplemental vitamin D can help manage the disease. A 2018 Cochrane Review analyzed 12 such trials that had a total of 933 participants with MS; the reviewers judged all of these trials to be of low quality \[[140](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en140)\]. Overall, vitamin D supplementation, when compared with placebo administration, had no effect on relevant clinical outcomes, such as recurrent relapse or worsened disability.  
没有临床试验检查补充维生素 D 是否可以预防 MS 的发作，但有几项试验调查了补充维生素 D 是否有助于控制这种疾病。2018 年的 Cochrane 综述分析了 12 项此类试验，共涉及 933 名 MS 参与者;评价员认为所有这些试验的质量都较低\[[140](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en140)\]。总体而言，与安慰剂给药相比，维生素 D 补充剂对相关临床结局没有影响，例如复发或残疾恶化。

Experts have reached no firm consensus on whether vitamin D can help prevent MS given the lack of clinical trial evidence \[[145](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en145)\]. In addition, studies have not consistently shown that vitamin D supplementation tempers the signs and symptoms of active MS or reduces rates of relapse.  
鉴于缺乏临床试验证据，专家们尚未就维生素 D 是否有助于预防 MS 达成明确的共识 \[[145](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en145)\]。此外，研究并未一致表明维生素 D 补充剂可以缓解活动性 MS 的体征和症状或降低复发率。

### Type 2 diabetes 2 型糖尿病

Vitamin D plays a role in glucose metabolism. It stimulates insulin secretion via the vitamin D receptor on pancreatic beta cells and reduces peripheral insulin resistance through vitamin D receptors in the muscles and liver \[[146](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en146)\]. Vitamin D might be involved in the pathophysiology of type 2 diabetes through its effects on glucose metabolism and insulin signaling as well as its ability to reduce inflammation and improve pancreatic beta-cell function \[[147](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en147),[148](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en148)\].  
维生素 D 在葡萄糖代谢中发挥作用。它通过胰腺β细胞上的维生素D受体刺激胰岛素分泌，并通过肌肉和肝脏中的维生素D受体降低外周胰岛素抵抗\[[146](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en146)\]。维生素 D 可能通过其对葡萄糖代谢和胰岛素信号传导的影响以及减轻炎症和改善胰腺 β 细胞功能的能力参与 2 型糖尿病的病理生理学 \[[147,148](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en147)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en148)

Observational studies have linked lower serum 25(OH)D levels to an increased risk of diabetes, but their results might have been confounded by the fact that many participants were overweight or had obesity and were therefore more predisposed to developing diabetes and having lower 25(OH)D levels \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]. A review of 71 observational studies in adults with and without type 2 diabetes from 16 countries found a significant inverse relationship between vitamin D status and blood sugar levels in participants who did and did not have diabetes \[[149](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en149)\].  
观察性研究将较低的血清 25（OH）D 水平与糖尿病风险增加联系起来，但他们的结果可能被许多参与者超重或肥胖的事实所混淆，因此更容易患糖尿病和 25（OH）D 水平较低 \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。一项回顾性研究纳入了来自 16 个国家的 71 项针对 2 型糖尿病成人和非 2 型糖尿病患者的观察性研究，发现患有糖尿病和未患有糖尿病的参与者的维生素 D 状况与血糖水平呈显著负相关 \[[149](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en149)\]。

In contrast to observational studies, clinical trials provide little support for the benefits of vitamin D supplementation for glucose homeostasis. One trial included 65 adult men and women (mean age 32 years) with overweight or obesity who were otherwise healthy, did not have diabetes, and had low serum vitamin D levels (at or below 50 nmol/L \[20 ng/mL\]) \[[150](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en150)\]. The investigators randomly assigned participants to receive either a bolus oral dose of 2,500 mcg (100,000 IU) vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> followed by 100 mcg (4,000 IU)/day or a placebo for 16 weeks. In the 54 participants who completed the study, vitamin D supplementation did not improve insulin sensitivity or insulin secretion in comparison with placebo.  
与观察性研究相比，临床试验对维生素 D 补充剂对葡萄糖稳态的益处几乎没有提供支持。一项试验纳入了65例超重或肥胖的成年男性和女性（平均年龄32岁），这些患者其他方面健康，没有糖尿病，血清维生素D水平较低（等于或低于50nmol/L\[20ng/mL\]）\[[150](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en150)\]。研究人员随机分配参与者接受 2,500 微克（100,000 IU）维生素<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">D 3</sub> 的推注口服剂量，然后每天 100 微克（4,000 IU）或安慰剂，持续 16 周。在完成研究的 54 名参与者中，与安慰剂相比，维生素 D 补充剂并没有改善胰岛素敏感性或胰岛素分泌。

One systematic review and meta-analysis evaluated 35 clinical trials that included 43,407 adults with normal glucose tolerance, prediabetes, or type 2 diabetes who received a median of 83 mcg (3,332 IU)/day vitamin D supplements or placebo for a median of 16 weeks \[[151](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en151)\]. Vitamin D had no significant effects on glucose homeostasis, insulin secretion or resistance, or hemoglobin A1c levels (a measure of average blood sugar levels over the previous 2–3 months), irrespective of the study population, vitamin D dose, or trial quality.  
一项系统评价和meta分析评估了35项临床试验，纳入了43,407例糖耐量正常、糖尿病前期或2型糖尿病的成人患者，这些患者接受维生素D补充剂的中位剂量为83μg（3,332IU）或安慰剂，中位治疗时间为16周\[[151](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en151)\]。维生素 D 对葡萄糖稳态、胰岛素分泌或抵抗或血红蛋白 A1c 水平（衡量过去 2-3 个月平均血糖水平的指标）没有显着影响，无论研究人群、维生素 D 剂量或试验质量如何。

Several trials have investigated whether vitamin D supplementation can prevent the transition from prediabetes to diabetes in patients with adequate 25(OH)D levels, and all have had negative results. In a trial in Norway, 511 men and women age 25–80 years (mean age 62 years) with prediabetes received 500 mcg (20,000 IU) vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> or a placebo each week for 5 years \[[152](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en152)\]. The results showed no significant differences in rates of progression to type 2 diabetes; in serum glucose, insulin, or hemoglobin A1c levels; or in measures of insulin resistance. At baseline, participants had an adequate mean serum 25(OH)D level of 60 nmol/L (24 ng/mL).  
几项试验调查了维生素 D 补充剂是否可以防止 25（OH）D 水平充足的患者从糖尿病前期过渡到糖尿病，但均得出阴性结果。在挪威的一项试验中，511 名年龄在 25-80 岁（平均年龄 62 岁）之间的糖尿病前期男性和女性每周接受 500 微克（20,000 IU）维生素<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">D 3</sub> 或安慰剂，持续 5 年\[[152](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en152)\]。结果显示，进展为 2 型糖尿病的比率没有显著差异;血清葡萄糖、胰岛素或血红蛋白 A1c 水平;或胰岛素抵抗的测量。基线时，参与者的血清 25（OH）D 平均水平为 60 nmol/L （24 ng/mL）。

The largest trial to date of vitamin D supplements for diabetes prevention randomized 2,423 men and women age 25 years and older (mean age 60 years) with prediabetes and overweight or obesity (mean BMI of 32.1) to 100 mcg (4,000 IU)/day vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> or placebo for a median of 2.5 years \[[148](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en148)\]. Most participants (78%) had adequate serum levels of vitamin D at baseline (at least 50 nmol/L \[20 ng/mL\]). Vitamin D did not significantly prevent the development of diabetes in comparison with placebo. However, a post hoc analysis showed a 62% lower incidence of diabetes among participants with low baseline serum 25(OH)D levels (less than 30 nmol/L \[12 ng/mL\]) who took the vitamin D supplement than among those who took the placebo \[[148](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en148),[153](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en153)\].  
迄今为止，最大规模的关于维生素D补充剂用于糖尿病预防的试验将2,423例年龄≥25岁（平均年龄60岁）的糖尿病前期和肥胖患者（平均BMI为32.1）随机分配至维生素D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub>组/日（4,000IU）或安慰剂组，中位治疗时间为2.5年\[[148](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en148)\]。大多数参与者 （78%） 在基线时血清维生素 D 水平充足（至少 50 nmol/L \[20 ng/mL\]）。与安慰剂相比，维生素 D 没有显着预防糖尿病的发展。然而，一项事后分析显示，服用维生素 D 补充剂的基线血清 25（OH）D 水平低（低于 30 nmol/L \[12 ng/mL\]）的参与者患糖尿病的几率比服用安慰剂的参与者低 62% \[[148,153](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en148)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en153)

Studies have also assessed the value of vitamin D supplementation for managing diabetes, and they have found that the vitamin offers limited benefits. One meta-analysis of 20 clinical trials compared the effects of 0.5 mcg (20 IU)/day to 1,250 mcg (50,000 IU)/week vitamin D supplementation for 2–6 months with those of placebo on glycemic control in 2,703 adults from around the world who had diabetes \[[146](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en146)\]. The vitamin D reduced insulin resistance to a small but significant degree, especially in people taking more than 50 mcg (2,000 IU)/day who were vitamin D deficient at baseline, had good glycemic control, did not have obesity, and were of Middle Eastern ethnicity. However, the supplementation had no significant effects on fasting blood glucose, hemoglobin A1c, or fasting insulin levels.  
研究还评估了维生素 D 补充剂对控制糖尿病的价值，他们发现维生素的好处有限。一项针对 20 项临床试验的荟萃分析比较了每天补充 0.5 微克（20 国际单位）至 1,250 微克（50,000 国际单位）/周维生素 D 持续 2-6 个月与安慰剂对世界各地 2,703 名糖尿病成人患者的血糖控制的影响\[[146](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en146)\]。维生素 D 在较小但显着的程度上降低了胰岛素抵抗，尤其是在每天服用超过 50 微克（2,000 IU）的人群中，这些人基线时维生素 D 缺乏，血糖控制良好，没有肥胖，并且是中东人种。然而，补充剂对空腹血糖、血红蛋白 A1c 或空腹胰岛素水平没有显着影响。

Clinical trials to date provide little evidence that vitamin D supplementation helps maintain glucose homeostasis, reduces the risk of progression from prediabetes to type 2 diabetes, or helps manage the disease, particularly in vitamin D-replete individuals.  
迄今为止，临床试验几乎没有证据表明维生素 D 补充剂有助于维持葡萄糖稳态，降低从糖尿病前期发展为 2 型糖尿病的风险，或有助于控制疾病，尤其是在维生素 D 充足的个体中。

### Weight loss 减肥

Observational studies indicate that greater body weights are associated with lower vitamin D status, and individuals with obesity frequently have marginal or deficient circulating 25(OH)D levels \[[154](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en154)\]. However, clinical trials do not support a cause-and-effect relationship between vitamin D and weight loss.  
观察性研究表明，体重增加与维生素 D 水平降低有关，肥胖个体的循环 25（OH）D 水平通常处于边缘或不足 \[[154](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en154)\]。然而，临床试验不支持维生素 D 与减肥之间的因果关系。

A systematic review and meta-analysis of 15 weight-loss intervention studies that used caloric restriction, exercise, or both, but not necessarily vitamin D supplementation or other treatments, found that people who lost weight had significantly greater increases in serum 25(OH)D levels than those who maintained their weight \[[155](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en155)\]. In another study, 10 mcg (400 IU)/day vitamin D and 1,000 mg/day calcium supplementation slightly, but significantly, reduced weight gain amounts in comparison with placebo in postmenopausal women, especially those with a baseline total calcium intake of less than 1,200 mg/day \[[156](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en156)\]. However, a meta-analysis of 12 vitamin D supplementation trials (including 5 in which body composition measurements were primary outcomes) found that vitamin D supplements without calorie restriction did not affect body weight or fat mass when the results were compared with those of placebo \[[157](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en157)\].  
一项系统评价和meta分析纳入了15项使用热量限制、运动或两者兼而有之，但不一定补充维生素D或其他治疗的减肥干预研究，发现减重者血清25（OH）D水平增幅显著大于保持体重者\[[155](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en155)\]。另一项研究显示，与安慰剂相比，10μg（400IU）维生素D和1,000mg/d钙补充剂略微但显著地减少了绝经后女性的体重增加量，尤其是基线总钙摄入量低于1,200mg/d的女性\[[156](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en156)\]。然而，一篇meta分析纳入了12项维生素D补充剂试验（包括5项以体成分测量为主要结局）的研究发现，与安慰剂相比，无热量限制的维生素D补充剂不会影响体重或脂肪量\[[157](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en157)\]。

Overall, the available research suggests that consuming higher amounts of vitamin D or taking vitamin D supplements does not promote weight loss.  
总体而言，现有研究表明，摄入大量维生素 D 或服用维生素 D 补充剂不会促进体重减轻。

## Health Risks from Excessive Vitamin D 过量维生素 D 的健康风险

Excess amounts of vitamin D are toxic. Because vitamin D increases calcium absorption in the gastrointestinal tract, vitamin D toxicity results in marked hypercalcemia (total calcium greater than 11.1 mg/dL, beyond the normal range of 8.4 to 10.2 mg/dL), hypercalciuria, and high serum 25(OH)D levels (typically greater than 375 nmol/l \[150 ng/mL\]) \[[158](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en158)\]. Hypercalcemia, in turn, can lead to nausea, vomiting, muscle weakness, neuropsychiatric disturbances, pain, loss of appetite, dehydration, polyuria, excessive thirst, and kidney stones.  
过量的维生素 D 是有毒的。由于维生素D会增加胃肠道对钙的吸收，因此维生素D中毒会导致显著的高钙血症（总钙大于11.1mg/dL，超出8.4-10.2mg/dL的正常范围）、高钙尿症和血清25（OH）D水平升高（通常大于375nmol/L\[150ng/mL\]）\[[158](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en158)\]。反过来，高钙血症会导致恶心、呕吐、肌肉无力、神经精神障碍、疼痛、食欲不振、脱水、多尿、过度口渴和肾结石。

In extreme cases, vitamin D toxicity causes renal failure, calcification of soft tissues throughout the body (including in coronary vessels and heart valves), cardiac arrhythmias, and even death. Vitamin D toxicity has been caused by consumption of dietary supplements that contained excessive vitamin D amounts because of manufacturing errors, that were taken inappropriately or in excessive amounts, or that were incorrectly prescribed by physicians, \[[158-160](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en158)\].  
在极端情况下，维生素 D 中毒会导致肾功能衰竭、全身软组织钙化（包括冠状动脉和心脏瓣膜）、心律失常，甚至死亡。由于制造错误导致摄入维生素 D 过量的膳食补充剂、服用不当或过量或医生开具错误处方的膳食补充剂会导致维生素 D 中毒\[[158-160](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en158)\]。

Experts do not believe that excessive sun exposure results in vitamin D toxicity because thermal activation of previtamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> in the skin gives rise to various non-vitamin D forms that limit formation of vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub>. Some vitamin D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> is also converted to nonactive forms \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]. However, frequent use of tanning beds, which provide artificial UV radiation, can lead to 25(OH)D levels well above 375–500 nmol/L (150–200 ng/mL) \[[161-163](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en161)\].  
专家不认为过度暴露在阳光下会导致维生素 D 中毒，因为皮肤中维生素前 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> 的热激活会产生各种限制维生素 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> 形成的非维生素 D 形式。一些维生素 D<sub data-immersive-translate-walked="d4f917fe-34a1-45eb-958b-6623d5e3e251">3</sub> 也会转化为非活性形式 \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。然而，频繁使用提供人工紫外线辐射的日光浴床会导致 25（OH）D 水平远高于 375-500 nmol/L （150-200 ng/mL） \[[161-163](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en161)\]。

The combination of high intakes of calcium (about 2,100 mg/day from food and supplements) with moderate amounts of vitamin D (about 19 mcg \[765 IU\]/day from food and supplements) increased the risk of kidney stones by 17% over 7 years among 36,282 postmenopausal women who were randomly assigned to take 1,000 mg/day calcium and 10 mcg (400 IU)/day vitamin D or a placebo \[[164](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en164)\]. However, other, shorter (from 24 weeks to 5 years) clinical trials of vitamin D supplementation alone or with calcium in adults found greater risks of hypercalcemia and hypercalciuria, but not of kidney stones \[[165](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en165),[166](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en166)\].  
在36,282名绝经后妇女中，高摄入量的钙（约2,100毫克/天，从食物和补充剂中摄取）与适量的维生素D（约19微克\[765 IU\]）相结合，使36,282名绝经后妇女患肾结石的风险在7年内增加了17%，这些妇女被随机分配为每天服用1,000毫克钙和10微克（400 IU）维生素D或安慰剂\[[164](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en164)\].然而，其他较短（从24周至5年）的成人单独补充维生素D或与钙一起补充维生素D的临床试验发现，高钙血症和高钙尿症的风险更高，但肾结石的风险更高\[[165,166](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en165)\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en166)

The FNB established ULs for vitamin D in 2010 (Table 4) \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]. While acknowledging that signs and symptoms of toxicity are unlikely at daily intakes below 250 mcg (10,000 IU), the FNB noted that even vitamin D intakes lower than the ULs might have adverse health effects over time. The FNB recommended avoiding serum 25(OH)D levels above approximately 125–150 nmol/L (50–60 ng/mL), and it found that even lower serum levels (approximately 75–120 nmol/L \[30–48 ng/mL\]) are associated with increases in rates of all-cause mortality, risk of cancer at some sites (e.g., pancreas), risk of cardiovascular events, and number of falls and fractures among older adults.  
FNB 于 2010 年制定了维生素 D 的 UL （表 4） \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]。虽然承认每日摄入量低于 250 微克（10,000 IU）时不太可能出现毒性体征和症状，但 FNB 指出，即使维生素 D 摄入量低于 UL，随着时间的推移也可能对健康产生不利影响。FNB 建议避免血清 25（OH）D 水平高于约 125-150 nmol/L （50-60 ng/mL），它发现更低的血清水平（约 75-120 nmol/L \[30-48 ng/mL\]）与全因死亡率、某些部位（例如胰腺）癌症风险、心血管事件风险、 以及老年人跌倒和骨折的数量。

Table 4: Tolerable Upper Intake Levels (ULs) for Vitamin D \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]  
表 4：维生素 D 的可耐受摄入量上限 （UL） \[[1](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en1)\]
| Age 年龄 | Male 雄 | Female 女性 | Pregnancy 怀孕 | Lactation 哺乳 |
| --- | --- | --- | --- | --- |
| 0–6 months 0-6 个月 | 25 mcg (1,000 IU) 25 微克（1,000 国际单位） | 25 mcg (1,000 IU) 25 微克（1,000 国际单位） |  |  |
| 7–12 months 7-12 个月 | 38 mcg (1,500 IU) 38 微克（1500 国际单位） | 38 mcg (1,500 IU) 38 微克（1500 国际单位） |  |  |
| 1–3 years 1-3 岁 | 63 mcg (2,500 IU) 63 微克（2,500 国际单位） | 63 mcg (2,500 IU) 63 微克（2,500 国际单位） |  |  |
| 4–8 years 4-8 岁 | 75 mcg (3,000 IU) 75 微克（3,000 国际单位） | 75 mcg (3,000 IU) 75 微克（3,000 国际单位） |  |  |
| 9–18 years 9 - 18 岁 | 100 mcg (4,000 IU) 100 微克（4,000 国际单位） | 100 mcg (4,000 IU) 100 微克（4,000 国际单位） | 100 mcg (4,000 IU) 100 微克（4,000 国际单位） | 100 mcg (4,000 IU) 100 微克（4,000 国际单位） |
| 19+ years 19+ 岁 | 100 mcg (4,000 IU) 100 微克（4,000 国际单位） | 100 mcg (4,000 IU) 100 微克（4,000 国际单位） | 100 mcg (4,000 IU) 100 微克（4,000 国际单位） | 100 mcg (4,000 IU) 100 微克（4,000 国际单位） |

 

## Interactions with Medications 与药物的相互作用

Vitamin D supplements may interact with several types of medications. A few examples are provided below. Individuals taking these and other medications on a regular basis should discuss their vitamin D intakes and status with their health care providers.  
维生素 D 补充剂可能与多种类型的药物相互作用。下面提供了几个示例。定期服用这些药物和其他药物的人应与他们的医疗保健提供者讨论他们的维生素 D 摄入量和状况。

### Orlistat 奥利司他

The weight-loss drug orlistat (Xenical and alli), together with a reduced-fat diet, can reduce the absorption of vitamin D from food and supplements, leading to lower 25(OH)D levels \[[167-170](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en167)\].  
减肥药奥利司他（Xenical 和 alli）与低脂饮食相结合，可以减少食物和补充剂中维生素 D 的吸收，从而降低 25（OH）D 水平 \[[167-170](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en167)\]。

### Statins 他汀类药物

Statin medications reduce cholesterol synthesis. Because endogenous vitamin D is derived from cholesterol, statins may also reduce vitamin D synthesis \[[170](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en170)\]. In addition, high intakes of vitamin D, especially from supplements, might reduce the potency of atorvastatin (Lipitor), lovastatin (Altoprev and Mevacor), and simvastatin (FloLipid and Zocor), because these statins and vitamin D appear to compete for the same metabolizing enzyme \[[170-173](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en170)\].  
他汀类药物可减少胆固醇合成。由于内源性维生素 D 来源于胆固醇，他汀类药物也可能减少维生素 D 的合成 \[[170](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en170)\]。此外，大量摄入维生素D，尤其是从补充剂中摄入的维生素D，可能会降低阿托伐他汀（Lipitor）、洛伐他汀（Altoprev和Mevacor）和辛伐他汀（FloLipid和Zocor）的效力，因为这些他汀类药物和维生素D似乎在竞争相同的代谢酶\[[170-173](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en170)\]。

### Steroids 类固醇

Corticosteroid medications, such as prednisone (Deltasone, Rayos, and Sterapred), are often prescribed to reduce inflammation. These medications can reduce calcium absorption and impair vitamin D metabolism \[[174-176](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en174)\]. In the NHANES 2001–2006 survey, 25(OH)D deficiency (less than 25 nmol/L \[10 ng/mL\]) was more than twice as common among children and adults who reported oral steroid use (11%) than in nonusers (5%) \[[177](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en177)\].  
皮质类固醇药物，如泼尼松（Deltasone、Rayos 和 Sterapred），通常用于减轻炎症。这些药物会减少钙的吸收并损害维生素D的代谢\[[174-176](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en174)\]。在 NHANES 2001-2006 调查中，报告口服类固醇的儿童和成人 （11%） 的 25（OH）D 缺乏症（低于 25 nmol/L \[10 ng/mL\]）的发生率是非使用者 （5%） 的两倍多 \[[177](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en177)\]。

### Thiazide diuretics 噻嗪类利尿剂

Thiazide diuretics (e.g., Hygroton, Lozol, and Microzide) decrease urinary calcium excretion. The combination of these diuretics with vitamin D supplements (which increase intestinal calcium absorption) might lead to hypercalcemia, especially among older adults and individuals with compromised renal function or hyperparathyroidism \[[170](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en170),[178](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en178),[179](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en179)\].  
噻嗪类利尿剂（例如 Hygroton、Lozol 和 Microzide）可减少尿钙排泄。这些利尿剂与维生素D补充剂（可增加肠道钙吸收）联合使用可能导致高钙血症，尤其是在老年人和肾功能受损或甲状旁腺功能亢进的个体中\[170,178,179\]。[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en170)[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en178)[](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional//#en179)

## Vitamin D and Healthful Diets 维生素 D 和健康饮食

The federal government’s 2020–2025 _Dietary Guidelines for Americans_ notes that “Because foods provide an array of nutrients and other components that have benefits for health, nutritional needs should be met primarily through foods. … In some cases, fortified foods and dietary supplements are useful when it is not possible otherwise to meet needs for one or more nutrients (e.g., during specific life stages such as pregnancy).”  
联邦政府的 2020-2025 年_美国人膳食指南_指出，“由于食物提供了一系列对健康有益的营养物质和其他成分，因此营养需求应主要通过食物来满足。…在某些情况下，当无法通过其他方式满足对一种或多种营养素的需求时（例如，在怀孕等特定生命阶段），强化食品和膳食补充剂是有用的。

For more information about building a healthy dietary pattern, refer to the _[Dietary Guidelines for Americans](https://www.dietaryguidelines.gov)[![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png)](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website")_ and the USDA’s _[MyPlate.](https://www.choosemyplate.gov/)[![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png)](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website")_有关建立健康饮食模式的更多信息，请参阅_[美国人](https://www.dietaryguidelines.gov)  [![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png)](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website")膳食指南_和美国农业部的 _[MyPlate。](https://www.choosemyplate.gov/) [![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png)](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website")_ 

The _Dietary Guidelines for Americans_ describes a healthy dietary pattern as one that  
_《美国人膳食指南_》将健康的饮食模式描述为：

-   Includes a variety of vegetables; fruits; grains (at least half whole grains); fat-free and low-fat milk, yogurt, and cheese; and oils.  
    包括各种蔬菜;水果;谷物（至少半个全谷物）;无脂和低脂牛奶、酸奶和奶酪;和油。
    -   Milk, many ready-to-eat cereals, and some brands of yogurt and orange juice are fortified with vitamin D. Cheese naturally contains small amounts of vitamin D. Vitamin D is added to some margarines.  
        牛奶、许多即食谷物以及一些品牌的酸奶和橙汁都添加了维生素 D。奶酪天然含有少量维生素 D。维生素 D 被添加到一些人造黄油中。
-   Includes a variety of protein foods such as lean meats; poultry; eggs; seafood; beans, peas, and lentils; nuts and seeds; and soy products.  
    包括各种蛋白质食物，如瘦肉;家禽;蛋;海鲜;豆类、豌豆和扁豆;坚果和种子;和豆制品。
    -   Fatty fish, such as salmon, tuna, and mackerel, are very good sources of vitamin D. Beef liver and egg yolks have small amounts of vitamin D.  
        富含脂肪的鱼，如鲑鱼、金枪鱼和鲭鱼，是维生素 D 的良好来源。牛肝和蛋黄含有少量维生素 D。
-   Limits foods and beverages higher in added sugars, saturated fat, and sodium.  
    限制添加糖、饱和脂肪和钠含量较高的食物和饮料。
-   Limits alcoholic beverages.  
    限制酒精饮料。
-   Stays within your daily calorie needs.  
    保持在您的每日卡路里需求范围内。

## References 引用

1.  Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academy Press, 2010.  
    医学研究所、食品和营养委员会。钙和维生素 D 的膳食参考摄入量。华盛顿特区：国家科学院出版社，2010 年。
2.  Norman AW, Henry HH. Vitamin D. In: Erdman JW, Macdonald IA, Zeisel SH, eds. Present Knowledge in Nutrition, 10th ed. Washington DC: Wiley-Blackwell, 2012.  
    诺曼 AW，亨利 HH。維生素D。在：Erdman JW， Macdonald IA， Zeisel SH， eds. 营养学中的现状知识，第 10 版。华盛顿特区：Wiley-Blackwell，2012 年。
3.  Jones G. Vitamin D. In: Ross AC, Caballero B, Cousins RJ, Tucker KL, Ziegler TR, eds. Modern Nutrition in Health and Disease, 11th ed. Philadelphia: Lippincott Williams & Wilkins, 2014.  
    Jones G. 维生素 D。在：Ross AC， Caballero B， Cousins RJ， Tucker KL， Ziegler TR， eds. 现代营养与疾病，第11版。 费城：Lippincott Williams & Wilkins，2014年。
4.  Silva MC, Furlanetto TW. Intestinal absorption of vitamin D: A systematic review. Nutr Rev 2018;76:60-76. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/29025082/)\]  
    席尔瓦 MC，Furlanetto TW。维生素 D 的肠道吸收：系统评价。营养修订版 2018;76：60-76。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/29025082/)\]
5.  Sempos CT, Heijboer AC, Bikle DD, Bollerslev J, Bouillon R, Brannon PM, et al. Vitamin D assays and the definition of hypovitaminosis D. Results from the First International Conference on Controversies in Vitamin D. Br J Clin Pharmacol 2018;84:2194-207. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/29851137/)\]  
    Sempos CT， Heijboer AC， Bikle DD， Bollerslev J， Bouillon R， Brannon PM， et al. 维生素 D 测定和维生素 D 缺乏症的定义。第一届维生素 D 争议国际会议的结果。Br J 临床药理学 2018;84：2194-207。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/29851137/)\]
6.  LeFevre ML. Screening for vitamin deficiency in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2015;162:133-40. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/25419853/)\]  
    成人维生素缺乏症筛查：美国预防服务工作组推荐声明。安实习医学 2015;162：133-40。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/25419853/)\]
7.  Brooks SPJ, Sempos CT. The importance of 25-hydroxyvitamin D assay standardization and the Vitamin D Standardization Program. Journal of AOAC International 2017;100:1223-4.  
    布鲁克斯 SPJ，康涅狄格州森波斯。25-羟基维生素 D 测定标准化和维生素 D 标准化计划的重要性。AOAC 国际杂志 2017;100：1223-4。
8.  Taylor CL, Sempos CT, Davis CD, Brannon PM. Vitamin D: moving forward to address emerging science. Nutrients 2017, 9, 1308; doi:10.3390/mu9121308. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/29194368/)\]  
    维生素 D：向前迈进，解决新兴科学问题。营养素 2017， 9， 1308;doi：10.3390/mu9121308.\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/29194368/)\]
9.  Sempos CT, Binkley N. 25-hydroxyvitamin D assay standardisation and vitamin D guidelines paralysis. Public Health Nutrition 2020;23:1153-64. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/32301688/)\]  
    Sempos CT， Binkley N. 25-羟基维生素 D 测定标准化和维生素 D 指南麻痹。公共卫生营养 2020;23：1153-64。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/32301688/)\]
10.  Office of Dietary Supplements, National Institutes of Health. [Vitamin D Standardization Program (VDSP)](https://ods.od.nih.gov/Research/VitaminD.aspx#vdsp).  
    美国国立卫生研究院膳食补充剂办公室。[维生素 D 标准化计划 （VDSP）。](https://ods.od.nih.gov/Research/VitaminD.aspx#vdsp)
11.  Demay MB, Pittas AG, Bikle DD, Diab DL, Kiely ME, et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2024 Jul 12;109(8):1907-1947. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/38828931/)\]  
    Demay MB， Pittas AG， Bikle DD， Diab DL， Kiely ME， et al. 维生素 D 预防疾病：内分泌学会临床实践指南。J Clin 内分泌代谢物。2024 年 7 月 12 日;109(8):1907-1947.\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/38828931/)\]
12.  Shah VP, Nayfeh T, Alsawaf Y, Saadi S, Farah M, et al. A Systematic Review Supporting the Endocrine Society Clinical Practice Guidelines on Vitamin D. J Clin Endocrinol Metab. 2024 Jul 12;109(8):1961-1974. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/38828942/)\]  
    Shah VP、Nayfeh T、Alsawaf Y、Saadi S、Farah M 等人。支持内分泌学会关于维生素 D. J 临床内分泌代谢的临床实践指南的系统评价。2024 年 7 月 12 日;109(8):1961-1974.\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/38828942/)\]
13.  Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/17634462/)\]  
    霍利克 MF。维生素 D 缺乏症。N Engl J Med 2007;357：266-81。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/17634462/)\]
14.  Brown LL, Cohen B, Tabor D, Zappala G, Maruvada P, Coates PM. The vitamin D paradox in Black Americans: A systems-based approach to investigating clinical practice, research, and public health—expert panel meeting report. BMC Proceedings, 2018;12(Suppl 6):6. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/30044889/)\]  
    Brown LL、Cohen B、Tabor D、Zappala G、Maruvada P、Coates PM。美国黑人的维生素 D 悖论：一种基于系统的方法，用于调查临床实践、研究和公共卫生——专家小组会议报告。BMC 论文集，2018 年;12（增刊 6）：6。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/30044889/)\]
15.  Bouillon R. Comparative analysis of nutritional guidelines for vitamin D. Nat Rev Endocrinol 2017;13:466-79. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/28387318/)\]  
    Bouillon R. 维生素 D 营养指南的比较分析。Nat Rev 内分泌 2017;13：466-79。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/28387318/)\]
16.  Scientific Advisory Committee on Nutrition. [Vitamin D and Health](https://www.gov.uk/government/publications/sacn-vitamin-d-and-health-report)[![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png)](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website"). 2016.  
    营养科学咨询委员会。[维生素 D 与健康](https://www.gov.uk/government/publications/sacn-vitamin-d-and-health-report)  [![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png)](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website").2016.
17.  Roseland JM, Phillips KM, Patterson KY, Pehrsson PR, Taylor CL. Vitamin D in foods: An evolution of knowledge. Pages 41-78 in Feldman D, Pike JW, Bouillon R, Giovannucci E, Goltzman D, Hewison M, eds. Vitamin D, Volume 2: Health, Disease and Therapeutics, Fourth Edition. Elsevier, 2018.  
    Roseland JM， Phillips KM， Patterson KY， Pehrsson PR， Taylor CL. 食物中的维生素 D：知识的演变。Feldman D、Pike JW、Bouillon R、Giovannucci E、Goltzman D、Hewison M、编辑维生素 D 第 41-78 页，第 2 卷：健康、疾病和治疗学，第四版。爱思唯尔，2018 年。
18.  U.S. Food and Drug Administration. Food additives permitted for direct addition to food for human consumption; vitamin D2 mushroom powder. Federal Register 2020;85:41916-20.  
    美国食品和药物管理局。允许直接添加到供人食用的食物中的食品添加剂;维生素 D2 蘑菇粉。联邦公报 2020;85：41916-20。
19.  Borel P, Caillaud D, Cano NJ. Vitamin D bioavailability: State of the art. Crit Rev Food Sci Nutr 2015;55:1193-205. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/24915331/)\]  
    Borel P， Caillaud D， 新泽西州卡诺。维生素 D 生物利用度：最先进的。Crit Rev 食品科学营养学 2015;55：1193-205。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/24915331/)\]
20.  Taylor CL, Patterson KY, Roseland JM, Wise SA, Merkel JM, Pehrsson PR, Yetley EA. Including food 25-hydroxyvitamin D in intake estimates may reduce the discrepancy between dietary and serum measures of vitamin D status. J Nutr 2014;144:654-9. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/24623845/)\]  
    Taylor CL、Patterson KY、Roseland JM、Wise SA、Merkel JM、Pehrsson PR、Yetley EA。在摄入量估计中包括食物 25-羟基维生素 D 可能会减少维生素 D 状况的饮食和血清测量之间的差异。营养学杂志 2014;144：654-9。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/24623845/)\]
21.  Cashman KD, Seamans KM, Lucey AJ, Stocklin E, Weber P, Kiely M, Hill TR. Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults. Am J Clin Nutr 2012;95:1350-6. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/22552038/)\]  
    Cashman KD， Seamans KM， Lucey AJ， Stocklin E， Weber P， Kiely M， Hill TR. 口服 25-羟基维生素 D3 和维生素 D3 在提高老年人冬季血清 25-羟基维生素 D 方面的相对有效性。美国临床营养学杂志 2012;95：1350-6。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/22552038/)\]
22.  Calvo MS, Whiting SJ, Barton CN. Vitamin D fortification in the United States and Canada: Current status and data needs. Am J Clin Nutr 2004;80:1710S-6S. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/15585792/)\]  
    Calvo MS、Whiting SJ、Barton CN。美国和加拿大的维生素 D 强化：现状和数据需求。Am J Clin Nutr 2004;80：1710S-6S. \[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/15585792/)\]
23.  Yetley EA. Assessing the vitamin D status of the US population. Am J Clin Nutr 2008;88:558S-64S. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/18689402/)\]  
    评估美国人口的维生素 D 状况。Am J Clin Nutr 2008 年;88：558S-64S. \[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/18689402/)\]
24.  U.S. Food and Drug Administration. [Vitamin D for milk and milk alternatives](https://www.fda.gov/food/food-additives-petitions/vitamin-d-milk-and-milk-alternatives)[![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png)](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website"). January 4, 2018.  
    美国食品和药物管理局。[用于牛奶和牛奶替代品](https://www.fda.gov/food/food-additives-petitions/vitamin-d-milk-and-milk-alternatives)  [![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png)](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website")的维生素 D .2018 年 1 月 4 日。
25.  U.S. Department of Agriculture, Agricultural Research Service. [FoodData Central](https://fdc.nal.usda.gov/index.html)[![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png)](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website").  
    美国农业部，农业研究服务。[FoodData Central](https://fdc.nal.usda.gov/index.html)  [![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png)](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website").
26.  U.S. Food and Drug Administration. [Food labeling: Revision of the Nutrition and Supplement Facts labels](https://www.federalregister.gov/documents/2016/05/27/2016-11867/food-labeling-revision-of-the-nutrition-and-supplement-facts-labels)[![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png)](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website"). Federal Register 81(103):33742-33999. 2016.  
    美国食品和药物管理局。[食品标签： 修订营养和补充剂成分标签](https://www.federalregister.gov/documents/2016/05/27/2016-11867/food-labeling-revision-of-the-nutrition-and-supplement-facts-labels)  [![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png)](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website")。联邦公报 81（103）：33742-33999。2016.
27.  Hossein-nezhad A, Holick MF. Vitamin D for health: A global perspective. Mayo Clin Proc 2013;88:720-55. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/23790560/)\]  
    侯赛因-内扎德 A，霍利克 MF。维生素 D 促进健康：全球视野。梅奥临床实验委员会 2013;88：720-55。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/23790560/)\]
28.  U.S. Department of Health and Human Services. [The Surgeon General’s Call to Action to Prevent Skin Cancer](https://www.surgeongeneral.gov/library/calls/prevent-skin-cancer/call-to-action-prevent-skin-cancer.pdf)[![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png)](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website"). Washington, DC: U.S. Dept of Health and Human Services, Office of the Surgeon General; 2014.  
    美国卫生与公众服务部。[卫生局局长呼吁采取行动预防皮肤癌](https://www.surgeongeneral.gov/library/calls/prevent-skin-cancer/call-to-action-prevent-skin-cancer.pdf)  [![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png)](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website")。华盛顿特区：美国卫生与公众服务部，卫生局局长办公室;2014.
29.  Holick MF. Vitamin D: the underappreciated D-lightful hormone that is important for skeletal and cellular health. Curr Opin Endocrinol Diabetes 2002;9:87-98.  
    霍利克 MF。维生素 D：一种被低估的 D-轻荷尔蒙，对骨骼和细胞健康很重要。Curr Opin 内分泌糖尿病 2002;9：87-98。
30.  Weisberg P, Scanlon KS, Li R, Cogswell ME. Nutritional rickets among children in the United States: review of cases reported between 1986 and 2003. Am J Clin Nutr 2004;80:1697S-705S. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/15585790/)\]  
    Weisberg P、Scanlon KS、Li R、Cogswell ME。美国儿童营养性佝偻病：1986 年至 2003 年间报告的病例回顾。Am J Clin Nutr 2004;80：1697S-705S. \[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/15585790/)\]
31.  Hirsch AL. [Industrial Aspects of Vitamin D](https://www.sciencedirect.com/science/article/pii/B978012381978910006X)[![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png)](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website"). In: Feldman D, Pike JW, Adams JS, eds. Vitamin D. 3rd ed. Academic Press; 2011:73-93.  
    维生素 D [![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png) ](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website")[的工业方面](https://www.sciencedirect.com/science/article/pii/B978012381978910006X) .在：Feldman D， Pike JW， Adams JS， eds. Vitamin D. 3rd ed. 学术出版社;2011:73-93.
32.  National Institutes of Health. [Dietary Supplement Label Database.](https://dsld.nlm.nih.gov/dsld/) 2020.  
    美国国立卫生研究院。[膳食补充剂标签数据库。](https://dsld.nlm.nih.gov/dsld/)2020.
33.  Tripkovic L, Lambert H, Hart K, Smith CP, Bucca G, Penson S, et al. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: A systematic review and meta-analysis. Am J Clin Nutr 2012;95:1357-64. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/22552031/)\]  
    Tripkovic L、Lambert H、Hart K、Smith CP、Bucca G、Penson S 等人。维生素 D2 和维生素 D3 补充剂在提高血清 25-羟基维生素 D 状态方面的比较：系统评价和荟萃分析。美国临床营养学杂志 2012;95：1357-64。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/22552031/)\]
34.  Lehmann U, Hirche F, Stangl GI, Hinz K, Westphal S, Dierkes J. Bioavailability of vitamin D2 and D3 in healthy volunteers, a randomised placebo-controlled trial. J Clin Endocrin Metab 2013;98:4339-45. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/24001747/)\]  
    Lehmann U， Hirche F， Stangl GI， Hinz K， Westphal S， Dierkes J. 健康志愿者中维生素 D2 和 D3 的生物利用度，一项随机安慰剂对照试验。临床内分泌代谢杂志 2013;98：4339-45。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/24001747/)\]
35.  Logan VF, Gray AR, Peddie MC, Harper MJ, Houghton LA. Long-term vitamin D3 supplementation is more effective than vitamin D2 in maintaining serum 25-hydroxyvitamin D status over the winter months. Br J Nutr 2013;109:1082-8. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/23168298/)\]  
    Logan VF、Gray AR、Peddie MC、Harper MJ、Houghton LA。长期补充维生素 D3 在冬季维持血清 25-羟基维生素 D 状态方面比维生素 D2 更有效。Br J 营养学 2013;109：1082-8。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/23168298/)\]
36.  Tripkovic L, Wilson LR, Hart K, Johnsen S, de Lusignan S, Smith CP, et al. Daily supplementation with 15 µg vitamin D2 compared with vitamin D3 to increase wintertime 25-hydroxyvitamin D status in healthy South Asian and white European women: A 12-wk randomized, placebo-controlled food-fortification trial. Am J Clin Nutr 2017;106:481-90. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/28679555/)\]  
    Tripkovic L、Wilson LR、Hart K、Johnsen S、de Lusignan S、Smith CP 等人。与维生素 D3 相比，每日补充 15 μg 维生素 D2 可增加健康南亚和欧洲白人女性冬季 25-羟基维生素 D 状态：一项 12 周随机、安慰剂对照食品强化试验。美国临床营养学杂志 2017;106：481-90。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/28679555/)\]
37.  Graeff-Armas LA, Bendik I, Kunz I, Schoop R, Hull S, Beck M. Supplemental 25-hydroxycholecalciferol is more effective than cholecalciferol in raising serum 25-hydroxyvitamin D concentrations in older adults. J Nutr 2020;150:73-81. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/31518424/)\]  
    Graeff-Armas LA， Bendik I， Kunz I， Schoop R， Hull S， Beck M. 补充 25-羟基胆钙化醇在提高老年人血清 25-羟基维生素 D 浓度方面比胆钙化醇更有效。营养学杂志 2020;150：73-81。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/31518424/)\]
38.  Quesada-Gomez JM, Bouillon R. Is calcifediol better than cholecalciferol for vitamin D supplementation? Osteoporos Int 2018;29:1697-1711. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/29713796/)\]  
    Quesada-Gomez JM， Bouillon R.钙化二醇在补充维生素 D 方面比胆钙化醇更好吗？骨质疏松症国际 2018;29：1697-1711。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/29713796/)\]
39.  [Percent reporting and mean amounts of selected vitamins and minerals food and beverages and dietary supplements by gender and age, in the United States, 2015-2016](https://www.ars.usda.gov/ARSUserFiles/80400530/pdf/1516/Table_37_SUP_GEN_15.pdf)[![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png)](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website"). What We Eat in America, NHANES 2015-2016. 2019.  
    [2015-2016 年美国按性别和年龄分列的选定维生素和矿物质食品和饮料以及膳食补充剂的报告百分比和平均数量](https://www.ars.usda.gov/ARSUserFiles/80400530/pdf/1516/Table_37_SUP_GEN_15.pdf)[。 ![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png)](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website")  我们在美国吃什么，NHANES 2015-2016。2019.
40.  [Usual nutrient intake from foods and beverages, by gender and age](https://www.ars.usda.gov/ARSUserFiles/80400530/pdf/usual/Usual_Intake_gender_WWEIA_2013_2016.pdf)[![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png)](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website"). What We Eat in America, NHANES 2013-2016. 2019.  
    [按性别和年龄](https://www.ars.usda.gov/ARSUserFiles/80400530/pdf/usual/Usual_Intake_gender_WWEIA_2013_2016.pdf)  [![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png)](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website")划分的通常从食品和饮料中摄入的营养物质。我们在美国吃什么，NHANES 2013-2016。2019.
41.  Rooney MR, Harnack L, Michos ED, Ogilvie RP, Sempos CT, Lutsey PL. Trends in use of high-dose vitamin D supplements exceeding 1000 or 4000 International Units daily, 1999-2014. JAMA 2017;317:2448-50. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/28632857/)\]  
    Rooney MR、Harnack L、Michos ED、Ogilvie RP、Sempos CT、Lutsey PL. 1999-2014 年每天超过 1000 或 4000 国际单位的高剂量维生素 D 补充剂的使用趋势。美国医学会 2017;317：2448-50。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/28632857/)\]
42.  Taylor CL, Roseland JM, Coates PM, Pehrsson PR. The emerging issue of 25-hydroxyvitamin D in foods. J Nutr 2016;146:855-6. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/27037407/)\]  
    泰勒 CL、罗斯兰 JM、科茨 PM、佩尔森公关。食品中 25-羟基维生素 D 的新问题。营养学杂志 2016;146：855-6。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/27037407/)\]
43.  Herrick KA, Storandt RJ, Afful J, Pfeiffer CM, Schleicher RL, Gahche JJ, Potischman N. Vitamin D status in the United States, 2011-2014. Am J Clin Nutr 2019;110:150-7. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/31076739/)\]  
    Herrick KA、Storandt RJ、Afful J、Pfeiffer CM、Schleicher RL、Gahche JJ、Potischman N. 2011-2014 年美国维生素 D 状况。美国临床营养学杂志 2019;110：150-7。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/31076739/)\]
44.  Elder CJ, Bishop NJ. Rickets. Lancet 2014;383:1665-76. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/24412049/)\]  
    CJ 长老，新泽西州主教。佝偻病。柳叶刀 2014;383：1665-76. \[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/24412049/)\]
45.  Munns CF, Shaw N, Kiely M, Specker BL, Thacher TD, Ozono K, et al. Global consensus recommendations on prevention and management of nutritional rickets. J Clin Endocrinol Metab 2016;101:394-415. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/26745253/)\]  
    Munns CF、Shaw N、Kiely M、Specker BL、Thacher TD、Ozono K 等人。关于预防和管理营养性佝偻病的全球共识建议。临床内分泌代谢杂志 2016;101：394-415。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/26745253/)\]
46.  Uday S, Hogler W. Nutritional rickets and osteomalacia in the twenty-first century: Revised concepts, public health, and prevention strategies. Curr Osteoporos Rep 2017;15:293-302. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/28612338/)\]  
    Uday S， Hogler W. 二十一世纪的营养性佝偻病和骨软化症：修订的概念、公共卫生和预防策略。Curr 骨质疏松症代表 2017;15：293-302。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/28612338/)\]
47.  Weisberg P, Scanlon KS, Li R, Cogswell ME. Nutritional rickets among children in the United States: Review of cases reported between 1986 and 2003. Am J Clin Nutr 2004;80:1697S-705S. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/15585790/)\]  
    Weisberg P、Scanlon KS、Li R、Cogswell ME。美国儿童营养性佝偻病：1986 年至 2003 年间报告的病例回顾。Am J Clin Nutr 2004;80：1697S-705S. \[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/15585790/)\]
48.  Thacher TM, Fischer PR, Tebben PJ, Singh RJ, Cha SS, Maxson JA, Yawn BP. Increasing incidence of nutritional rickets: A population-based study in Olmsted County, Minnesota. Mayo Clin Proc 2013;88:176-83. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/23374621/)\]  
    Thacher TM、Fischer PR、Tebben PJ、Singh RJ、Cha SS、Maxson JA、Yawn BP。营养性佝偻病发病率增加：明尼苏达州奥姆斯特德县的一项基于人群的研究。梅奥临床实验委员会 2013;88：176-83。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/23374621/)\]
49.  Ward LM, Gaboury I, Ladhani M, Zlotkin S. Vitamin D-deficiency rickets among children in Canada. CMAJ 2007;177:161-6. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/17600035/)\]  
    Ward LM， Gaboury I， Ladhani M， Zlotkin S. 加拿大儿童维生素 D 缺乏性佝偻病。中国医学杂志 2007;177：161-6。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/17600035/)\]
50.  Rajakumar K. Vitamin D, cod-liver oil, sunlight, and rickets: A historical perspective. Pediatrics 2003;112:e132-5. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/12897318/)\]  
    维生素 D、鱼肝油、阳光和佝偻病：历史视角。儿科 2003;112：e132-5。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/12897318/)\]
51.  Creo AL, Thacher TD, Pettifor JM, Strand MA, Ficsher PR. Nutritional rickets around the world: An update. Paediatr Int Child Health 2017;37:84-98. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/27922335/)\]  
    Creo AL、Thacher TD、Pettifor JM、Strand MA、Ficsher PR. 世界各地的营养佝偻病：更新。儿科国际儿童健康 2017;37：84-98。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/27922335/)\]
52.  Rockwell M, Kraak V, Hulver M, Epling J. Clinical management of low vitamin D: A scoping review of physicians’ practices. Nutrients 2018 Apr 16;10(4). pii: E493. doi: 10.3390/nu10040493. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/29659534/)\]  
    Rockwell M， Kraak V， Hulver M， Epling J. 低维生素 D 的临床管理：医生实践的范围审查。营养素 2018 年 4 月 16 日;10(4).pii：E493。doi：10.3390/nu10040493。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/29659534/)\]
53.  Taylor CL, Thomas PR, Aloia JF, Millard PS. Questions about vitamin D for primary care practice: Input from an NIH conference. Am J Med 2015;128:1167-70. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/26071820/)\]  
    Taylor CL， Thomas PR， Aloia JF， Millard PS. 关于初级保健实践中维生素 D 的问题：来自 NIH 会议的意见。美国医学杂志 2015;128：1167-70。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/26071820/)\]
54.  Taylor CL, Rosen CJ, Dwyer JT. Considerations in dietetic counseling for vitamin D. J Acad Nutr Diet 2019;119:901-9. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/30005822/)\]  
    维生素 D 营养咨询的注意事项。J Acad Nutr Diet 2019;119：901-9。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/30005822/)\]
55.  Agency for Healthcare Research and Quality. Screening for vitamin D deficiency: Systematic review for the U.S. Preventive Services Task Force recommendation. Evidence Synthesis Number 118. AHRQ-Pub No. 13-05183-EF-1. June 2014.  
    医疗保健研究和质量局。维生素 D 缺乏症筛查：美国预防服务工作组建议的系统评价。证据综合编号 118。AHRQ-出版物编号 13-05183-EF-1。2014 年 6 月。
56.  Picciano MF. Nutrient composition of human milk. Pediatr Clin North Am 2001;48:53-67. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/11236733/)\]  
    Picciano MF.母乳的营养成分。儿科临床北方美国 2001;48：53-67。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/11236733/)\]
57.  Wagner CL, Greer FR, American Academy of Pediatrics Section on Breastfeeding, American Academy of Pediatrics Committee on Nutrition. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics 2008;122:1142-52. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/18977996/)\]  
    Wagner CL、Greer FR、美国儿科学会母乳喂养部、美国儿科学会营养委员会。预防婴儿、儿童和青少年的佝偻病和维生素 D 缺乏症。儿科 2008;122：1142-52。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/18977996/)\]
58.  Dawodu A, Tsang RC. Maternal vitamin D status: Effect on milk vitamin D content and vitamin D status of breastfeeding infants. Adv Nutr 2012;3:353-61. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/22585912/)\]  
    Dawodu A， Tsang RC.母体维生素 D 状况：对母乳喂养婴儿牛奶维生素 D 含量和维生素 D 状况的影响。高级营养学 2012;3：353-61。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/22585912/)\]
59.  Davis CD, Dwyer JT. The ‘sunshine vitamin’: benefits beyond bone? J Natl Cancer Inst 2007;99:1563-5. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/17971523/)\]  
    戴维斯 CD，德怀尔 JT。“阳光维生素”：骨骼之外的好处？国家癌症研究所杂志 2007;99：1563-5。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/17971523/)\]
60.  Simon AE, Ahrens KA. Adherence to vitamin D intake guidelines in the United States. Pediatrics 2020;145:e20193574. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/32424077/)\]  
    西蒙 AE，阿伦斯 KA。遵守美国的维生素 D 摄入量指南。儿科 2020;145：e20193574.\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/32424077/)\]
61.  Chalcraft JR, Cardinal LM, Wechsler PJ, Hollis BW, Gerow KG, Alexander BM, et al. Vitamin D synthesis following a single bout of sun exposure in older and younger men and women. Nutrients 2020; 12, 2237; doi:10.3390/nu12082237. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/32727044/)\]  
    Chalcraft JR， Cardinal LM， Wechsler PJ， Hollis BW， Gerow KG， Alexander BM， et al. 老年和年轻男性和女性单次日晒后的维生素 D 合成。营养素 2020;12, 2237;doi：10.3390/nu12082237.\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/32727044/)\]
62.  Sowah D, Fan X, Dennett L, Hagtvedt R, Straube S. Vitamin D levels and deficiency with different occupations: A systematic review. BMC Public Health 2017;17:519. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/28637448/)\]  
    Sowah D， Fan X， Dennett L， Hagtvedt R， Straube S. 不同职业的维生素 D 水平和缺乏症：系统评价。BMC 公共卫生 2017;17：519。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/28637448/)\]
63.  Pappa HM, Bern E, Kamin D, Grand RJ. Vitamin D status in gastrointestinal and liver disease. Curr Opin Gastroenterol 2008;24:176-83. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/18301268/)\]  
    帕帕 HM、伯尔尼 E、卡明 D、大 RJ。胃肠道和肝脏疾病中的维生素 D 状态。Curr Opin 胃肠病 2008;24：176-83。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/18301268/)\]
64.  Drincic A, Fuller E, Heaney RP, Armas LAG. 25-hydroxyvitamin D response to graded vitamin D3 supplementation among obese adults. J Clin Endocrinol Metab 2013;98:4845-51. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/24037880/)\]  
    Drincic A、Fuller E、Heaney RP、Armas LAG。肥胖成人对分级维生素 D3 补充剂的 25-羟基维生素 D 反应。临床内分泌代谢杂志 2013;98：4845-51。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/24037880/)\]
65.  Ekwaru JP, Zwicker JD, Holick MF, Giovannucci E, Veugelers PJ. The importance of body weight for the dose response relationship of oral vitamin D supplementation and serum 25-hydroxyvitamin D in healthy volunteers. PLOS ONE 2014;9:e111265. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/25372709/)\]  
    Ekwaru JP， Zwicker JD， Holick MF， Giovannucci E， Veugelers PJ.体重对健康志愿者口服维生素 D 补充剂和血清 25-羟基维生素 D 剂量反应关系的重要性。PLOS ONE 2014 年;9：e111265.\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/25372709/)\]
66.  Chakhtoura M, Rahme M, Fuleihan E-H. Vitamin D metabolism in bariatric surgery. Endocrinol Metab Clin North Am 2017;46:947-82. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/29080645/)\]  
    Chakhtoura M， Rahme M， Fuleihan EH.减肥手术中的维生素 D 代谢。内分泌代谢临床 North Am 2017;46：947-82。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/29080645/)\]
67.  Peterson L, Zeng X, Caufield-Noll CP, Schweitzer MA, Magnuson TH, Steele KE. Vitamin D status and supplementation before and after bariatric surgery: A comprehensive literature review. Surg Obes Relat Dis 2016;12:693-702. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/27036669/)\]  
    Peterson L， Zeng X， Caufield-Noll CP， Schweitzer MA， Magnuson TH， Steele KE.减肥手术前后维生素 D 状况和补充：全面的文献综述。外科肥胖相关疾病 2016;12：693-702。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/27036669/)\]
68.  Chakhtoura MT, Nakhoul N, Akl EA, Mantzoros CS, El Hajj Guleihan GA. Guidelines on vitamin D replacement in bariatric surgery? Identification and systematic appraisal. Metabolism 2016;65:586-97. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/26833101/)\]  
    Chakhtoura MT、Nakhoul N、Akl EA、Mantzoros CS、El Hajj Guleihan GA. 减肥手术中维生素 D 替代指南？鉴定和系统评价。代谢 2016;65：586-97。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/26833101/)\]
69.  Newberry SJ, Chung M, Shekelle PG, Booth MS, Liu JL, Maher AR, et al. [Vitamin D and calcium: A systematic review of health outcomes (update)](https://www.ncbi.nlm.nih.gov/books/NBK253540/). Evidence Report/Technology Assessment No. 217. (Prepared by the Southern California Evidence-based Practice Center under Contract No. 290- 2012-00006-I.) AHRQ Publication No. 14-E004-EF. Rockville, MD: Agency for Healthcare Research and Quality. September 2014.  
    Newberry SJ， Chung M， Shekelle PG， Booth MS， Liu JL， Maher AR， et al. [维生素 D 和钙：健康结果的系统评价（更新）。](https://www.ncbi.nlm.nih.gov/books/NBK253540/)证据报告/技术评估第 217 号。（由南加州循证实践中心根据合同编号 290-2012-00006-I 编制。AHRQ 出版物编号 14-E004-EF。马里兰州罗克维尔：医疗保健研究和质量局。2014 年 9 月。
70.  Sempos CT, Carter GD, Binkley NC. 25-hydroxyvitamin D assays: Standardization, guidelines, problems, and interpretation. Pages 939-57 in Feldman D, Pike JW, Bouillon R, Giovannucci E, Goltzman D, Hewison M, eds. Vitamin D, Volume 1: Biochemistry, Physiology and Diagnostics, Fourth Edition. Elsevier, 2018.  
    森波斯 CT，卡特 GD，北卡罗来纳州宾克利。25-羟基维生素 D 测定：标准化、指南、问题和解释。Feldman D、Pike JW、Bouillon R、Giovannucci E、Goltzman D、Hewison M、编辑维生素 D，第 1 卷：生物化学、生理学和诊断学，第 4 版，第 939-57 页。爱思唯尔，2018 年。
71.  Jin, J. Vitamin D and calcium supplements for preventing fractures. JAMA 2018;319:1630. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/29677304/)\]  
    Jin， J. 预防骨折的维生素 D 和钙补充剂。美国医学会 2018;319：1630。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/29677304/)\]
72.  National Institutes of Health Osteoporosis and Related Bone Diseases National Resource Center. [Osteoporosis Overview](https://www.bones.nih.gov/health-info/bone/osteoporosis/overview).  
    美国国立卫生研究院骨质疏松症和相关骨病国家资源中心。 [骨质疏松症概述](https://www.bones.nih.gov/health-info/bone/osteoporosis/overview)。
73.  Hansen D, Bazell C, Pelizzari P, Pyenson B. [Medicare cost of osteoporotic fractures](https://static1.squarespace.com/static/5c0860aff793924efe2230f3/t/5d76b949deb7e9086ee3d7dd/1568061771769/Medicare+Cost+of+Osteoporotic+Fractures+20190827.pdf)[![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png)](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website"). Milliman research report, August 2019.  
    Hansen D， Bazell C， Pelizzari P， Pyenson B. [骨质疏松性骨折的](https://static1.squarespace.com/static/5c0860aff793924efe2230f3/t/5d76b949deb7e9086ee3d7dd/1568061771769/Medicare+Cost+of+Osteoporotic+Fractures+20190827.pdf)  [![external link disclaimer](https://ods.od.nih.gov/images/Common/externallink.png)](https://ods.od.nih.gov/About/exit_disclaimer.aspx "External Website")医疗保险费用。Milliman 研究报告，2019 年 8 月。
74.  Chung M, Balk EM, Brendel M, Ip S, Lau J, Lee J, et al. Vitamin D and calcium: A systematic review of health outcomes. Evidence Report/Technology Assessment No. 183 prepared by the Tufts Evidence-based Practice Center under Contract No. 290-2007-10055-I. AHRQ Publication No. 09-E015. Rockville, MD: Agency for Healthcare Research and Quality, 2009.  
    维生素 D 和钙：健康结果的系统评价。证据报告/技术评估第 183 号，由塔夫茨循证实践中心根据合同编号 290-2007-10055-I 准备。AHRQ 出版物编号 09-E015。马里兰州罗克维尔：医疗保健研究与质量局，2009 年。
75.  U.S. Preventive Services Task Force. Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults. US Preventive Services Task Force recommendation statement. JAMA 2018;319:1592-9. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/29677309/)\]  
    美国预防服务工作组。维生素 D、钙或联合补充剂，用于社区居民成人骨折的一级预防。美国预防服务工作组建议声明。美国医学会 2018;319：1592-9。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/29677309/)\]
76.  Kahwati LC, Weber RP, Pan H, Gourlay M, LeBlanc E, Coker-Schwimmer M, Viswanathan M. Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults: Evidence report and systematic review for the US Preventive Services Task Force. JAMA 2018;319:1600-12. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/29677308/)\]  
    Kahwati LC， Weber RP， Pan H， Gourlay M， LeBlanc E， Coker-Schwimmer M， Viswanathan M. 维生素 D、钙或联合补充剂对社区居民成人骨折的一级预防：美国预防服务工作组的证据报告和系统评价。美国医学会 2018;319：1600-12。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/29677308/)\]
77.  Guirguis-Blake JM, Michael YL, Perdue LA, Coppola EL, Beil TL. Interventions to prevent falls in older adults: Updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2018;319:1705-16. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/29710140/)\]  
    Guirguis-Blake JM、Michael YL、Perdue LA、Coppola EL、Beil TL。预防老年人跌倒的干预措施：美国预防服务工作组的最新证据报告和系统评价。美国医学会 2018;319：1705-16。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/29710140/)\]
78.  U.S. Preventive Services Task Force. Interventions to prevent falls in community-dwelling older adults. US Preventive Services Task Force recommendation statement. JAMA 2018;319:1696-1704. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/29710141/)\]  
    美国预防服务工作组。预防社区老年人跌倒的干预措施。美国预防服务工作组建议声明。美国医学会 2018;319：1696-1704。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/29710141/)\]
79.  Bolland MJ, Grey A, Avenell A. Effects of vitamin D supplementation on musculoskeletal health: A systematic review, meta-analysis, and trial sequential analysis. Lancet Diabetes Endocrinol 2018;6:847-58. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/30293909/)\]  
    Bolland MJ， Grey A， Avenell A. 维生素 D 补充剂对肌肉骨骼健康的影响：系统评价、荟萃分析和试验序贯分析。柳叶刀糖尿病内分泌 2018;6：847-58。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/30293909/)\]
80.  Gallagher JC. Vitamin D and bone density, fractures, and falls: The end of the story? Lancet Diabetes Endocrinol 2018;6:834-5. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/30293910/)\]  
    加拉格尔 JC。维生素 D 和骨密度、骨折和跌倒：故事的结局？柳叶刀糖尿病内分泌 2018;6：834-5。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/30293910/)\]
81.  Yao P, Bennett D, Mafham M, Lin X, Chen Z, Armitage J, Clarke R. Vitamin D and calcium for the prevention of fracture: A systematic review and meta-analysis. JAMA Network Open 2019;2(12):e1917789. doi: 10.1001/jamanetworkopen.2019.17789.  
    Yao P， Bennett D， Mafham M， Lin X， Chen Z， Armitage J， Clarke R. 维生素 D 和钙预防骨折：系统评价和荟萃分析。2019 年 JAMA 网络公开赛;2（12）：e1917789。doi：10.1001/jamanetworkopen.2019.17789。
82.  LeBoff MS, Chou SH, Ratliff KA, Cook NR, Khurana B, Kim E, et al. Supplemental vitamin D and incident fractures in midlife and older adults. N Eng J Med 2022;387:299-309. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/35939577/)\]  
    LeBoff MS、Chou SH、Ratliff KA、Cook NR、Khurana B、Kim E 等人。补充维生素 D 和中年人和老年人的骨折。工程医学杂志 2022;387：299-309。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/35939577/)\]
83.  Aloia JF, Talwar SA, Pollack S, Yeh J. A randomized controlled trial of vitamin D3 supplementation in African American women. Arch Intern Med 2005;165:1618-23. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/16043680/)\]  
    Aloia JF， Talwar SA， Pollack S， Yeh J.一项非裔美国女性补充维生素 D3 的随机对照试验。Arch Intern Med 2005;165：1618-23。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/16043680/)\]
84.  Aloia JF, Rubinova R, Fazzari M, Islam S, Mikhail M, Ragolia L. Vitamin D and falls in older African American women: The PODA randomized clinical trial. J Am Geriatr Soc 2019;67:1043-49. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/30698279/)\]  
    Aloia JF， Rubinova R， Fazzari M， Islam S， Mikhail M， Ragolia L. 维生素 D 和老年非裔美国女性的跌倒：PODA 随机临床试验。J Am Geriatr Soc 2019;67：1043-49。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/30698279/)\]
85.  Vaes AMM, Tieland M, Toussaint N, Nilwik R, Verdijk LB, van Loon LJC, de Groot CPGM. Cholecalciferol or 25-hydroxycholecalciferol supplementation does not affect muscle strength and physical performance in prefrail and frail older adults. J Nutr 2018;148:712-20. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/30053278/)\]  
    Vaes AMM， Tieland M， Toussaint N， Nilwik R， Verdijk LB， van Loon LJC， de Groot CPGM.补充胆钙化醇或 25-羟基胆钙化醇不会影响虚弱和虚弱老年人的肌肉力量和身体机能。营养学杂志 2018;148：712-20。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/30053278/)\]
86.  Shea MK, Fielding RA, Dawson-Hughes B. The effect of vitamin D supplementation on lower-extremity power and function in older adults: a randomized controlled trial. Am J Clin Nutr 2019;109:369-79. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/30715090/)\]  
    谢伊 MK，菲尔丁 RA，道森-休斯 B。补充维生素 D 对老年人下肢力量和功能的影响：一项随机对照试验。美国临床营养学杂志 2019;109：369-79。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/30715090/)\]
87.  Manson JE, Bassuk SS, Buring JE. Vitamin D, calcium, and cancer: Approaching daylight? JAMA 2017;317:1217-8. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/28350909/)\]  
    曼森 JE，巴苏克 SS，伯林 JE。维生素 D、钙和癌症：接近天亮？美国医学会 2017;317：1217-8。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/28350909/)\]
88.  Yin L, Ordonez-Mena JM, Chen T, Schottker B, Arndt V, Brenner H. Circulating 25-hydroxyvitamin D serum concentration and total cancer incidence and mortality: A systematic review and meta-analysis. Preventive Medicine 2013;57:753-64. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/24036014/)\]  
    Yin L， Ordonez-Mena JM， Chen T， Schottker B， Arndt V， Brenner H. 循环 25-羟基维生素 D 血清浓度和总癌症发病率和死亡率：系统评价和荟萃分析。预防医学 2013;57：753-64。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/24036014/)\]
89.  Han J, Guo X, Yu X, Liu S, Cui X, Zhang B, Liang H. 25-hydroxyvitamin D and total cancer incidence and mortality: A meta-analysis of prospective cohort studies. Nutrients 2019;11,2295; doi:10.3390/nu11102295. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/31561503/)\]  
    Han J， Guo X， Yu X， Liu S， Cui X， Zhang B， Liang H. 25-羟基维生素 D 和癌症总发病率和死亡率：前瞻性队列研究的荟萃分析。营养素 2019;11,2295;doi：10.3390/nu11102295.\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/31561503/)\]
90.  Keum N, Giovannucci E. Vitamin D supplements and cancer incidence and mortality: A meta-analysis. British Journal of Cancer 2014;111:976-80. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/24918818/)\]  
    Keum N， Giovannucci E. 维生素 D 补充剂与癌症发病率和死亡率：荟萃分析。英国癌症杂志 2014;111：976-80。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/24918818/)\]
91.  Keum N, Lee DH, Greenwood DC, Manson JE, Giovannucci E. Vitamin D supplementation and total cancer incidence and mortality: A meta-analysis of randomized controlled trials. Ann Oncol 2019;30:733-43. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/30796437/)\]  
    Keum N， Lee DH， Greenwood DC， Manson JE， Giovannucci E. 维生素 D 补充剂与癌症总发病率和死亡率：随机对照试验的荟萃分析。安昂科尔 2019;30：733-43。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/30796437/)\]
92.  Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Krstic G, Wetterslev J, Gluud C. Vitamin D supplementation for prevention of cancer in adults. Cochrane Database Syst Rev 2014; 23(6):CD007469. doi: 10.1002/14651858.CD007469.pub2. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/24953955/)\]  
    Bjelakovic G， Gluud LL， Nikolova D， Whitfield K， Krstic G， Wetterslev J， Gluud C. 补充维生素 D 预防成人癌症。Cochrane 数据库系统修订版 2014;23（6）：CD007469。doi：10.1002/14651858.CD007469.pub2.\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/24953955/)\]
93.  Manson JE, Cook NR, Lee I-M, Christen W, Bassuk S, Mora S, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med 2019:380:33-44. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/30415629/)\]  
    Manson JE， Cook NR， Lee IM， Christen W， Bassuk S， Mora S， et al. 维生素 D 补充剂和预防癌症和心血管疾病。N Engl J Med 2019：380：33-44。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/30415629/)\]
94.  Brunner RL, Wactawski-Wende J, Caan BJ, Cochrane BB, Chlebowski RT, et al. The effect of calcium plus vitamin D on risk for invasive cancer: results of the Women’s Health Initiative (WHI) calcium plus vitamin D randomized clinical trial. Nutr Cancer. 2011;63(6):827-41.  \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/21774589/)\]  
    Brunner RL、Wactawski-Wende J、Caan BJ、Cochrane BB、Chlebowski RT 等。钙加维生素 D 对浸润性癌风险的影响：女性健康倡议 （WHI） 钙加维生素 D 随机临床试验的结果。营养癌。2011;63(6):827-41.\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/21774589/)\]
95.  Thomson CA, Aragaki AK, Prentice RL, Stefanick ML, Manson JE, et al. Long-Term Effect of Randomization to Calcium and Vitamin D Supplementation on Health in Older Women : Postintervention Follow-up of a Randomized Clinical Trial. Ann Intern Med. 2024 Apr;177(4):428-438.  \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/38467003/)\]  
    Thomson CA， Aragaki AK， Prentice RL， Stefanick ML， Manson JE， et al. 随机补充钙和维生素 D 对老年女性健康的长期影响：随机临床试验的干预后随访。Ann Intern Med. 2024 年 4 月;177(4):428-438.\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/38467003/)\]
96.  McNamara M, Rosenberger KD. The significance of vitamin D status in breast cancer: A state of the science review. J Midwifery Womens Health 2019;64:276-88. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/30977263/)\]  
    麦克纳马拉 M，罗森伯格 KD。维生素 D 状况在乳腺癌中的意义：科学状况评价。助产士妇女健康杂志 2019;64：276-88。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/30977263/)\]
97.  O’Brien KM, Sandler DP, Taylor JA, Weinberg CR. Serum vitamin D and risk of breast cancer within five years. Environ Health Perspect 2017;125(7):077004. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/28728134/)\]  
    O'Brien KM、Sandler DP、Taylor JA、Weinberg CR. 五年内血清维生素 D 和患乳腺癌的风险。环境健康观察 2017;125(7):077004.\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/28728134/)\]
98.  Skaaby T, Husemoen LLN, Thuesen BH, Pisinger C, Jorgensen T, Roswall N, et al. Prospective population-based study of the association between serum 25-hydroxyvitamin-D levels and the incidence of specific types of cancer. Cancer Epidemiol Biomarkers Prev 2014;23:1220-9. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/24789846/)\]  
    Skaaby T、Husemoen LLN、Thuesen BH、Pisinger C、Jorgensen T、Roswall N 等人。血清 25-羟基维生素 D 水平与特定类型癌症发病率之间关联的前瞻性人群研究。癌症流行病生物标志物上一页 2014;23：1220-9。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/24789846/)\]
99.  Yao S, Kwan ML, Ergas IJ, Roh JM, Cheng T-YD, Hong C-C, et al. Association of serum level of vitamin D at diagnosis with breast cancer survival: A case-cohort analysis in the Pathways Study. JAMA Oncol 2017;3:351-7. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/27832250/)\]  
    Yao S， Kwan ML， Ergas IJ， Roh JM， Cheng T-YD， Hong C-C， et al.诊断时血清维生素 D 水平与乳腺癌生存率的关联：Pathways 研究中的病例队列分析。美国医学会肿瘤学 2017;3：351-7。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/27832250/)\]
100.  Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 2007;100:1581-91. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/19001601/)\]  
    Chlebowski RT、Johnson KC、Kooperberg C、Pettinger M、Wactawski-Wende J、Rohan T 等人。钙加维生素 D 补充剂和患乳腺癌的风险。国家癌症研究所杂志 2007;100：1581-91。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/19001601/)\]
101.  Cauley JA, Chlebowski RT, Wactawski-Wende J, Robbins JA, Rodabough RJ, Chen Z, et al. Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: The Women’s Health Initiative. J Womens Health 2013:22,915-29. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/24131320/)\]  
    Cauley JA、Chlebowski RT、Wactawski-Wende J、Robbins JA、Rodabough RJ、Chen Z 等人。积极干预结束五年后钙加维生素 D 补充剂和健康结果：女性健康倡议。妇女健康杂志 2013：22,915-29。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/24131320/)\]
102.  McCullough ML, Zoltick ES, Weinstein SJ, Fedirko V, Wang M, Cook NR, et al. Circulating vitamin D and colorectal cancer risk: An international pooling project of 17 cohorts. J Natl Cancer Inst 2019;111:158-69. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/29912394/)\]  
    McCullough ML、Zoltick ES、Weinstein SJ、Fedirko V、Wang M、Cook NR 等人。循环维生素 D 和结直肠癌风险：一个由 17 个队列组成的国际汇集项目。国家癌症研究所杂志 2019;111：158-69。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/29912394/)\]
103.  Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O’Sullivan MJ, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:684-96. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/16481636/)\]  
    Wactawski-Wende J、Kotchen JM、Anderson GL、Assaf AR、Brunner RL、O'Sullivan MJ 等人。钙加维生素 D 补充剂和结直肠癌的风险。N Engl J Med 2006;354：684-96. \[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/16481636/)\]
104.  Crockett SD, Barry EL, Mott LA, Ahnen DJ, Robertson DJ, Anderson JC, et al. Calcium and vitamin D supplementation and increased risk of serrated polyps: Results from a randomised clinical trial. Gut. 2019 Mar;68(3):475-486. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/29496722/)\]  
    Crockett SD、Barry EL、Mott LA、Ahnen DJ、Robertson DJ、Anderson JC 等人。钙和维生素 D 补充剂和锯齿状息肉风险增加：一项随机临床试验的结果。肠。2019 年 3 月;68(3):475-486.\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/29496722/)\]
105.  Song M, Lee IM, Manson JE, Buring JE, Dushkes R, Gordon D, et al. No association between vitamin D supplementation and risk of colorectal adenomas or serrated polyps in a randomized trial. Clin Gastroeterol Hepatol 2020. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/32062040/)\]  
    Song M， Lee IM， Manson JE， Buring JE， Dushkes R， Gordon D 等人。在一项随机试验中，维生素 D 补充剂与结直肠腺瘤或锯齿状息肉的风险之间没有关联。Clin Gastroeterol Hepatol 2020 年。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/32062040/)\]
106.  Muller DC, Hodge AM, Fanidi A, Albanes D, Mai XM, Shu XO, et al. No association between circulating concentrations of vitamin D and risk of lung cancer: An analysis in 20 prospective studies in the Lung Cancer Cohort Consortium (LC3). Ann Oncol 2018;29:1468-75. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/29617726/)\]  
    Muller DC、Hodge AM、Fanidi A、Albanes D、Mai XM、Shu XO 等人。维生素 D 的循环浓度与肺癌风险之间没有关联：肺癌队列联盟 （LC3） 的 20 项前瞻性研究分析。安昂科尔 2018;29：1468-75。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/29617726/)\]
107.  van Duijnhoven FJB, Jenab M, Hveem K, Siersema PD, Fedirko V, Duell EJ, et al. Circulating concentrations of vitamin D in relation to pancreatic cancer risk in European populations. Int J Cancer 2018;142:1189-201. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/29114875/)\]  
    van Duijnhoven FJB、Jenab M、Hveem K、Siersema PD、Fedirko V、Duell EJ 等人。欧洲人群中维生素 D 的循环浓度与胰腺癌风险的关系。国际癌症杂志 2018;142：1189-201。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/29114875/)\]
108.  Stolzenberg-Solomon RZ, Vieth R, Azad A, Pietinen P, Taylor PR, Virtamo J, et al. A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Res 2006;66:10213-9. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/17047087/)\]  
    Stolzenberg-Solomon RZ、Vieth R、Azad A、Pietinen P、Taylor PR、Virtamo J 等人。一项关于男性吸烟者维生素 D 状况和胰腺癌风险的前瞻性嵌套病例对照研究。癌症研究 2006;66：10213-9。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/17047087/)\]
109.  Helzlsouer KJ for the VDPP Steering Committee. Overview of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010;172:4-9. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/20562193/)\]  
    VDPP 指导委员会的 Helzlsouer KJ。罕见癌症队列联盟维生素 D 混合项目概述。美国流行病学杂志 2010;172：4-9。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/20562193/)\]
110.  Xu Y, Shao X, Yao Y, Xu L, Chang L, Jiang Z, Lin Z. Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: New findings from an updated meta-analysis. J Cancer Res Clin Oncol 2014;140:1465-77. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/24838848/)\]  
    徐 Y， 邵 X， 姚 Y， 徐 L， 张 L， 江 Z， 林 Z. 循环 25-羟基维生素 D 水平与前列腺癌风险之间的正相关：更新的荟萃分析的新发现。J 癌症研究临床肿瘤学杂志 2014;140：1465-77。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/24838848/)\]
111.  Kristal AR, Till C, Song X, Tangen CM, Goodman PJ, Neuhauser ML, et al. Plasma vitamin D and prostate cancer risk: Results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 2014;23:1494-504. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/24732629/)\]  
    Kristal AR、Till C、Song X、Tangen CM、Goodman PJ、Neuhauser ML 等人。血浆维生素 D 和前列腺癌风险：硒和维生素 E 癌症预防试验的结果。癌症流行病生物标志物 Prev 2014;23：1494-504。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/24732629/)\]
112.  Schenk JM, Till CA, Tangen CM, Goodman PJ, Song X, Torkko KC, et al. Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: Results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 2014;23:1484-93. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/25085836/)\]  
    Schenk JM、Till CA、Tangen CM、Goodman PJ、Song X、Torkko KC 等人。血清 25-羟基维生素 D 浓度和前列腺癌风险：前列腺癌预防试验的结果。癌症流行病生物标志物上一页 2014;23：1484-93。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/25085836/)\]
113.  Heath AK, Hodge AM, Ebeling PR, Eyles DW, Kvaskoff D, Buchanan DD, et al. Circulating 25-hydroxyvitamin D concentration and risk of breast, prostate, and colorectal cancers: The Melbourne Collaborative Cohort Study. Cancer Epidemiol Biomarkers Prev 2019;28:900-8. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/30842127/)\]  
    Heath AK、Hodge AM、Ebeling PR、Eyles DW、Kvaskoff D、Buchanan DD 等人。循环 25-羟基维生素 D 浓度与乳腺癌、前列腺癌和结直肠癌的风险：墨尔本合作队列研究。癌症流行病生物标志物上一页 2019;28：900-8。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/30842127/)\]
114.  Jiang X, Dimou NL, Al-Dabhani K, Lewis SJ, Martin RM, Haycock PC, et al. Circulating vitamin D concentrations and risk of breast and prostate cancer: A Mendelian randomization study. International Journal of Epidemiology 2019;48:1416-24. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/30597039/)\]  
    江 X， Dimou NL， Al-Dabhani K， 刘易斯 SJ， 马丁 RM， 海科克 PC 等。循环维生素 D 浓度与乳腺癌和前列腺癌的风险：一项孟德尔随机化研究。国际流行病学杂志 2019;48：1416-24。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/30597039/)\]
115.  Travis RC, Perez-Cornago A, Appleby PN, Albanes D, Joshu CE, Lutsey PL, et al. A collaborative analysis of individual participant data from 19 prospective studies assesses circulating vitamin D and prostate cancer risk. Cancer Res 2019;79:274-85. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/30425058/)\]  
    Travis RC、Perez-Cornago A、Appleby PN、Albanes D、Joshu CE、Lutsey PL 等人。对来自 19 项前瞻性研究的个体参与者数据进行协作分析，评估循环维生素 D 和前列腺癌风险。癌症研究 2019;79：274-85。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/30425058/)\]
116.  Nair-Shalliker V, Bang A, Egger S, Clements M, Gardiner RA, Kricker A, et al. Post-treatment levels of plasma 25- and 1,25-dihydroxy vitamin D and mortality in men with aggressive prostate cancer. Scientific Reports 2020;10:7736. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/32385370/)\]  
    Nair-Shalliker V、Bang A、Egger S、Clements M、Gardiner RA、Kricker A 等人。侵袭性前列腺癌男性治疗后血浆 25 和 1,25-二羟基维生素 D 水平和死亡率。科学报告 2020;10：7736。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/32385370/)\]
117.  Song Z-y, Yao Q, Zhuo Z, Ma Z, Chen G. Circulating vitamin D level and mortality in prostate cancer patients: A dose-response meta-analysis. Endocrine Connections 2018;7:R294-303. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/30352424/)\]  
    Song Z-y， Yao Q， Zhuo Z， 马 Z， Chen G. 前列腺癌患者的循环维生素 D 水平和死亡率：剂量反应荟萃分析。内分泌连接 2018;7：R294-303。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/30352424/)\]
118.  Shahvazi S, Soltani S, Ahmadi SM, de Souza RJ, Salehi-Abargouei A. The effect of vitamin D supplementation on prostate cancer: A systematic review and meta-analysis of clinical trials. Horm Metab Res 2019;51:11-21. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/30522147/)\]  
    Shahvazi S， Soltani S， Ahmadi SM， de Souza RJ， Salehi-Abargouei A.维生素 D 补充剂对前列腺癌的影响：临床试验的系统评价和荟萃分析。Horm Metab Res 2019;51：11-21。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/30522147/)\]
119.  US Preventive Services Task Force; Mangione CM, Barry MJ, Nicholson WK, Cabana M, et al. Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2022 Jun 21;327(23):2326-2333. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/35727271/)\]  
    美国预防服务工作组;Mangione CM、Barry MJ、Nicholson WK、Cabana M 等人。预防心血管疾病和癌症的维生素、矿物质和多种维生素补充剂：美国预防服务工作组推荐声明。美国医学会。2022 年 6 月 21 日;327(23):2326-2333.\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/35727271/)\]
120.  Kassi E, Adamopoulos C, Basdra EK, Papavassiliou AG. Role of vitamin D in atherosclerosis. Circulation 2013;128:2517-31. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/24297817/)\]  
    Kassi E， Adamopoulos C， Basdra EK， Papavassiliou AG.维生素 D 在动脉粥样硬化中的作用。流通 2013;128：2517-31。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/24297817/)\]
121.  Mheid IA, Quyyumi AA. Vitamin D and cardiovascular disease: Controversy unresolved. J Am Coll Cardiol 2017;70:89-100. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/28662812/)\]  
    Mheid IA，Quyyumi AA。维生素 D 与心血管疾病：争议未解决。J Am Coll 心脏杂志 2017;70：89-100。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/28662812/)\]
122.  Zhang R, Li B, Gao X, Tian R, Pan Y, Jiang Y, et al. Serum 25-hydroxyvitamin D and the risk of cardiovascular disease: Dose-response meta-analysis of prospective studies. Am J Clin Nutr 2017;105:810-9. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/28251933/)\]  
    张 R， 李 B， 高 X， 田 R， 潘 Y， 江 Y， 等.血清 25-羟基维生素 D 和心血管疾病风险：前瞻性研究的剂量反应荟萃分析。美国临床营养学杂志 2017;105：810-9。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/28251933/)\]
123.  Durup D, Jorgensen HL, Christensen J, Tjonnland A, Olsen A, Halkjaer J, et al. A reverse J-shaped association between serum 25-hydroxyvitamin D and cardiovascular disease mortality: The CopD study. J Clin Endorcinol Metab 2015;100:2339-46. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/25710567/)\]  
    Durup D、Jorgensen HL、Christensen J、Tjonnland A、Olsen A、Halkjaer J 等人。血清 25-羟基维生素 D 与心血管疾病死亡率之间的反向 J 型关联：CopD 研究。临床 Endorcinol Metab 杂志 2015;100：2339-46。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/25710567/)\]
124.  Brondum-Jacobsen P, Benn M, Jensen GB, Nordestgaard BG. 25-hydroxyvitamin D levels and risk of ischemic heart disease, myocardial infarction, and early death: Population-based study and meta-analyses of 18 and 17 studies. Arterioscler Thromb Vasc Biol 2012;32:2794-802. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/22936341/)\]  
    Brondum-Jacobsen P、Benn M、Jensen GB、Nordestgaard BG。25-羟基维生素 D 水平和缺血性心脏病、心肌梗塞和早期死亡的风险：基于人群的研究以及 18 项和 17 项研究的荟萃分析。动脉血栓血管生物学 2012;32：2794-802。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/22936341/)\]
125.  Zhou R, Wang M, Huang H, Li W, Hu Y, Wu T. Lower vitamin D status is associated with an increased risk of ischemic stroke: A systematic review and meta-analysis. Nutrients 2018; 10, 277;doi:10.3390/nu10030277. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/29495586/)\]  
    周 R， Wang M， Huang H， Li W， 胡 Y， Wu T. 较低的维生素 D 状态与缺血性中风风险增加有关：系统评价和荟萃分析。营养素 2018;10, 277;doi：10.3390/nu10030277.\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/29495586/)\]
126.  Scragg R, Stewart AW, Waayer D, Lawes CMM, Toop L, Sluyter J, et al. Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the Vitamin D Assessment Study: A randomized clinical trial. JAMA Cardiol 2017;2:608-16. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/28384800/)\]  
    Scragg R、Stewart AW、Waayer D、Lawes CMM、Toop L、Sluyter J 等人。维生素 D 评估研究中每月高剂量维生素 D 补充剂对心血管疾病的影响：一项随机临床试验。美国医学会心脏杂志 2017;2：608-16。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/28384800/)\]
127.  Ford JA, MacLennan GS, Avenell A, Bolland M, Grey A, Witham M. Cardiovascular disease and vitamin D supplementation: Trial analysis, systematic review, and meta-analysis. Am J Clin Nutr 2014;100:746-55. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/25057156/)\]  
    Ford JA， MacLennan GS， Avenell A， Bolland M， Grey A， Witham M. 心血管疾病和维生素 D 补充剂：试验分析、系统评价和荟萃分析。美国临床营养学杂志 2014;100：746-55。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/25057156/)\]
128.  Hsia J, Heiss G, Ren H, Allison M, Dolan NC, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation. 2007 Feb 20;115(7):846-54.  \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/17309935/)\]  
    夏 J， 海斯 G， 任 H， 艾莉森 M， 多兰 NC， 等。钙/维生素 D 补充剂和心血管事件。流通。2007 年 2 月 20 日;115(7):846-54.\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/17309935/)\]
129.  Dibaba DT. Effect of vitamin D supplementation on serum lipid profiles: A systematic review and meta-analysis. Nutr Rev 2019;77:890-902. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/31407792/)\]  
    迪巴巴 DT.维生素 D 补充剂对血脂谱的影响： 系统评价和荟萃分析。营养修订版 2019;77：890-902。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/31407792/)\]
130.  Beveridge LA, Struthers AD, Khan F, Jorde R, Scragg R, Macdonald HM, et al. Effect of vitamin D supplementation on blood pressure: A systematic review and meta-analysis incorporating individual patient data. JAMA Intern Med 2015;175:745-54. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/25775274/)\]  
    Beveridge LA、Struthers AD、Khan F、Jorde R、Scragg R、Macdonald HM 等人。维生素 D 补充剂对血压的影响：纳入个体患者数据的系统评价和荟萃分析。美国医学会实习医学 2015;175：745-54。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/25775274/)\]
131.  Golzarand M, Shab-Bidar S, Koochakpoor G, Speakman JR, Djafarian K. Effect of vitamin D3 supplementation on blood pressure in adults: An updated meta-analysis. Nutr Metab Cardiovasc Dis 2016;26:663-73. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/27287826/)\]  
    Golzarand M， Shab-Bidar S， Koochakpoor G， Speakman JR， Djafarian K. 补充维生素 D3 对成人血压的影响：更新的荟萃分析。Nutr Metab 心血管疾病 2016;26：663-73。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/27287826/)\]
132.  Vimaleswaran KS, Cavadino A, Berry DJ, Jorde R, Dieffenbach AK, Lu C, et al. Association of vitamin D status with arterial blood pressure and hypertension risk: A mendelian randomisation study. Lancet Diabetes-Endocrinol 2014;2:719-29. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/24974252/)\]  
    Vimaleswaran KS、Cavadino A、Berry DJ、Jorde R、Dieffenbach AK、Lu C 等人。维生素 D 状况与动脉血压和高血压风险的关联：一项孟德尔随机化研究。柳叶刀糖尿病内分泌 2014;2：719-29。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/24974252/)\]
133.  Anglin RES, Samaan Z, Walter SD, McDonald SD. Vitamin D deficiency and depression in adults: Systematic review and meta-analysis. The British Journal of Psychiatry 2013;202:100-7. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/23377209/)\]  
    成人维生素 D 缺乏症和抑郁症：系统评价和荟萃分析。英国精神病学杂志 2013;202：100-7。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/23377209/)\]
134.  Gowda U, Mutowo MP, Smith BJ, Wluka AE, Renzaho AMN. Vitamin D supplementation to reduce depression in adults: Meta-analysis of randomized controlled trials. Nutrition 2015;31:421-9. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/25701329/)\]  
    Gowda U、Mutowo MP、Smith BJ、Wluka AE、Renzaho AMN。补充维生素 D 以减少成人抑郁症：随机对照试验的荟萃分析。营养学 2015;31：421-9。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/25701329/)\]
135.  Jorde R, Kubiak J. No improvement in depressive symptoms by vitamin D supplementation: Results from a randomised controlled trial. Journal of Nutrition Science 2018;7:1-7. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/30510695/)\]  
    Jorde R， Kubiak J. 补充维生素 D 对抑郁症状没有改善：一项随机对照试验的结果。营养科学杂志 2018;7：1-7。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/30510695/)\]
136.  de Koning EJ, Lips P, Penninx BWJH, Elders PJM, Heijboer AC, den Heijer M, et al. Vitamin D supplementation for the prevention of depression and poor physical function in older persons: The D-Vitaal study, a randomized clinical trial. Am J Clin Nutr 2019;110:1119-30. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/31340012/)\]  
    de Koning EJ， Lips P， Penninx BWJH， Elders PJM， Heijboer AC， den Heijer M， et al. 维生素 D 补充剂预防老年人抑郁和身体机能不佳：D-Vitaal 研究，一项随机临床试验。美国临床营养学杂志 2019;110：1119-30。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/31340012/)\]
137.  Jorde R, Grimnes G. Vitamin D: No cure for depression. Am J Clin Nutr 2019;110:1043-4. PMID: 31504098 \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/31504098/)\]  
    Jorde R， Grimnes G. 维生素 D：无法治愈抑郁症。美国临床营养学杂志 2019;110：1043-4。PMID：31504098 \[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/31504098/)\]
138.  Okereke OI, Reynolds III CF, Mischoulon D, Chang G, Vyas CM, Cook NR, et al. Effect of long-term vitamin D3 supplementation vs placebo on risk of depression or clinically relevant depressive symptoms and on change in mood scores: A randomized clinical trial. JAMA 2020;324:471-80. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/32749491/)\]  
    Okereke OI、Reynolds III CF、Mischoulon D、Chang G、Vyas CM、Cook NR 等人。长期补充维生素 D3 与安慰剂对抑郁风险或临床相关抑郁症状以及情绪评分变化的影响：一项随机临床试验。美国医学会 2020;324：471-80。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/32749491/)\]
139.  MedLinePlus. [Multiple sclerosis.](https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3Aproject=medlineplus&v%3Asources=medlineplus-bundle&query=ms&_ga=2.37114720.1394485401.1566930319-1661442768.1566930319) 2020.  
    MedLinePlus 的。[多发性硬化症。](https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3Aproject=medlineplus&v%3Asources=medlineplus-bundle&query=ms&_ga=2.37114720.1394485401.1566930319-1661442768.1566930319)2020.
140.  Jagannath VA, Filippini G, Di Pietrantonj C, Asokan GV, Robak EW, Whamond L, Robinson SA. Vitamin D for the management of multiple sclerosis (review). Cochrane Database of Systematic Reviews 2018, issue 9, Art. No.: CD008422. DOI: 10.1002/14651858.CD008422.pub3. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/30246874/)\]  
    Jagannath VA、Filippini G、Di Pietrantonj C、Asokan GV、Robak EW、Whamond L、Robinson SA。维生素 D 用于治疗多发性硬化症（综述）。Cochrane 系统评价数据库 2018 年，第 9 期，Art.编号：CD008422。DOI：10.1002/14651858.CD008422.pub3.\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/30246874/)\]
141.  Sintzel MB, Rametta M, Reder AT. Vitamin D and multiple sclerosis: A comprehensive review. Neurol Ther 2018;7:59-85. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/29243029/)\]  
    辛策尔 MB， 拉梅塔 M， 雷德 AT.维生素 D 和多发性硬化症：综合综述。神经学 2018;7：59-85。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/29243029/)\]
142.  Munger K, Hongell K, Aivo J, Soilu-Hanninen M, Surcel H-M, Ascherio A. 25-hydroxyvitamin D deficiency and risk of MS among women in the Finnish Maternity Cohort. Neurology 2017;89: 1578-83. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/28904091/)\]  
    Munger K， Hongell K， Aivo J， Soilu-Hanninen M， Surcel HM， Ascherio A. 芬兰产科队列中女性的 25-羟基维生素 D 缺乏症和多发性硬化症风险。神经病学 2017;89: 1578-83.\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/28904091/)\]
143.  Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832-8. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/17179460/)\]  
    Munger KL， Levin LI， Hollis BW， Howard NS， Ascherio A. 血清 25-羟基维生素 D 水平和多发性硬化症的风险。美国医学会 2006;296：2832-8。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/17179460/)\]
144.  Salzer J, Hallmans G, Nystrom M, Stenlund H. Wadell G, Sundstrom P. Vitamin D as a protective factor in multiple sclerosis. Neurology 2012;79:2140-5. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/23170011/)\]  
    Salzer J， Hallmans G， Nystrom M， Stenlund H. Wadell G， Sundstrom P. 维生素 D 作为多发性硬化症的保护因子。神经病学 2012;79：2140-5。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/23170011/)\]
145.  Marrie RA, Beck CA. Preventing multiple sclerosis: To (take) vitamin D or not to (take) vitamin D? Neurology 2017;89:1538-9. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/28904085/)\]  
    预防多发性硬化症：（服用）维生素 D 还是不（服用）维生素 D？神经病学 2017;89：1538-9。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/28904085/)\]
146.  Li X, Liu Y, Zheng Y, Wang P, Zhang Y. The effect of vitamin D supplementation on glycemic control in type 2 diabetes patients: A systematic review and meta-analysis. Nutrients 2018; 10, 375; doi:10.3390/nu10030375 \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/29562681/)\]  
    李 X， 刘 Y， 郑 Y， 王 P， 张 Y.维生素 D 补充剂对 2 型糖尿病患者血糖控制的影响：系统评价和荟萃分析。营养素 2018;10, 375;doi：10.3390/nu10030375 \[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/29562681/)\]
147.  Mousa A, Naderpoor N, Teede H, Scragg R, de Courten, B. Vitamin D supplementation for improvement of chronic low-grade inflammation in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Nutr Rev 2018;76:380-94. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/29490085/)\]  
    Mousa A， Naderpoor N， Teede H， Scragg R， de Courten， B. 维生素 D 补充剂改善 2 型糖尿病患者的慢性低度炎症：随机对照试验的系统评价和荟萃分析。营养修订版 2018;76：380-94。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/29490085/)\]
148.  Pittas A, Dawson-Hughes B, Sheehan P, Ware JH, Knowler WC, Aroda VR, et al. Vitamin D supplementation and prevention of type 2 diabetes. N Engl J Med 2019;381:520-30. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/31173679/)\]  
    Pittas A， Dawson-Hughes B， Sheehan P， Ware JH， Knowler WC， Aroda VR， et al. 维生素 D 补充剂和预防 2 型糖尿病。N Engl J Med 2019;381：520-30。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/31173679/)\]
149.  Rafiq S, Jeppesen PB. Is hypovitaminosis D related to incidence of type 2 diabetes and high fasting glucose level in healthy subjects: A systematic review and meta-analysis of observational studies. Nutrients 2018, 10, 59; doi:10.3390/nu10010059. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/29320437/)\]  
    Rafiq S， Jeppesen PB.维生素 D 缺乏症是否与健康受试者的 2 型糖尿病发病率和高空腹血糖水平有关：观察性研究的系统评价和荟萃分析。营养素 2018， 10， 59;doi：10.3390/nu10010059.\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/29320437/)\]
150.  Mousa A, Naderpoor N, de Courten MPJ, Teede H, Kellow N, Walker K, et al. Vitamin D supplementation has no effect on insulin sensitivity or secretion in vitamin D-deficient, overweight or obese adults: A randomized placebo-controlled trial. Am J Clin Nutr 2017;105:1372-81. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/28490514/)\]  
    Mousa A， Naderpoor N， de Courten MPJ， Teede H， Kellow N， Walker K， et al. 维生素 D 补充剂对维生素 D 缺乏、超重或肥胖成人的胰岛素敏感性或分泌没有影响：一项随机安慰剂对照试验。美国临床营养学杂志 2017;105：1372-81。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/28490514/)\]
151.  Seida JC, Mitri J, Colmers IN, Majumdar SR, Davidson MB, Edwards AL, et al. Effect of vitamin D3 supplementation on improving glucose homeostasis and preventing diabetes: A systematic review and meta-analysis. J Clin Endocrinol Metab 2014;99:3551-60. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/25062463/)\]  
    Seida JC、Mitri J、Colmers IN、Majumdar SR、Davidson MB、Edwards AL 等人。补充维生素 D3 对改善葡萄糖稳态和预防糖尿病的影响：系统评价和荟萃分析。临床内分泌代谢杂志 2014;99：3551-60。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/25062463/)\]
152.  Jorde R, Sollid ST, Svartberg J, Schirmer H, Joakimsen RM, Njolstad I, et al. Vitamin D 20 000 IU per week for five years does not prevent progression from prediabetes to diabetes. J Clin Endocrinol Metab 2016;101:1647-55. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/26829443/)\]  
    Jorde R， Sollid ST， Svartberg J， Schirmer H， Joakimsen RM， Njolstad I， et al. 维生素 D 每周 20 000 IU，持续五年并不能防止从糖尿病前期发展为糖尿病。临床内分泌代谢杂志 2016;101：1647-55。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/26829443/)\]
153.  Pittas A, Dawson-Hughes B, Staten M. The authors reply: Vitamin D supplementation and prevention of type 2 diabetes. N Engl J Med 2019;381:1785-6. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/31665590/)\]  
    皮塔斯 A， 道森-休斯 B， 斯塔滕 M.作者回答：维生素 D 补充剂和预防 2 型糖尿病。N Engl J Med 2019;381：1785-6。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/31665590/)\]
154.  Earthman CP, Beckman LM, Masodkar K, Sibley SD. The link between obesity and low circulating 25-hydroxyvitamin D concentrations: considerations and implications. Int J Obes (Lond) 2012;36:387-96. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/21694701/)\]  
    Earthman CP、Beckman LM、Masodkar K、Sibley SD。肥胖与低循环 25-羟基维生素 D 浓度之间的联系：考虑因素和影响。国际 J Obes （Lond） 2012;36：387-96。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/21694701/)\]
155.  Mallard SR, Howe AS, Houghton LA. Vitamin D status and weight loss: A systematic review and meta-analysis of randomized and nonrandomized controlled weight-loss trials. Am J Clin Nutr 2016;104:1151-9. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/27604772/)\]  
    Mallard SR，Howe AS，Houghton LA。维生素 D 状况和体重减轻：随机和非随机对照减肥试验的系统评价和荟萃分析。美国临床营养学杂志 2016;104：1151-9。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/27604772/)\]
156.  Caan B, Neuhouser M, Aragaki A, Lewis CB, Jackson R, LeBoff MS, et al. Calcium plus vitamin D supplementation and the risk of postmenopausal weight gain. Arch Intern Med 2007;167:893-902. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/17502530/)\]  
    Caan B、Neuhouser M、Aragaki A、Lewis CB、Jackson R、LeBoff MS 等。钙加维生素 D 补充剂和绝经后体重增加的风险。Arch Intern Med 2007;167：893-902。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/17502530/)\]
157.  Pathak K, Soares MJ, Calton EK, Zhao Y, Hallett J. Vitamin D supplementation and body weight status: A systematic review and meta-analysis of randomized controlled trials. Obes Rev 2014;15:528-37. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/24528624/)\]  
    Pathak K， Soares MJ， Calton EK， Zhao Y， Hallett J. 维生素 D 补充剂和体重状况：随机对照试验的系统评价和荟萃分析。OBES 修订版 2014;15：528-37。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/24528624/)\]
158.  Galior K, Grebe S, Singh R. Development of vitamin D toxicity from overcorrection of vitamin D deficiency: A review of case reports. Nutrients 2018, 10, 953. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/30042334/)\]  
    Galior K， Grebe S， Singh R. 维生素 D 缺乏症过度矫正导致维生素 D 毒性的发展：病例报告回顾。营养素 2018， 10， 953。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/30042334/)\]
159.  Auguste BL, Avila-Casado C, Bargman JM. Use of vitamin D drops leading to kidney failure in a 54-year-old man. CMAJ 2019;191:E390-4. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/30962197/)\]  
    奥古斯特 BL、阿维拉-卡萨多 C、巴格曼 JM。使用维生素 D 滴剂导致一名 54 岁男性肾功能衰竭。CMAJ 2019;191：E390-4。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/30962197/)\]
160.  Vogiatzi MG, Jacobson-Dickman E, DeBoer MD. Vitamin D supplementation and risk of toxicity in pediatrics: A review of current literature. J Clin Endocrinol Metab 2014;99:1132-41. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/24456284/)\]  
    Vogiatzi MG、Jacobson-Dickman E、DeBoer 医学博士。维生素 D 补充剂和儿科毒性风险：当前文献综述。临床内分泌代谢杂志 2014;99：1132-41。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/24456284/)\]
161.  Singh P, Trivedi N. Tanning beds and hypervitaminosis D: A case report. Ann Intern Med 2014;160:810-1. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/24887628/)\]  
    Singh P， Trivedi N. 日光浴床和维生素过多症 D：病例报告。安实习医学 2014;160：810-1。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/24887628/)\]
162.  Laurent MR, Gielen E, Pauwels S, Vanderschueren D, Bouillon R. Hypervitaminosis D associated with tanning bed use: A case report. Ann Intern Med 2017;166:155-6. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/28114469/)\]  
    Laurent MR、Gielen E、Pauwels S、Vanderschueren D、Bouillon R. 与日光浴床使用相关的维生素过多症 D：病例报告。安实习医学 2017;166：155-6。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/28114469/)\]
163.  Perez-Castrillon JL, Vega G, Abad L, Sanz A, Chaves J, Hernandez G, Duenas A. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 2007;99:903-5. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/17398180/)\]  
    Perez-Castrillon JL， Vega G， Abad L， Sanz A， Chaves J， Hernandez G， Duenas A. 阿托伐他汀对急性缺血性心脏病患者维生素 D 水平的影响。美国心脏杂志 2007;99：903-5。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/17398180/)\]
164.  Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669-82. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/16481635/)\]  
    Jackson RD、LaCroix AZ、Gass M、Wallace RB、Robbins J、Lewis CE 等。钙加维生素 D 补充剂和骨折风险。N Engl J Med 2006;354：669-82。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/16481635/)\]
165.  Malihi Z, Lawes CMM, Wu Z, Huang Y, Waayer D, Toop L, et al. Monthly high-dose vitamin D supplementation does not increase kidney stone risk or serum calcium: Results from a randomized controlled trial. Am J Clin Nutr 2019;109:1578-87. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/31005969/)\]  
    Malihi Z、Lawes CMM、Wu Z、Huang Y、Waayer D、Toop L 等人。每月高剂量补充维生素 D 不会增加肾结石风险或血清钙：一项随机对照试验的结果。美国临床营养学杂志 2019;109：1578-87。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/31005969/)\]
166.  Malihi Z, Wu Z, Stewart AW, Lawes CMM, Scragg R. Hypercalcemia, hypercalciuria, and kidney stones in long-term studies of vitamin D supplementation: A systematic review and meta-analysis. Am J Clin Nutr 2016;104:1039-51. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/27604776/)\]  
    Malihi Z、Wu Z、Stewart AW、Lawes CMM、Scragg R. 维生素 D 补充剂长期研究中的高钙血症、高钙尿症和肾结石：系统评价和荟萃分析。美国临床营养学杂志 2016;104：1039-51。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/27604776/)\]
167.  Gotfredsen A, Westergren Hendel H, Andersen T. Influence of orlistat on bone turnover and body composition. Int J Obes Relat Metab Disord 2001;25:1154-60. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/11486790/)\]  
    Gotfredsen A， Westergren Hendel H， Andersen T. 奥利司他对骨转换和身体成分的影响。国际 J Obes relat Metab Disord 2001;25：1154-60。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/11486790/)\]
168.  James WP, Avenell A, Broom J, Whitehead J. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes Relat Metab Disord 1997;21:S24-30. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/9225173/)\]  
    詹姆斯 WP， 阿文内尔 A， 布鲁姆 J， 怀特海德 J.一项为期一年的试验，旨在评估奥利司他在肥胖管理中的价值。Int J Obes relat Metab Disord 1997;21：S24-30。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/9225173/)\]
169.  McDuffie JR, Calis KA, Booth SL, Uwaifo GI, Yanovski JA. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 2002;22:814-22. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/12126214/)\]  
    麦克达菲 JR、恰里斯 KA、布斯 SL、乌瓦福 GI、亚诺夫斯基 JA。奥利司他对肥胖青少年脂溶性维生素的影响。药物治疗 2002;22：814-22。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/12126214/)\]
170.  Robien K, Oppeneer SJ, Kelly JA, Hamilton-Reeves JM. Drug-vitamin D interactions: A systematic review of the literature. Nutr Clin Pract 2013;28:194-208. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/23307906/)\]  
    Robien K、Oppeneer SJ、Kelly JA、Hamilton-Reeves JM。药物-维生素 D 相互作用：文献系统评价。营养临床实践 2013;28：194-208。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/23307906/)\]
171.  Schwartz JB. Effects of vitamin D supplementation in atorvastatin-treated patients: A new drug interaction with an unexpected consequence. Clin Pharmacol Ther 2009;85:198-203. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/18754003/)\]  
    施瓦茨 JB。补充维生素 D 对阿托伐他汀治疗患者的影响：具有意想不到后果的新药物相互作用。临床药理学技术 2009;85：198-203。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/18754003/)\]
172.  Perez-Castrillon JL, Vega G, Abad L, Sanz A, Chaves J, Hernandez G, Duenas A. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 2007;99:903-5. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/17398180/)\]  
    Perez-Castrillon JL， Vega G， Abad L， Sanz A， Chaves J， Hernandez G， Duenas A. 阿托伐他汀对急性缺血性心脏病患者维生素 D 水平的影响。美国心脏杂志 2007;99：903-5。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/17398180/)\]
173.  Aloia JF, Li-Ng M, Pollack S. Statins and vitamin D. Am J Cardiol 2007;100:1329. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/17920383/)\]  
    Aloia JF、Li-Ng M、Pollack S. 他汀类药物和维生素 D. Am J Cardiol 2007;100：1329。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/17920383/)\]
174.  Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;125:961-8. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/8967706/)\]  
    钙和维生素 D3 补充剂可防止类风湿性关节炎患者因低剂量皮质类固醇而继发的脊柱骨质流失。一项随机、双盲、安慰剂对照试验。安实习医学 1996;125：961-8。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/8967706/)\]
175.  de Sevaux RGL, Hoitsma AJ, Corstens FHM, Wetzels JFM. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol 2002;13:1608-14. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/12039990/)\]  
    de Sevaux RGL， Hoitsma AJ， Corstens FHM， Wetzels JFM.维生素 D 和钙治疗可减少肾移植后的骨质流失：一项随机研究。J Am Soc 肾素 2002;13：1608-14。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/12039990/)\]
176.  Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-64. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/2407167/)\]  
    糖皮质激素诱导的骨质疏松症：发病机制和管理。安实习医学 1990;112：352-64。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/2407167/)\]
177.  Skversky AL, Kumar J, Abramowitz MK, Kaskel FJ, Melamed ML. Association of glucocorticoid use and low 25-hydroxyvitamin D levels: Results from the National Health and Nutrition Examination Survey (NHANES): 2001-2006. J Clin Endocrinol Metab 2011;96:3838-45. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/21956424/)\]  
    Skversky AL、Kumar J、Abramowitz MK、Kaskel FJ、Melamed ML. 糖皮质激素使用与低 25-羟基维生素 D 水平的关联：全国健康和营养检查调查 （NHANES） 的结果：2001-2006 年。临床内分泌代谢杂志 2011;96：3838-45。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/21956424/)\]
178.  Drinka PJ, Nolten WE. Hazards of treating osteoporosis and hypertension concurrently with calcium, vitamin D, and distal diuretics. J Am Geriatr Soc 1984;32:405-7. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/6715769/)\]  
    Drinka PJ，诺尔滕 WE。与钙、维生素 D 和远端利尿剂同时治疗骨质疏松症和高血压的危害。J Am Geriatr Soc 1984;32：405-7。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/6715769/)\]
179.  Crowe M, Wollner L, Griffiths RA. Hypercalcaemia following vitamin D and thiazide therapy in the elderly. Practitioner 1984;228:312-3. \[[PubMed abstract](https://pubmed.ncbi.nlm.nih.gov/6709583/)\]  
    Crowe M， Wollner L， Griffiths RA.老年人维生素 D 和噻嗪类治疗后的高钙血症。从业者 1984;228：312-3。\[[PubMed 摘要](https://pubmed.ncbi.nlm.nih.gov/6709583/)\]

## Disclaimer 免責聲明

This fact sheet by the National Institutes of Health (NIH) Office of Dietary Supplements (ODS) provides information that should not take the place of medical advice. We encourage you to talk to your health care providers (doctor, registered dietitian, pharmacist, etc.) about your interest in, questions about, or use of dietary supplements and what may be best for your overall health. Any mention in this publication of a specific product or service, or recommendation from an organization or professional society, does not represent an endorsement by ODS of that product, service, or expert advice.

**Updated:** July 26, 2024 [History of changes to this fact sheet](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/45/history?l=en)  
**已更新：** 2024 年 7 月 26 日[本情况说明书的更改历史](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/45/history?l=en)